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Abstract  
Chronic bronchiectasis is the irreversible dilation of the airways that can result from a variety of 
insults to the airway walls. This airway dilation is accompanied by chronic inflammation, mucus 
hypersecretion and recurrent bacterial infection. Whilst an association exists with severe childhood 
respiratory infection, the origin of bronchiectasis is considered idiopathic in a substantial proportion 
of cases. Bronchiectasis is characterised by a chronic, neutrophil dominated, inflammatory 
response. The cellular and molecular nature of the inflammation are poorly understood. 
Identification of the mechanisms that drive this inflammation is important for the improvement of 
therapy.  Macrolide antibiotics can influence mucus production and inflammatory response. In 
particular, azithromycin and erythromycin have been shown to be beneficial in patients with chronic 
respiratory diseases. However, the mechanisms by which these positive treatment outcomes are 
achieved are not known. 
 
This project aimed to characterise the nature of inflammation in bronchiectasis, the expression of 
mucin glycoproteins, the expression of tissue remodelling markers, and the response of these 
parameters to macrolide therapy (erythromycin). To address this, bronchial biopsies, 
bronchoalveolar lavage fluid (BALF) and induced sputum samples were collected as part of the 
BLESS randomised trial of placebo vs long term low dose oral erythromycin.   
 
Concentrations of pro-inflammatory chemokines and cytokines associated with both innate and 
adaptive immunity including IL-8, IL-1β, TNF-α, IFN-, IL-13, IL-17A and IL-23 (P<0.001),  were 
elevated in bronchoalveolar lavage fluid from bronchiectatic patients, demonstrating a complex 
mixed inflammatory response. Significant correlations were observed between sputum levels of IL-
8 and IL-1 and the presence of bacterial pathogens in sputum, elevated serum CRP and poor lung 
function. Airway biopsies from bronchiectasis subjects showed increased expression of genes 
encoding  chemokines (IL-8), antimicrobial molecules (DEFB1, LYZ, SAA1, SERPINA3) and goblet 
cell/mucin associated proteins (AGR2, TFF1, TFF3). The relative abundance of a specific isoform 
of the key airway gel-forming mucin, MUC5B, was also significantly higher in induced-sputum 
from bronchiectatic vs healthy individuals. Concentrations of tissue remodelling markers were also 
elevated in BALF from bronchiectatic subjects (EGF, bFGF, neutrophil elastase and total MMP 
activity).  However, concentration of VEGF-A in BALF from bronchiectatic subjects was lower 
than in healthy individuals, and was negatively correlated to the number of total exacerbations in 
the preceding 12 months. Neither VEGF-A concentrations nor mucin protein levels correlated with 
levels of any individual inflammatory cytokine. Patterns of inflammation in BALF remained largely 
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unchanged in placebo-treated patients after 48 weeks (r=0.83 and r=0.73 for sputum IL-1 and 
BALF IL-17A, respectively, P<0.0001), indicating a consistent mixed immune response. 
 
In vitro cell culture of primary bronchial epithelial cells obtained from both patients with 
bronchiectasis and healthy controls was performed to assess whether bronchiectatic epithelial cells 
contribute to abnormal mucosal barrier function. Higher expression of CXCL10 and SERPINB2 
were detected in bronchiectatic epithelial cells, however, no significant difference in transepithelial 
electrical resistance, or expression of genes encoding mucins (MUC5AC, MUC5B) was observed. 
Inflammatory mediator stimulation by BALF from bronchiectasis subjects resulted in an increase in 
IL-8 gene expression and decreased transepithelial electrical resistance. The decrease in 
transepithelial electrical resistance in epithelial cells from bronchiectasis subjects was significantly 
greater than in cells from healthy controls. These data suggest that primary defects in airway 
epithelial cells may reflect a predisposition to bronchiectasis.  
 
Low dose erythromycin therapy significantly reduced the occurrence of pulmonary exacerbations, 
and the production of sputum. However, these outcomes were not associated with changes in 
concentrations of inflammatory markers in airway secretions. Further, no change in expression of 
the gene encoding IL-8, and genes induced by inflammation (DEFB1, LYZ, SAA1, SERPINA3, 
AGR2, MUC5AC, MUC5B, TFF1, and TFF3) were seen in airway biopsies from erythromycin-
treated bronchiectasis subjects. A subtle shift in the inflammatory pattern was observed after 
erythromycin treatment, and a significant reduction in neutrophil elastase activity was detected in 
subjects with reduction in sputum volume. These findings indicate that long-term low-dose 
erythromycin treatment does not have a direct anti-inflammatory effect in patients with 
bronchiectasis. In order to assess whether specific groups of patients would benefit more from 
erythromycin, patients were grouped according to Pseudomonas aeruginosa culture positivity or 
prior exacerbation frequency as a marker of clinical outcome. No significant effect of erythromycin 
on airway inflammation was observed in these subgroups.  
 
Comprehensive characterisation of inflammation and mucin production in the non-CF 
bronchiectasis airway revealed a highly complex inflammatory profile, indicating concordant 
activation of multiple immune pathways. Cytokine concentrations correlated with airway bacterial 
infection and were consistent over 48 weeks. VEGF-A concentration negatively correlated with the 
number of total exacerbations in the preceding 12 months. In vitro analysis raised the possibility of 
primary defects in airway epithelial cells. In spite of erythromycin therapy being associated with 
significant clinical improvement in bronchiectasis, this comprehensive, double-blind, placebo-
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controlled analysis of airway samples failed to show suppression of inflammation. These data 
suggest an alternative mechanism by which macrolides achieve clinical benefit in bronchiectasis. 
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Chapter 1 Introduction and literature review 
1.1 Introduction 
Bronchiectasis, first described by Dr. Rene Laennec in 1819, is characterised by irreversibly airway 
dilatation. Clinical features including consistent cough, production of purulent sputum, and 
recurrent chest infections can dramatically affect quality of life. Bronchiectasis is generally believed 
to be a sequel of severe lung infections which damage the airway wall, however most cases are 
idiopathic in origin. It is commonly accepted that airway inflammation as a response to bacterial 
pathogens plays a significant underlying role in bronchiectasis, however the mechanism of the 
disease and the nature of the underlying inflammation are still inadequately investigated. Physical 
therapy and various medications are used in the hope of controlling frequency of exacerbations, 
however currently there are few effective or specific therapies and certainly no cure for this disease. 
 
1.2 Epidemiology of bronchiectasis 
Bronchiectasis may be diagnosed at any age, but recognition of the onset of disease is most 
common in individuals between 50-60 years of age, and peaks at ages 80-84 years old. In the USA, 
0.29% of the population over 75 years old has bronchiectasis (Weycker et al., 2005). It is more 
commonly recognised in developing countries, where malnutrition, overcrowding and social 
disadvantage, poor hygiene and poor access to vaccines and antibiotic therapies are likely to lead to 
greater risks of childhood broncho-destructive respiratory infections, in addition to impairing 
immune function. The prevalence of bronchiectasis in Indigenous Australian children is about 
1.47% (Chang et al., 2003), however data in broader Australian population is still lacking. To date, 
there is no comprehensive study suggesting genetic causes of non-CF bronchiectasis in Indigenous 
Australians. However, more frequent exposure to wood fire, limited access to quality healthy 
services, and inadequate medical follow-up could be contributing to the higher prevalence of 
bronchiectasis in the Indigenous population. (Chang et al., 2003). 
 
The personal and community costs related to bronchiectasis are mainly the recurrent need for 
antibiotic therapy to treat infective exacerbations of chronic lung disease, decreases in productivity 
and lifetime earnings, and quality years of life lost due to disease. Maintenance therapies are needed 
to improve interval symptomatology and reduce the frequency and severity of these exacerbations 
(Stafler and Carr, 2010). The average annual cost to treat a patient with bronchiectasis is higher than 
other comparable chronic diseases such as diabetes ($13,244 USD versus $8,000 USD) (Weycker et 
al., 2005). 
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1.3 The respiratory system 
The human respiratory system provides the path for air from the external environment to enter the 
body, and provides a large surface area for passive gas exchange between the external environment 
and blood (West, 2008). Air enters from the nose, down the nasal cavity, nasopharynx and 
oropharynx, larynx, trachea, bronchi, bronchioles, terminal bronchioles, and finally enters the 
alveoli. Air is warmed, moistened and cleaned through the airway, and gas exchange takes place in 
alveoli via diffusion. The larger airways are supported by the C-shaped incomplete rings of 
cartilage, and the smaller bronchioles are supported only by layers of smooth muscle. Inside the 
airway, respiratory epithelium is covered by cilia and a thin layer of mucus. When external particles 
(eg. dusts, pollen and bacteria) enter the airway, they are trapped in the mucus and are moved 
towards the oropharynx by the co-ordinated beating of cilia. This is called “mucociliary clearance”, 
which is an important mechanism in the respiratory tract to prevent external particles from 
depositing within the lung (Cloutier, 2007). Ciliary dysfunction and impaired mucociliary clearance 
can result in chronic respiratory diseases including bronchiectasis (Boon et al., 2013). 
 
The pseudostratified ciliated columnar epithelium lining the airways is composed of five cell types 
(Figure 1.1).  Mucus secreting cells (goblet cells in the larger airways and Club cells in the smaller 
airways) secrete mucus which traps inhaled particles and microbes. Ciliated columnar cells beat 
their cilia toward the oropharynx, moving mucus upwards. Non-ciliated columnar cells do not 
possess cilia, but have microvilli on their apical surface. Basal cells are undifferentiated stem cells 
whose progeny are differentiated into goblet cells, ciliated columnar cells or nonciliated columnar 
cells. Small granule cells are neuroendocrine cells that synthesise catecholamines. Goblet cells and 
cilia are found all the way from the respiratory nasal cavity down to the bronchi, and as the number 
of ciliated cells decreases in the conducting bronchioles Club cells, which secrete surface-active 
lipoproteins and mucins, predominate. Under the influence of TH2 cytokines, the Club cells 
transdifferentiate into goblet cells and produce large amounts of mucus (Chen et al., 2009; Park et 
al., 2007). Beneath the epithelium is the lamina propria, which is formed from loose connective 
tissue that contains seromucous and mucous glands, and a resident mononuclear inflammatory cell 
population, including plasma cells, lymphocytes, and macrophages.  
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Figure 1.1. Human respiratory epithelium. (A) Sectional view of the tracheal wall (hematoxylin and 
eosin stain, medium magnification) (Eroschenko, 2008). (B) and (C) Pseudostratified columnar 
ciliated epithelium. C = cilia, G = goblet cells, BM = basement membrane. ((C) hematoxylin and 
eosin stain, x200) (Barbara Young et al., 2006)   
 
1.4 Chronic airway diseases 
1.4.1 Bronchiectasis (BE) 
Bronchiectasis is characterised by irreversibly dilated airways and clinical symptoms including 
mucus hypersecretion, purulent sputum, and susceptibility to airway infection (McShane et al., 
2013). Diagnosis using high-resolution CT scan (HRCT) provides evidence of dilated airways 
(Figure 1.2A). Significant infection in early childhood, which causes structural damage to the 
developing lung, is believed to be the commonest identifiable cause of bronchiectasis, however, in 
most series the majority of cases are idiopathic (Pasteur et al., 2010). As the immune system is less 
effective in young children and elderly adults, increased incidence of infection in these two groups 
may contribute to the development of bronchiectasis. Microbial infection causes inflammation 
resulting in tissue damage and impaired mucociliary motility (Figure 1.2B and 1.2C). Impaired 
mucociliary clearance, persistent bacterial infection, acute or chronic inflammation and irreversible 
fibrotic changes are both cause and effect, which eventually lead to progressive decline in lung 
function. Recurrent infective pulmonary exacerbations are the predominant determinants of 
(A) 
(B) (C) 
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morbidity and mortality in bronchiectasis (Loebinger et al., 2009). Physiotherapy, antibiotics, and 
airway clearance drugs are used to control the disease state and the frequency of exacerbations 
(King and Holmes, 2012), however currently there is no cure or specific treatments addressing the 
underlying pathophysiology of the disease. Lobectomy and lung transplant are surgical options that 
may be considered in highly selected patients.  
 
   
Figure 1.2. Clinical and pathological data from patients with bronchiectasis in the BLESS trial. (A) 
HRCT of the lungs demonstrating the dilated airways (arrow) that characterise bronchiectasis. 
Endobronchial biopsy from a patient with bronchiectasis showing (B) a dense inflammatory 
infiltrate and hyperplasia of submucosal glands (hematoxylin and eosin stain, x10) and (C) scarred 
airway characterised by parallel wavy bundles of mature collagen fibrosis. (haematoxylin and eosin 
stain, x40) 
 
Whitwell described the anatomical pathology of the bronchiectatic lung by categorising the disease 
into three categories (follicular, saccular and atelectatic) (Whitwell, 1952). However, over 50% of 
the specimens did not fit into any of these three categories. The most common form was follicular 
bronchiectasis, characterised by the presence of lymphoid follicles in the bronchial wall. In 
follicular bronchiectasis it was hypothesised that inflammation commenced in the small airway, 
causing the release of proteases which damage the large airways. This leads to loss of elastin, 
muscle and cartilage in the large airway, thus, large airways become dilated, but the small and 
medium airways are characterised by airflow obstruction predominantly arising from thickening of 
the bronchial wall by inflammation. With progression of the disease lymphoid follicles enlarge in 
size and cause airflow obstruction in the small airways. Under this model, the final event is spread 
of the inflammation beyond the airways to cause interstitial pneumonia. This condition most 
commonly involves the lower lobes, which may have reflected failure of mucociliary clearance and 
gravity-dependent retention of infected secretions. It is not known if bronchiectasis starts in one 
section of the respiratory tract and then spreads or if it begins as a generalised process. Mechanisms 
for elastin, muscle and cartilage loss are still yet to be investigated. To a lesser extent comparing to 
follicular bronchiectasis, saccular bronchiectasis was described with gross loss of bronchial 
(A) (B) (C) 
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structures in the saccules, and peripheral bronchial obstruction was a key characteristic of atelectatic 
bronchiectasis. 
 
Recurrent bacterial infection is one of the characteristics of bronchiectasis, with a diverse 
prevalence of bacteria found in sputum samples between different age groups and disease states. 
Comprehensive characterisation of airway microbiota in bronchiectasis is still lacking (Tunney et 
al., 2013), however sputum cultures demonstrated that Haemophilus influenzae is the most common 
pathogen (range 29% - 70%), followed by Pseudomonas aeruginosa (range 12% - 31%), and 
numerous other organisms including Streptococcus pneumoniae, Staphylococcus aureus and 
nontuberculous mycobacteria amongst others (2% - 10%) (Angrill et al., 2002; King, 2009; King et 
al., 2007; Nicotra et al., 1995). These pathogens not only produce glycoproteins that attract 
neutrophils, but may also inhibit mucociliary clearance. Mediators released by H. influenzae, P. 
aeruginosa, and Streptococcus pneumoniae may directly interfere with ciliary function, damage 
ciliated epithelium, and inhibit mucus transport (Bailey et al., 2012; Steinfort et al., 1989; Wilson et 
al., 1987). H. influenzae can cause direct damage to airway epithelium and can invade into the 
bronchial wall and interstitium of the lung (Bandi et al., 2001). P. aeruginosa has the capacity to 
form biofilms, in which an impenetrable matrix around the Pseudomonas colony is formed, 
protecting it from the effects of the immune system and antibiotics, and permitting infections to 
cause damage to the underlying lung epithelium (Davies and Bilton, 2009; King, 2009).  
 
Microbial flora in patients with bronchiectasis appears to change with disease severity. Subjects 
with the best preserved lung function are most likely to have no pathogenic bacteria isolated, but as 
lung function declines, H. influenzae becomes predominant and finally in patients with the most 
severe disease the usual pathogen isolated is P. aeruginosa (King et al., 2007). Subjects with airway 
P. aeruginosa infection tend to have more sputum production, more extensive bronchiectasis, more 
hospitalisations, and poorer quality of life. The role of viral infection in bronchiectasis is not well 
defined, however it is well determined that viral infections could proceed the bacterial infections in 
children and the elderly, particularly influenza (Short et al., 2012; Zeller and Bricaire, 2003). 
Influenza A infections inhibit neutrophil function in bronchiectasis subjects (Pang et al., 2000), and 
adenovirus has been identified as a risk factor for the development of bronchiectasis in young 
children (Becroft, 1971). Hence, secondary bacterial infection after viral infection may be important 
in development of bronchiectasis. The nature of airway inflammation will be further discussed in 
Chapter 1.6. 
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1.4.2 Other airway diseases 
Other better characterized airway diseases with clinical overlap and some pathological features in 
common, but the differing mechanisms of disease, causes, outcomes and complications are briefly 
described here to allow comparison to bronchiectasis. 
 
 Cystic fibrosis (CF) is an autosomal recessive disease caused by mutation of the cystic fibrosis 
transduction regulator (CFTR) gene. The most commonly occurring mutation is the ΔF508 
gene mutation caused by the deletion of phenylalanine at the 508 position. The mutation 
affects the production of an ATP-binding cassette transporter, which functions as a chloride 
channel. Malfunction of the chloride channel increases viscosity and stickiness of mucus in all 
mucosal tissues. In the case of Δ508, the CFTR precursor misfolds in the endoplasmic 
reticulum (ER) and does not reach the cell surface, whilst also initiating ER stress (see Chapter 
1.6 for further details) (Bartoszewski et al., 2008). Cystic fibrosis influences many epithelial 
organs including the lung, pancreas, intestine, liver, gallbladder, sweat gland, and male 
reproductive tract. Its effect on secretion of pancreatic enzymes leads to poor nutrient 
absorption, thus intestinal manifestations became the major challenge for newborn CF infants. 
However, lung infection becomes the major cause of morbidity and mortality from early 
childhood after their first respiratory infection. Sputum produced by CF patients is tenacious 
and difficult to clear, and CF patients develop severe bronchiectasis associated with bacterial 
superinfection. Many believe that modifying the quality of CF airway mucus will decrease 
morbidity and disease specific mortalitys (Daviskas et al., 2002).  
 Chronic obstructive pulmonary disease (COPD) is characterised by narrowed small airways 
and low airflow, which in western societies is usually caused by tobacco smoking (Crapo, 
2010). Clinical symptoms include chronic cough, production of sputum, shortness of breath, 
and persistent airway infection and inflammation. Activated innate and adaptive immunity, 
elevated protease activity and mucus hypersecretion have been shown in patients with COPD, 
however there is no specific treatment for the disease (Rovina et al., 2013). Exacerbations 
become more frequent as disease severity increases, and a frequent-exacerbation phenotype is 
associated with elevated white cell counts (Hurst et al., 2010).  
 Asthma involves hyperreactivity of the respiratory epithelial immune system, either 
intrinsically or directed against inhaled allergens that include respiratory pathogens. Recurrent 
bronchospasm, in which widespread constriction of smooth muscle in the bronchi and 
bronchioles decreases their diameter, leads to expiratory wheezing exacerbated by mucus 
hypersecretion. The majority of asthmatic patients have an eosinophilic and Th2 dominant 
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inflammation, however neutrophil accumulation is also common (Hansel et al., 2013). Asthma 
attacks are often associated with viral infections during which inflammatory mediators are 
increased. A common acute treatment for mild asthma is 2-agonists, which relax the 
bronchiolar smooth muscle, thus increasing air flow. Prophylactic treatment also helps to 
prevent the inflammatory cascade beginning. 
 Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease of unknown 
cause. Prevalence of the disease increases with age in people over age of 50, median survival is 
3 years, and respiratory failure is a common cause of death (Kim et al., 2006). Genetic 
mutations together with epithelial cell dysfunction, aging and environmental exposures seem to 
set the disease off. Although eosinophilia and neutrophilia have been described in IPF, 
however, acute worsening of the disease is often due to an unknown cause (Wolters et al., 
2013). 
 
Table 1.1. Characteristics of chronic respiratory disease 
 
Site of lung 
pathology 
Lung  
function 
Mucus 
hypersecretion 
Irreversible 
airway damage 
Type of 
inflammation 
Bacteria 
colonisation likely 
Cause of disease 
BE Proximal airways 
Obstructive  
or restrictive 
Yes Yes Neutrophilic Yes Unknown / infection 
CF Proximal airways Obstructive Yes Yes Neutrophilic Yes Genetic 
COPD Proximal airways Obstructive Yes Yes Neutrophilic Yes 
Smoking / pollution 
/ infection 
Asthma 
Distal airways 
Proximal airways 
Normal or 
Obstructive 
Some cases No 
Eosinophilic 
Neutrophilic 
No 
Unknown / allergen 
/ pollution 
IPF Lung interstitium Restrictive Yes 
No airway damage 
Interstitium affected 
- No Unknown / genetic 
 
The pathophysiology of these chronic respiratory diseases differ from one another between the site 
of pathology within the lung, whether the condition impacts on lung function, and differential host 
responses against viral versus bacterial infections. Some common features between these chronic 
respiratory diseases are airway mucus hypersecretion and aberrant inflammatory responses. 
 
1.5 Airway mucins    
Airway epithelium acts as the front-line defence for dusts and air-borne pathogens to protect the 
lung from foreign body damage and infection. In the normal trachea, a layer of mucus (300 µm 
thick) covers the airway epithelium. Further down the respiratory tract, this mucus layer becomes 
thinner (5 µm thick in the terminal bronchioles) (Barbara Young et al., 2006). This airway mucus is 
composed mainly of mucin glycoproteins and water, and provides a matrix for a wide variety of 
antimicrobial molecules including antibodies, defensins, protegrins, collectins, cathlecidins, 
lysozyme, histatins, and nitric oxide, which make up some of the more than 250 proteins and 
nonprotein components found in human sputum (Nicholas et al., 2006). When external particles (eg. 
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dust, pollen and bacteria) enter the airway, they are trapped in the mucus and are moved towards the 
oropharynx by the co-ordinated beating of cilia. This mucociliary clearance is an important 
mechanism to prevent inhaled particulate matter and microbes from retention within the lung. 
Impaired mucociliary clearance due to inherited ciliopathies results in chronic pathology, including 
forms of bronchiectasis. 
 
Quinton et al. proposed that a watery layer is laid between cells and mucus. This watery layer 
allows cilia to beat in a liquid environment, while the tips of cilia contract the mucus to move 
mucus towards the oropharynx. The percentage of water in this watery layer and in the mucus may 
play a critical role in causing airway diseases such as CF, which is characterised by malfunction of 
cilial beating (Quinton, 2008). However, an alternative hypothesis suggested that this layer between 
cells and mucus is occupied by densely tethered macromolecules, stabilising the two-layer mucus 
clearance system by preventing mucus penetration into the interciliary space (Button et al., 2012). 
In this alternative model, the distribution of water between the two layers is controlled by the 
periciliary layer brush during normal mucus clearance. Change in osmotic modulus of the mucus 
layer can reflect either a decrease in the amount of solvent or an increase in amount of secreted 
mucins in chronic respiratory diseases (Button et al., 2012). In CF airways, an increase in mucin 
secretion and/or a decrease in airway surface liquid volume could result in an increased mucin 
concentration and partial osmotic pressure, which lead to slow/impaired mucus clearance 
(Henderson et al., 2014; Matsui et al., 1998). 
 
Airway mucins can be classified into secreted gel-forming mucins, cell surface mucins, and 
secreted non-gel-forming mucins (Thornton et al., 2008). The gel-forming mucins provide the 
rheological properties of normal mucus. Microbes must penetrate the mucus barrier to either attach 
to the surface of epithelial cells decorated with cell surface mucins or release toxins to disrupt the 
epithelium (Button et al., 2012). Many bacterial adhesins bind oligosaccharides present on both cell 
surface and secreted non-gel forming mucins. When the mucus barrier is aberrant or damaged or 
depleted, the risk of opportunistic microbial infection is increased. There are 17 MUC genes 
encoding the production of epithelial mucins, and each mucin varies in size and number of repeats. 
 
1.5.1 Gel-forming mucins 
The epithelial mucins are a family of large complex glycoproteins containing a dense array of O-
linked carbohydrates concentrated in large peptide domains of repeating amino-acid sequences rich 
in serine and threonine. MUC5AC and MUC5B are the main gel-forming mucins in the airway, and 
MUC2 can be detected to a lesser extent. MUC5AC is expressed mostly by the goblet cells of the 
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surface epithelium, which may be an acute-response mucin that is produced as a result of insults 
arriving at the upper airway surfaces. MUC5B is expressed mostly in the mucous cells in 
submucosal glands that may be involved in the response to more chronic insults such as chronic 
infection and chronic inflammation, and it is also continuously produced by Club cells (Buisine et 
al., 1999). Secretion of these gel-forming mucins occurs via both constitutive and regulated 
pathways. Secreted airway mucin is mainly synthesised in the goblet cells of the surface epithelium 
and submucosal glands (mucous cells) underlying the airway epithelium and to a lesser extent, Club 
cells. Mucin macromolecules are stored in dehydrated form within secretory granules and are 
released by regulated secretion both constitutively and in response to a range of external challenges. 
Upon release secreted mucins mix with water to form mucus up to 1000 times their original 
volume. Underneath the mucus layer, the epithelial cells present a diversity of glycoproteins and 
glycolipids, which form the glycocalyx which overlies the apical surface of each epithelial cell. 
Both the secreted and adherent mucosal barriers are frequently renewed and can be promptly 
adjusted in reaction to environmental stimuli and presence of microbes penetrating the mucus layer.  
 
1.5.2 Cell surface mucins 
Membrane-anchored cell surface mucin glycoproteins are a major constituent of the glycocalyx in 
mucosal tissues. Cell surface mucins have both a barrier and reporter function on the apical surface 
of all mucosal epithelial cells (Lillehoj et al., 2004). Like the gel-forming mucins, cell surface 
mucins are also constitutively produced in normal airways. Cell surface mucins found in respiratory 
airways include MUC1, MUC4, MUC13 and MUC16 (Hattrup and Gendler, 2008). In order to 
result in infection, microbes must penetrate through the epithelial layer into the submucosa, or 
direct binding to cause disease. The cell surface mucins which are different in size greatly limit the 
size of particles that could enter the interciliary space (Button et al., 2012; Sheehan et al., 2006). 
Also, they can act as a releasable decoy ligand or initiate intracellular signalling in response to 
bacteria, suggesting that they have both a barrier and reporting function on the apical surface of all 
mucosal epithelial cells. MUC1, the most studied cell surface mucin, has been shown to have an 
anti-inflammatory property by suppressing bacteria and virus-induced inflammation (Choi et al., 
2011; Kyo et al., 2012; Li et al., 2010; Ueno et al., 2008) .  
 
1.5.3 Regulation of goblet cell differentiation 
Goblet cell differentiation is regulated by several transcription factors including forkhead box A2 
(FOXA2) and SAM pointed domain-containing ETS transcription factor (SPDEF). FOXA2 is 
essential in maintaining normal differentiation of conducting airway epithelial cells (Wan et al., 
2004). SPDEF is expressed in epithelial cells in various tissues, and is highly involved in regulating 
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a transcriptional network mediating the goblet cell differentiation and mucus hyperproduction 
associated with chronic pulmonary disorders (Chen et al., 2009). SPDEF was markedly induced in 
analysis of genes influenced by a phosphorylation mutant of Thyroid transcription factor 1 (TTF-1), 
a key player in lung morphogenesis, which suggests that SPDEF might participate with TTF-1 to 
affect genetic programming regulating differentiation of the respiratory epithelium. Initial cell-
lineage-tracing analysis identified nonciliated secretory epithelial cells (Club cells) as the 
progenitors of goblet cells induced by pulmonary allergen exposure in vivo. In vivo expression of 
SPDEF in Club cells caused rapid and reversible goblet cell differentiation in the absence of cell 
proliferation, demonstrating its role in the regulation of airway epithelial transdifferentiation (Park 
et al., 2007). This was associated with enhanced expression of genes regulating goblet cell 
differentiation and protein glycosylation, including forkhead box A3 (FOXA3) and anterior gradient 
2 (AGR2). Levels of SPDEF and FOXA3 were increased in mouse goblet cells after sensitization 
with pulmonary allergen, and the SPDEF and FOXA3 proteins were colocalised in goblet cells 
lining the airways of patients with chronic lung diseases (Chen et al., 2009).  
 
1.5.4 Regulation of mucin production 
Increased production of airway cell surface and gel-forming mucins by mucosal epithelial cells can 
be stimulated by adherence of probiotic bacteria and microbial products to assist clearance of 
pathogens. Expression and production of mucins can also be upregulated by inflammatory 
cytokines including IL-1(Gray et al., 2004), IL-4 (Dabbagh et al., 1999), IL-6 (Neveu et al., 
2009), IL-9 (Reader et al., 2003), IL-13 (Zhen et al., 2007), TNF-(Delmotte et al., 2001), nitric 
oxide (Song et al., 2007), neutrophil elastase (Zhou et al., 2013), and other uncharacterised 
inflammatory factors, which might contribute to pathogenesis in human inflammatory airway 
disorders. However, if the increased production of mucin proteins is not resolved, it may become 
pathogenic and contribute to the pathogenesis of human inflammatory airway disorders. 
 
1.5.5 Mucins and airway diseases 
Overproduction of airway mucus is a common problem in many airway diseases including 
bronchiectasis, CF and COPD. Assessment of bronchial biopsies showed larger goblet cell size and 
number in smokers than healthy individuals with an increase in the volume of stored mucin in the 
epithelium per surface area of basal lamina. Stored mucin was significantly higher in the subgroup 
of smokers with airflow obstruction and correlated with FEV1/FVC. The highest epithelial mucin 
stores were found in smokers with airflow obstruction, suggesting a mechanistic link between 
epithelial mucin dysregulation and airflow obstruction (Innes et al., 2006). The composition of 
airway mucus is altered in disease states, with increases in MUC5AC and a low-charge isoform of 
11 
 
MUC5B reported in asthma and COPD (Kirkham et al., 2008; Kirkham et al., 2002). These changes 
in mucin composition were correlated with lung function and airflow obstruction in COPD subjects 
and smokers (Innes et al., 2006; Kirkham et al., 2008; Kirkham et al., 2002). Although there is an 
increase in mucin-producing cells in pathological conditions, immunohistochemistry has shown that 
there is no major change in the cellular distribution of MUC5AC and MUC5B. It is believed that 
these changes in MUC5AC and MUC5B mucin production could have deleterious consequences for 
the mucus gel matrix if they disturb the optimal physiology of the gel and render epithelial cells 
more vulnerable to airborne pathogens. Alternatively, these changes may represent a protective 
response.  
 
In IPF subjects, the distal airway contains pseudostratified mucocilary epithelium that express 
MUC5B (Seibold et al., 2013). A common polymorphism in the promoter of MUC5B, rs35705950, 
has been linked to idiopathic pulmonary fibrosis and other interstitial lung diseases. (Hunninghake 
et al., 2013; Seibold et al., 2013; Seibold et al., 2011). This specific allele frequency was 4 times 
higher in IPF than in population controls, and in the healthy subjects, this allele was linked to 
increased MUC5B gene expression in lung tissue. However, in IPF subjects, this genetic variant was 
associated with improved survival, suggesting that this genetic variant could contribute to a 
subgroup of IPF with relatively low severity phenotype (Peljto et al., 2013). These findings suggest 
that dysregulated MUC5B expression could be involved in the pathogenesis of IPF, and mucin 
production could be switched on in cell types that do not usually produce mucins. These may 
further lead to malfunction of protein production in the endoplasmic reticulum, which will be 
further discussed in Chapter 1.7. 
 
Little is known about functional differences between MUC5AC and the two isoforms of MUC5B, 
which are likely to represent two differing glycosylation states of MUC5B possibly as a 
consequence of two different cells of origin (Schulz et al., 2007; Xia et al., 2005).  Recent studies in 
mouse models suggest that Muc5b is essential in airway defence, and overexpression of Muc5ac 
may have a protective role against influenza infection (Ehre et al., 2012; Roy et al., 2013). 
Deficiency of Muc5b leads to impaired mucociliary clearance, accumulation of apoptotic 
macrophages and high mortality upon infection in older mice, emphasising its crucial roles in 
airway host defence (Roy et al., 2013). Therefore, although controlling mucus overproduction and 
mucin hypersecretion might be beneficial to patients with chronic airway disease, the essential 
functions of Muc5b suggest that targeting to inhibit mucin secretion may not be suitable. Moreover, 
the mouse is not an ideal model for airway disease research as the anatomy of the lung is different 
from the human, the cell types that produce mucins are different, and the inflammatory response is 
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also distinct (Liu et al., 2006; Persson, 2002). In the human, it is not known if MUC5AC and the 
different variants of MUC5B form gels with different transport and other functional properties or 
whether the mucins are mixed within a single gel or form distinct sublayers within the gel. Both the 
total quantity of mucin secretion and the relative abundance of cell surface and secreted mucins can 
change during chronic inflammation, and mucus hypersecretion is one of the clinical features of 
bronchiectasis. However, the relative abundance of different mucin glycoproteins in bronchiectatic 
airways has not been characterised.  
 
1.6 Airway inflammation and remodelling     
Many chronic respiratory conditions, including bronchiectasis, CF and COPD, are associated with 
long-term recurrent airway inflammation. When pathogens enter the airway lumen, they activate the 
immune response on the airway epithelium, resulting in release of inflammatory chemokines and 
cytokines which exacerbate local cellular inflammation. In bronchiectasis, neutrophilic 
inflammation plays a major role; adaptive T-cell mediated immunity including Th1, Th2 and Th17 
responses also contribute to immunopathology. Prolonged inflammation further leads to 
remodelling of the airways, with airway scarring secondary to chronic inflammation a key feature 
of bronchiectasis. The scarred airway wall is characterised by the loss of elasticity and increased 
airway smooth muscle hyperplasia and hypertrophy, as seen in children with chronic inflammatory 
lung diseases that include CF, asthma, and bronchiectasis (Regamey et al., 2008).  
 
1.6.1 Neutrophilic inflammation 
Neutrophils, an important component in innate immunity, are thought to be the most prominent cell 
type involved in the inflammatory process in bronchiectasis. Upon infection, neutrophils are 
recruited into the airway lumen mediated by pro-inflammatory cytokines including IL-1, IL-8, 
TNF- and LTB4 (Zheng et al., 2001). Activated neutrophils in the airway wall stimulate release of 
elastase and recruitment of macrophages and lymphocytes into the airway lumen, which slows cilial 
beating frequency, disrupts mucus secretion and causes structural changes in the airway wall 
(Amitani et al., 1991). Under normal conditions, neutrophilic inflammation is resolved by apoptosis 
of neutrophils, which are then removed by macrophages using a phagocyte recognition mechanism. 
When this apoptosis clearance mechanism does not happen efficiently, neutrophils are removed by 
mucociliary clearance, which leads to release of protease and chemoattractants, and eventually 
cause structural changes in the airway wall. Many inflammatory mediators are involved in the 
regulation of neutrophil recruitment, including cytokines produced from the Th17 immune response 
(Laan et al., 1999; Stoppelenburg et al., 2013). 
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1.6.2 Th17 pathway 
Th17 cells are a class of CD4+ T cells producing IL-17A, and potentially other related cytokines 
including IL-22, IL-17E (IL-25) and IL-17F, induced to deal with extracellular pathogens. IL-17A 
is a pro-inflammatory cytokine made by CD4+ T cells that regulates both granulopoiesis and 
recruitment of neutrophils into sites of inflammation through induction of CXC chemokines and 
regulation of the expression of G-CSF (Ye et al., 2001). IL-6 and TGF- were found to induce 
naïve T cells to produce IL-17 (Bettelli et al., 2006). The IL-17 producing cells can be generated in 
vitro with IL-23 and arise independently of Stat4 and Stat6 which are critical for the generation of 
Th2 and Th1 cells, respectively. In humans, Th17 cell development seems optimal in the presence 
of TGF- and IL-1 with either IL-21 or IL-23. Interestingly, products of Th1 cells such as IFN- 
or of Th2 cells such as IL-4 suppress the development of IL-17 producing T-cells (Harrington et al., 
2005; Park et al., 2005). On the other hand, whether Th17 cells may be suppressive or enhancing of 
other Th cells is still debatable, and controversial findings have been shown in different models. IL-
17 decreased ongoing Th2 cytokine production, eosinophil recruitment and chemokine expression 
in vivo and modulated the activity of dendritic cells in vitro. However, IL-17A also enhances IL-13 
production, which further promotes excessive mucus production in a RSV-infected murine model 
(Kallal et al., 2010). In the respiratory airway, IL-17A and IL-17F both regulate neutrophil 
migration and macrophage inflammation in the lung (Alcorn et al., 2010), and is often associated 
with immune responses against extracellular pathogens such as P. aeruginosa (Tiringer et al., 
2013). 
 
1.6.3 Matrix metalloproteinases (MMPs) 
The airway remodelling process involves excess matrix synthesis along with distorted deposition of 
that matrix. Matrix metalloproteinases (MMPs) that mediate the major part of the tissue destruction 
in chronic inflammatory diseases are important proteases involved in chronic airway tissue 
remodelling. MMPs are secreted by almost all cell types including activated macrophage, 
neutrophils, fibroblasts, and epithelial cells. They are capable of degrading almost all extracellular 
matrix (ECM) and basement membrane components including collagen, fibronectin, and elastin. 
The fine balance of MMPs and their natural inhibitors, tissue inhibitors of metalloproteases 
(TIMPs), determines how a tissue injury is healed and whether fibrosis will take place. Other than 
their roles in tissue remodelling, MMPs are also involved in modulation of inflammation and innate 
immunity (Parks et al., 2004). Their roles in activation of anti-microbial molecules (Ouellette and 
Selsted, 1996), activation of inflammatory cytokines (Gearing et al., 1994; Schonbeck et al., 1998), 
enhancement or inactivation of chemokine activities (Li et al., 2002; McQuibban et al., 2000), and 
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regulation of cell-surface mucin shedding (Thathiah and Carson, 2004) further emphasise their 
importance in modulating chronic airway inflammation. 
 
1.6.4 Inflammation and remodelling in bronchiectasis 
Patients with stable bronchiectasis display an increased percentage of neutrophils in 
bronchoalveolar lavage fluid (BALF), and higher concentrations of elastase, myeloperoxidase, 
TNF-, IL-8, and IL-6 in BALF (Angrill et al., 2001). Bronchial biopsies also show significantly 
higher neutrophil, macrophage and TNF--positive cell densities in the lamina propria of 
bronchiectatic airways compared to control airways. Neutrophil density is negatively correlated 
with percent-predicted FVC among patients with bronchiectasis, suggesting that airway 
macrophages could contribute to neutrophil influx into airway walls through their production of 
TNF-(Zheng et al., 2001). Other studies demonstrated using sputum samples also showed similar 
findings. Spontaneously expectorated sputum showed high levels of elastase (Stockley et al., 1984; 
Tsang et al., 2000), IL-8 (Richman-Eisenstat et al., 1993) and TNF-(Shum et al., 2000), and 
sputum elastase concentration correlated with predicted FEV1/FVC, leucocyte output and sputum 
purulence. Histopathology of bronchiectasis is characterized by intense cellular infiltrates within the 
bronchial mucosa, comprising both neutrophilia and increased numbers of CD8+ lymphocytes, 
predominantly just beneath the basement membrane, though intraepithelial and submucosal 
infiltration are also seen. Cell mediated recruitment of neutrophils by chemotactic cytokines is 
mediated by IL-8 (Eller et al., 1994; Silva et al., 1989). Higher numbers of IL-17-positive cells were 
also found in endobronchial biopsies of non-CF bronchiectasis children undergoing pulmonary 
exacerbation (Tan et al., 2011). Th17 immunity in adult  bronchiectasis has not been reported so far, 
however, elevated levels of IL-17A and IL-17F were measured in BALF and sputum of adult CF 
patients undergoing pulmonary exacerbation, and IL-23 was elevated in sputum (McAllister et al., 
2005).  
 
The progressive bronchial dilatation in bronchiectasis is most likely due to continued airway matrix 
destruction. Protease activities in the airways have been linked to bronchiectasis disease progression 
and disease severity (Bergin et al., 2013; Sly et al., 2013). Increased MMP9 concentration and 
activity in the airway after IL-17 stimulation further suggested that Th17 immunity may play a role 
in chronic airway inflammation (Prause et al., 2004). Significantly higher densities of MMP-8 and 
MMP-9 positive cells are present in the lamina propria of bronchiectatic tissues compared to 
controls (Zheng et al., 2002). Overexpression of neutrophil MMPs in bronchiectatic airways may 
explain the continuation of airway destruction in bronchiectasis. Although MMPs have been shown 
to be elevated in patients with bronchiectasis, the process and the specific cells involved in the 
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destruction of airway cartilage and development of bronchiectasis are still yet to be investigated 
(Dubin et al., 2007). A subgroup of MMPs, membrane-type MMPs (MT-MMPs) with 
transmembrane domains, are bound to the cell membranes. MT-MMPs consist of five enzymes 
including MT1-MMP, and are capable of activating other MMPs. The MT1-MMP/MMP-2 cascade 
is present and active in asthma and bronchiectasis (Maisi et al., 2002).  
 
1.7 Endoplasmic reticulum (ER) stress 
The endoplasmic reticulum (ER) is important for both calcium homeostasis and is responsible for 
the initial steps of biosynthesis of secretory pathway proteins including N-glycosylation, disulfide 
bond formation, other posttranslational modifications and some aspects of protein quality control, 
which ensures newly-made proteins are suitable for function on the cell surface or secretion. A 
range of chaperones and enzymes resident with the ER are essential for correct protein folding. 
These chaperones disengage from proteins once the correct conformation is achieved. When an 
excess of unfolded protein is present, or intracellular Ca2
+
 levels are disturbed, the unfolded protein 
response (UPR) is triggered. As a result of the UPR, homeostasis is achieved by decreased 
translation, upregulation of ER chaperones and other molecules associated with productive folding 
(ERAF), and increased degradation of misfolded protein (ERAD) (McGuckin et al., 2010).  
 
Many factors may contribute to increased rates of misfolding, including increased rates of protein 
synthesis, missense polymorphisms in individual proteins, energy depletion, osmotic stress, viral 
infection, and increased temperature. Prolonged ER stress can eventually lead to inflammatory 
signalling and premature apoptosis. The UPR has been linked to the pathogenesis of diabetes, 
inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, and some respiratory 
conditions including CF (Bartoszewski et al., 2008; Kerbiriou et al., 2007), COPD (Malhotra et al., 
2009), asthma (Cantero-Recasens et al., 2010), and IPF (Korfei et al., 2008; Lawson et al., 2008). 
 
The secreted mucin glycoproteins are large in size, contain highly folded cysteine-rich domains 
containing multiple intra- and inter-molecular disulphide bonds formed in the ER and therefore 
present a substantial challenge for correct folding in the ER. ER stress occurs when proteins misfold 
during biosynthesis, and goblet cell ER stress can occur during inflammation and could thus be a 
feature of airway diseases, especially those involving mucus hypersecretion. Goblet cell ER stress 
has been demonstrated in a mouse model, in which aberrant mucin biosynthesis in gut epithelial 
goblet cells leads to an inflammatory bowel disease phenotype (Heazlewood et al., 2008). 
Mediators that can induce ER stress in the gut and airway epithelial cells include oxidative stress 
and pro-inflammatory cytokines (Anjos et al., 2012; Hao et al., 2012). It is logical to suspect that 
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the large demand of mucin glycoprotein production and the inflammatory environment in 
bronchiectatic epithelial cells could result in ER stress, which further leads to inflammatory 
signalling and non-resolving inflammation. Furthermore, the MUC5B promoter polymorphism 
appears to switching on mucin production in cells that lack the well developed ER and necessary 
accessory molecules to produce mucin, potentially leading to mucin misfolding and ER stress 
(Seibold et al., 2013).  
 
1.8 Bronchiectasis treatment using macrolide antibiotics 
Macrolide antibiotics including azithromycin, clarithromycin and erythromycin have been used 
worldwide in treating pulmonary infections for more than 50 years.  Increasing use of macrolide 
antibiotics has seen the emergence of macrolide-resistant microorganisms, which threatens the 
effectiveness of this class of antibiotics (Dias and Canica, 2004; Malhotra-Kumar et al., 2007). 
Development of macrolide resistance associated with azithromycin use is likely to be related to its 
long half-life (up to 70 h) and intracellular accumulation (up to 100 times serum levels), which 
allow for longer periods of sub-inhibitory concentrations. Erythromycin, on the other hand, has the 
benefits related to intracellular accumulation (up to 20 times extracellular levels) (Martin et al., 
1985), and has a half-life of only 1.4 hours. Erythromycin is less likely to develop macrolide 
resistant Streptococci strains comparing to Azithromycin or Clarithromycin, and is a relatively 
cheaper drug. Evidence suggests that prophylactic antibiotics are associated with a reduction in 
symptoms including purulent sputum production, however no significant effect upon lung function 
or frequency of exacerbations (Evans et al., 2007).  
 
A pilot study suggested prophylactic oral erythromycin may be useful in preventing infective 
exacerbations in patients with bronchiectasis. Sixteen subjects with proven non-CF bronchiectasis 
showed erythromycin therapy was associated with a 50% reduction in frequency of exacerbations 
and a 52% reduction in total days of antibiotics (Serisier and Martin, 2011). Data from this study 
were used to power a definitive randomized, double-blind, placebo-controlled control trial of 
prophylactic oral erythromycin in bronchiectasis, the Bronchiectasis and Low-dose Erythromycin 
Study (BLESS), led by Dr. David Serisier at the Mater Adult Hospital. Diverse aspects of both 
clinical and scientific knowledge were incorporated into this study, including monitoring of lung 
function, bacterial profiling, histopathological scoring and evaluation of immune-modulatory 
markers. Clinical outcomes of the BLESS study show fewer pulmonary exacerbations, preservation 
of lung function and reduced sputum volume with erythromycin therapy (Serisier et al., 2013).  
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1.8.1 Erythromycin 
Erythromycin is a 14-membered lactone ring macrolide antibiotic commonly used in respiratory 
tract infections. It was first isolated from a strain of Streptomyces erythreus in 1949 and has an 
antimicrobial spectrum similar to penicillin but with better coverage of atypical organisms including 
mycoplasma species. The most frequent adverse reactions of erythromycin are gastrointestinal 
symptoms including nausea and diarrhoea. Cardiac arrhythmias and hearing loss may occur when 
administered in high dosages. No evidence is available concerning the incidence of ototoxicity 
during long-term erythromycin use at lower doses. Emerging evidence shows that macrolide 
antibiotics have a diverse range of anti-inflammatory and immunomodulatory effects in respiratory 
diseases, including CF and diffuse panbronchiolitis (DPB).  
 
1.8.2 Immunomodulatory effects of erythromycin 
Immunomodulatory effects are seen exclusively with the 14- and 15- membered ring macrolides, 
which include erythromycin (EM), azithromycin (AZM), clarithromycin, and roxithromycin 
(derived from erythromycin) (Altenburg et al., 2010; Borszcz et al., 2005; Kanai et al., 2004; 
Shimizu and Shimizu, 2012; Shinkai et al., 2007; Tanabe et al., 2011). Erythromycin, in vitro, 
inhibits neutrophil migration (Kadota et al., 1993) and oxidative burst (Abdelghaffar et al., 1997), 
inhibits neutrophil elastase activity (Gorrini et al., 2001), modulates inflammatory cytokine release 
from epithelial cells (importantly reducing IL-8 expression and release) (Takizawa et al., 1997), 
reduces adhesion of neutrophils on endothelial cells induced by H. influenzae endotoxin (Khair et 
al., 1995), reduces P. aeruginosa activity and biofilm formation (Yanagihara et al., 2002), and 
reduces goblet cell mucus hypersecretion (Shimizu et al., 2003). Thus many diverse mechanisms of 
action have been proposed to underlie therapeutic efficacy of macrolides in chronic respiratory 
diseases. 
 
Long-term low-dose erythromycin treatment was first tested as a therapy for inflammatory airway 
disease by Kudoh et al. in 1987, showing improved clinical symptoms in diffuse panbronchiolitis 
(DPB).  A larger subsequent trial of 500 DPB patients showed a significant improvement in 5 year 
survival (Kudoh et al., 1998). Uncontrolled studies of erythromycin therapy in DPB patients have 
shown reductions in BALF neutrophil counts, neutrophil elastase activity (Ichikawa et al., 1992), 
and -defensin and IL-8 levels (Ashitani et al., 1998).  
 
1.8.3 Macrolide clinical trials in non-CF bronchiectasis 
A few small randomised controlled trials investigating the efficacy of macrolide antibiotics in non-
CF bronchiectasis have been carried out in the last decade, suggesting improved clinical parameters 
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and/or decreased production of inflammatory cytokines. Tsang et al. performed a double blind 
placebo-controlled study with 21 non-CF bronchiectasis patients, administering low-dose 
erythromycin (500 mg twice daily) for 8 weeks (Tsang et al., 1999). This study showed significant 
improvement in lung function (FEV1 and FVC) and reduced 24 hour sputum volume, but no 
parallel reduction in microbes cultured from sputum (P. aeruginosa, H. influenza, S. pneumonia, S. 
aureus and Gram-negative bacilli), sputum leukocyte counts and inflammatory cytokine 
concentrations (IL-1, IL-8, TNF-, or LTB4).  In another randomised controlled trial of 34 
children with non-CF bronchiectasis using clarithromycin (15 mg/kg daily) no improvement in 
pulmonary function was seen, but a significant decrease in IL-8 levels, total cell count, neutrophil 
ratios in BALF and daily sputum production was observed (Yalçın et al., 2006). However, the 
control group did not receive a placebo and a baseline difference in severity of inflammation and 
sputum volume was present between the two study groups, making it difficult to accept these 
results. Another double-blinded placebo-controlled study using low-dose roxithromycin (4 mg/kg 
twice daily) in 25 children with non-CF bronchiectasis for 12 weeks also showed no change in 
pulmonary function, but a significant reduction in sputum purulence and sputum leukocyte score 
after treatment (Koh et al., 1997).  
 
Most randomised controlled trials investigating the efficacy of macrolide antibiotics in non-CF 
bronchiectasis show a positive influence on lung function, sputum volume, and inflammation but 
are limited by study design, small numbers of patients, brief duration and use of differing 
macrolides. There are also variations in the parameters assessed for each sample type, and a 
frequent inability to correlate molecular findings with clinical outcomes. The potential effect of 
macrolide maintenance therapy on lung function and inflammation remains uncertain. Assessment 
of both clinical features and inflammatory markers in a larger sampling group with longer treatment 
period is required to identify the efficacy of long-term low-dose macrolide treatment in 
bronchiectasis. 
 
Recently, three large randomised controlled trials reported on the clinical benefits of macrolides in 
non-CF bronchiectasis subjects. The BLESS study randomised 117 bronchiectasis subjects to 
receive 400 mg erythromycin ethylsuccinate or placebo twice daily for 48 weeks (Serisier et al., 
2013). The BAT study randomised 83 bronchiectasis subjects to receive 250 mg azithromycin or 
placebo daily for 12 months (Altenburg et al., 2013). The EMBRACE study randomised 141 
bronchiectasis subjects to receive 500 mg azithromycin or placebo three times a week for 6 months 
(Wong et al., 2012). All three studies showed reduced numbers of protocol defined pulmonary 
exacerbations with long-term, low-dose azithromycin or erythromycin. These studies also 
19 
 
demonstrated other clinical and non-clinical benefits including improved lung function (increase in 
FEV1% predicted in the BLESS trial and the BAT trial, and increased post-bronchodilator FVC in 
the EMBRACE study), reduced 24 hour sputum volume (BLESS), reduced serum CRP 
(EMBRACE), reduced white blood cell count (EMBRACE), and improved quality of life scores 
(BAT). In the BLESS trial in particular, subjects with more severe bronchiectasis derived 
significant clinical benefits from long-term, low-dose erythromycin. However, these benefits are at 
the cost of an increased proportion of macrolide-resistant respiratory pathogens (BLESS and BAT; 
EMBRACE lacks microbiology data). So far, no mechanistic analyses have been published from 
the BAT or the EMBRACE trials to help demonstrate how long-term, low-dose macrolides achieve 
efficacy in non-CF bronchiectasis. 
 
1.9 Experimental directions 
Compared to other respiratory diseases, there are relatively limited data characterising the nature of 
non-CF bronchiectasis. Although CF patients develop bronchiectasis, and COPD patients also 
suffer from chronic airway inflammation, the underlying causes of disease, symptoms and course of 
disease differ from bronchiectasis. To date, there are no studies that link the histopathology of the 
bronchial mucosa with markers of inflammation within the airways, and relatively little direct 
information on the determinants of mucin and mucus production by respiratory epithelium in 
bronchiectasis. No study in bronchiectasis has compared inflammatory mediators measured in 
induced sputum against the BALF in parallel to validate their roles in understanding airway 
inflammation. Considering that sputum is a much more accessible specimen derived by a non-
invasive, low risk procedure, the validation of using sputum specimens for research has the 
potential to increase participation and provide access to a larger number of specimens.  In addition, 
no previous studies have evaluated the effect of therapy upon measures of inflammation or infection 
in BALF, and none have assessed within-patient variability of these measures.  
 
Some key knowledge gaps in bronchiectasis pathophysiology which this thesis attempts to address 
include: 
 What is the inflammatory pattern in non-CF bronchiectasis at its disease stable stage (that is 
not during infectious exacerbation)?  
- Other than the neutrophilic inflammation previously characterised in non-CF 
bronchiectasis, what arms of innate and adaptive inflammatory responses are activated? 
- Are specific inflammatory mediators associated with specific characteristics of the 
disease phenotype and disease progression?  
- Can inflammatory biomarkers predict disease progression?   
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- Are specific elements of the inflammatory response good potential targets for disease 
treatment? 
 Is mucus hypersecretion in bronchiectatic airways characterized by changes in the relative 
abundance or characteristics of specific mucin glycoproteins, or simply hypersecretion of 
normally constituted mucus? If there are changes in mucus constituency, could the 
dysregulated mucin production lead to altered mucus quality resulting in aberrant 
mucociliary clearance perpetuating infection and inflammation? 
 What are the effects of long-term macrolide therapy upon measures of inflammation or 
infection in subjects with bronchiectasis? 
- Can a subgroup of patients with bronchiectasis that have a better response to macrolide 
therapy be defined? 
 
This study evaluates the influence of long-term erythromycin therapy upon cellular constituents that 
influence airway mucus production. Bronchial biopsies were evaluated for localisation of mucins 
within bronchial epithelium. Bronchial biopsy RNA was extracted for qRT-PCR analysis of 
inflammatory, mucin, and tissue remodelling gene expression. The BALF specimens enable a much 
more thorough exploration of the link between histopathology and bronchial luminal mediator 
activity, as well as allowing the validation of inflammatory mediator assessments in concurrently 
obtained induced sputum specimens against these measures. Data from this study was compared to 
a group of normal controls to allow further characterisation of these abnormalities in this disease 
group. 
 
1.10 Hypothesis 
This thesis addresses the following hypotheses: 
1. The Th17 pathway is an important inflammatory pathway in bronchiectatic airways that 
contributes to the pathophysiology of bronchiectasis. 
The Th17 immune response is activated in response to extracellular pathogens which are 
abundant in the bronchiectatic airways, and will promote neutrophil recruitment and 
activation and remodelling of the airway wall. 
2. Abnormal airway mucin production contributes to dysregulated mucociliary clearance in 
bronchiectatic airways. 
Production and secretion of airway mucin glycoproteins can be induced by the 
inflammatory cytokines and pathogenic microbes characteristic of bronchiectatic airways. 
Both increased mucin secretion and altered relative abundance of individual mucins in 
mucus could contribute to aberrant mucociliary clearance.  
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3. ER stress occurs in epithelial secretory cells in bronchiectatic airways. 
Airway gel-forming mucins are large complex proteins which present a substantial 
challenge for correct folding in the ER. Increased mucin biosynthesis and oxidative stress 
due to inflammatory cytokines and local reactive oxygen species released by neutrophils are 
likely to increase mucin misfolding in bronchiectatic airways. ER stress in airway mucin 
producing cells could increase chemokine production, thus perpetuating airway 
inflammation.  
4. Activation of proteases involved in tissue remodelling is associated with disease progression 
in bronchiectasis. 
Dilated airways in subjects with bronchiectasis are the result of tissue remodelling. 
Neutrophil elastase, an important mediator in tissue remodelling, has been identified as a 
marker for development of bronchiectasis in children with cystic fibrosis. Production of 
neutrophil elastase and matrix metalloproteinases could promote disease progression in 
adult bronchiectasis.  
5. Long-term low-dose oral erythromycin reduces inflammation, alters the volume of mucus 
production, and the relative abundance of secreted mucins in sputum in patients with 
bronchiectasis. 
Anti-inflammatory properties of macrolide antibiotics, including reduction in neutrophilic 
inflammation and reduction in mucin production, have been shown in chronic respiratory 
diseases and in in vitro cell cultures. If clinical responses to macrolides in bronchiectasis 
are due to these anti-inflammatory functions decreased inflammation should be evident in 
responding patients. 
 
1.11 Aims 
The hypotheses were addressed via the following aims: 
1. To characterise the nature of inflammation and the potential role of Th17 immune response 
in bronchiectasis by comparing inflammatory markers in bronchiectatic versus normal 
airways. 
2. To characterise bronchiectatic airway mucus producing cells and mucin production by 
measuring the expression of transcription factors regulating respiratory secretory cells and 
the relative abundance of individual mucin glycoproteins in bronchiectasis versus the 
normal airways. 
3. To characterise the potential role of ER stress in bronchiectatic epithelium by measuring the 
expression of markers of ER stress, ERAD and the UPR in bronchiectatic versus normal 
airways. 
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4. To identify the potential role of tissue remodelling in bronchiectasis pathophysiology and 
progression by linking levels of protease activities with clinical measurements of airway 
function and histological pathophysiology in bronchiectatic airways. 
5. To explore the anti-inflammatory effects of long-term low-dose erythromycin treatment in 
the BLESS trial by determining the change in inflammatory mediator concentrations after 
the treatment.  
6. To identify potential intrinsic epithelial defects in bronchiectatic epithelial cells by 
characterising chemokine production, mucin production and ER stress in human bronchial 
epithelial cells from bronchiectatic vs healthy subjects cultured in vitro. 
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Chapter 2 General methodology 
2.1 General plan 
This project involves a wide range of cell and molecular biology techniques to assess inflammatory 
patterns implicated in bronchiectasis. The project is based around the BLESS trial in which 117 
patients with bronchiectasis were recruited for a double-blinded randomised trial of placebo versus 
the macrolide antibiotics erythromycin (Serisier et al., 2013). 400 mgs oral erythromycin or placebo 
were administered twice daily for 48 weeks in subjects with proven non-CF bronchiectasis, 
followed by a 4 week washout of the drug (Figure 2.1). Clinical features were assessed at 9 visits 
during the 12 month trial period as described in Figure 2.1. Sputum samples were collected on 
visits 1, 2, 5, 8 and 9. Bronchial biopsies and bronchoalveolar lavage fluid (BALF) were collected 
in a subset of bronchiectasis patients (20 from each erythromycin and placebo group) on visits 1, 2 
and 8. Outside of the trial, 20 individuals without pulmonary disease were recruited as normal 
controls, and bronchial biopsy, BALF and induced sputum samples were obtained from each 
volunteer at one time point. 
 
 
Figure 2.1. Timeline for each sampling visit during the BLESS trial 
 
A broad range of measurements were generated within this trial, including lung function, sputum 
rheology, sputum bacterial community profiling, sputum mucin content and inflammatory response 
in relation to long-term low-dose erythromycin treatment. This project focused on characterizing 
both the degree and pattern of inflammation, and relative levels of secreted mucin production using 
a range of techniques. Expression of transcription factors regulating differentiation of respiratory 
secretory cells, mucin glycoproteins, key genes related to inflammation, fibrosis, angiogenesis and 
ER stress were assessed by qRT-PCR. Cytokine measurements were performed on the BALF using 
Luminex bead assays to assess levels of key inflammatory cytokines. Production of mucin 
glycoproteins was assessed by immunohistochemistry of bronchial biopsies and Western blotting of 
mucins extracted from sputum. In vitro cell culture using healthy and bronchiectatic bronchial 
epithelial cells was carried out to further understand the response of these cells to inflammatory 
factors found in the bronchiectatic airways. These data were able to link back to the clinical 
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assessments (eg. St. George’s respiratory questionnaire, pulmonary function test and assessment of 
quality of life) and results acquired from other parts of the study (eg. sputum rheology and sputum 
bacterial community profiling) in order to illuminate the pathogenesis of bronchiectasis, and 
illustrate the effect of maintenance low dose erythromycin in patients with bronchiectasis. 
 
2.2 Ethics 
This research was approved by the Mater Health Services Human Research and Ethics Committee. 
Under the approval for project number 1244a, for this study we were permitted to collect 
bronchoscopic tissue samples, sputum and BALF from patients attending the Mater Adult Hospital 
Department of Respiratory Medicine for treatment of bronchiectasis. After discussion with the trial 
supervisor, each patient gave informed consent.  All study samples were completely de-identified 
immediately after collection and all laboratory determinations were made blind to the diagnosis and 
treatment.  
  
2.3 Subjects and procedures  
At baseline, all 117 subjects enrolled in the BLESS study had induced sputum collected and a 
subgroup of 41 subjects with no evidence of additional (non-bronchiectasis) chronic respiratory 
disease underwent bronchoscopy with bronchoalveolar lavage (BAL) and endobronchial biopsy. 
Twenty healthy control subjects also underwent sputum induction and bronchoscopy. Sputum and 
bronchoscopy procedures were repeated at week 48 with results from subjects in the placebo arm 
presented here. All control and bronchoscopy subgroup subjects were lifelong non-smokers (<2 
pack year history), aged 18-85 years, with no history of asthma or atopy, recent respiratory tract 
infection (within 4 weeks) or conditions with the potential to impact the safe performance of 
bronchoscopy.  
 
Sputum induction with 4.5% hypertonic saline was performed between 48 h and 5 days prior to 
bronchoscopy, using methods previously described (Rogers et al., 2010). Induced sputum 
specimens were aliquoted, one aliquot placed on ice immediately and transferred for inflammatory 
cell count processing within 60 min and the remaining aliquots rapidly frozen at -80⁰ C. 
Bronchoscopy was performed as an outpatient procedure under conscious sedation. After the 
application of lignocaine to the airways, BAL was first performed in the right middle lobe and then 
endobronchial biopsies collected from subsegmental carinae of the lower lobes. BALF samples 
were placed on ice and processed immediately following the procedure (Full details in Appendix 1). 
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2.4 Samples     
2.4.1 Endobronchial biopsies 
Endobronchial biopsies were collected during bronchoscopy for RNA extraction and for 
histological analysis. Two endobronchial biopsy specimens for RNA extraction were immersed in 
RNAlater solution (Life Technologies, Carlsbad, CA) immediately. The tubes were stored at 4C 
for at least 24 h before removal of the biopsy tissue, then stored at -80C prior to RNA extraction. 
Another two biopsies were fixed in 10% formalin, and then embedded in paraffin. These formalin-
fixed biopsies were serial sectioned at 100 m intervals for H&E staining to provide complete 
analysis through all of the biopsy.  
 
2.4.2 Bronchoalveolar lavage fluid 
The BALF samples were delivered to the laboratory on ice immediately post procedure. Two 
aliquots of the crude suspension were snap frozen, and stored at -80C. The remainder of the BALF 
was centrifuged at 500 g for 5 min at 4C, the cell pellets distributed between two eppendorf tubes, 
snap frozen, and stored at -80C prior to RNA and protein extraction. The supernatants were then 
centrifuged at 16,000 g for 10 min at 4C, and the resultant supernatant collected and filtered 
through a 0.2 μm filter syringe before storage at -80C, in aliquots with or without protease 
inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche, Basel, Switzerland).  
 
2.4.3 Induced sputum for detection of inflammatory markers 
Frozen aliquots of induced sputum samples were thawed and then diluted 1 in 4 in PBS on ice, and 
vortexed for 15 s. The sputum samples were then centrifuged at 16,000 g for 10 min at 4C and the 
resultant supernatant collected, protease inhibitor added, and stored at -80C. 
 
2.5 In vitro culture 
2.5.1 Expansion of bronchial epithelial cells in vitro from airway brushings 
Processing of bronchial brushings to generate primary bronchiectatic and healthy control cell 
cultures was performed according to previously described methods for other patient groups. Airway 
brushings were transported back to the laboratory in cool RPMI-1640 media with 20% heat 
inactivated fetal calf serum for immediate processing. Cells were removed from the brush by brief 
vortexing, and then centrifuged at 460 g for 7 min at 4°C. The cell pellet was resuspended in pre-
warmed Basal Epithelial cell Growth Media (BEGM) (LONZA, Basel, Switzerland), supplemented 
with BPE, insulin, hydrocortisone, GA-1000, retinoic acid, transferrin, triiodothyronine, 
epinephrine and hEGF as per manufacturer’s instruction for the human bronchial epithelial cell 
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culture. Further suspension was achieved by passing the cells through a 25G syringe for 4~5 times, 
and then through a 27G syringe for 4~5 times. The entire cell suspension was dispensed into a T-25 
flask with pre-warmed BEGM, 2x penstrep and 2% ultroser G (PALL, Port Washington, NY), a 
serum substitute. Cells were grown in a 5% CO2 humidified atmosphere at 37° C. Once the cells 
reached 80% confluence, they were harvested by trypsinisation or frozen in 10% DMSO, 40% fetal 
calf serum and 50% BEGM for storage in liquid nitrogen for subsequent culture. 
 
2.5.2 Bronchial epithelial cell culture 
Human bronchial epithelial cells purchased from LONZA or established from airway brushings 
were brought back into culture from frozen aliquots. Cells were expanded in BEGM at 37C, 5% 
CO2, humidified incubator, and were harvested and seeded onto transwell inserts when they reached 
80% confluence. Transwell inserts were pre-coated with 0.03 mg/mL collagen by incubating in the 
collagen solution at 37C for 45 min, and then rinsed gently with PBS. 1.5x105 cells/cm2 were 
seeded onto the transwell inserts. 1 mL and 0.5 mL LONZA BEGM was added into the basal and 
apical chambers respectively, and the culture medium was replced with BEGM on the following 
day and then every second day (Figure 2.2). After reaching confluence, cells were maintained for 3 
days before introducing an air-liquid interphase by removing media in the apical chamber and 
replacing basal chamber media with Differentiation Medium (LONZA, Basel, Switzerland), 
supplemented with BPE, insulin, hydrocortisone, GA-1000, transferrin, epinephrine, hEGF, inducer 
from the SingleQuote kit, and 50 nM fresh retinoic acid (Sigma-Aldrich, St Louis, MO). Cells were 
fed with 1mL Differentiation Medium to the basal chamber on every second day for at least 20 days 
before use for experiments. 
 
 
Figure 2.2. Human Bronchial Epithelial Cell Air-liquid interphase (HBEC ALI) culture system. 
Inflammatory cytokines and ER stressors can be added in the media in basal chamber. 
 
Epithelial cells
Collagen matrix
Permeable membrane
Media in basal chamber
Inflammatory cytokines & ER stressors
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2.6 Gene expression 
2.6.1 RNA extraction 
RNA extraction from airway biopsy and BAL cell pellets was performed using an on-column 
method as per the manufacturer’s instruction for the RNeasy RNA Extraction Kit (QIAGEN, 
Hilden, Germany). Extracted RNA were stored at -80⁰C.  
 
2.6.2 RNA quality assessment 
RNA quality was assessed by detecting the 18S and 28S rRNA using electrophoresis method as per 
the manufacturer’s instruction for the Experion RNA StdSens Analysis Kit (Bio-Rad, Hercules, 
CA). 
 
2.6.3 RNA amplification 
Due to low RNA yields from airway biopsies, whole transcriptome amplification was performed as 
per the manufacturer’s instruction for the WT-Ovation RNA Amplification Kit (NuGen, San Carlos, 
CA), and the end product in this protocol was cDNA. 
 
2.6.4 cDNA synthesis 
cDNA synthesis for the non-amplified RNA samples was performed as per the manufacturer’s 
instruction for the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). 1 µg RNA from each 
sample was used as template in each cDNA synthesis reaction. 
 
2.6.5 Gene expression microarray for determination of genes of interest 
A preliminary RNA expression microarray experiment was conducted, in a subset of samples (8 
healthy control and 12 bronchiectasis) with the highest RNA quality, to identify candidate genes 
differentially expressed in bronchiectasis. Gene expression microarrays were outsourced to Dr Sean 
Grimmond’s laboratory (Institute for Molecular Biology, UQ) and Australian Genome Research 
Facility (AGRF) in two batches. 100 ng total RNA was used per reaction analysed using Illumina 
Human HT-12 V4 Expression Beadchips (Illumina, San Diego, CA). Results were analysed using 
Ingenuity Pathway Analysis software to identify target pathways for further study. From these 
candidate genes, a selection of 20 genes (representing either the most consistently highly expressed 
genes in the microarray or genes thought to be important based upon preceding literature) were 
selected for RT-PCR analysis. 
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2.6.6 Reverse transcription polymerase chain reaction (RT-PCR) 
RNA was extracted from biopsies or HBEC, and expression of selected genes was determined using 
the TaqMan detection system as per the manufacturer’s instructions (Microfluidic Cards, Life 
Technologies, Carlsbad, CA). The average CT of three housekeeping genes (2-microglobulin, -
actin and Cyclophilin A) was used for standardization. 
 
2.7 Determination of chemokine, cytokine and growth factor concentrations 
2.7.1 BALF protein concentration 
BALF were concentrated (~10-fold, measured precisely) using a 10 kDa cut-off centrifugal 
concentrator (PALL, Port Washington, NY). Protein concentration was measured using the A280 
measurement on a Nano-drop.  
 
2.7.2 Luminex cytokine array 
We used the Procarta Luminex cytokine and chemokine array which measures IL-1, IL-1, IL-4, 
IL6, IL-8, IL-10, IL-13, IL-17A, IL-23, CXCL5, CXCL10, TNF-, IFN-, Eotaxin, MPO, EGF, 
bFGF, PDGF-BB and VEGF-A (Affymetrix, Santa Clara, CA). The assay detection range was from 
1 to 10000 pg/mL. The assay was carried out as per the manufacturer’s instruction using 50 μL 
concentrated BALF with protease inhibitor (see Chapter 1.4.2). 
 
2.7.3  Enzyme-linked immunosorbent assay (ELISA) for chemokines and cytokines 
IL-8, IL-1, IL-17A, IFN- and TNF- concentrations in induced sputum samples were measured 
using ELISA as per the manufacturer’s instruction (BD Biosciences, San Jose, CA). Different 
dilution factors were applied for each cytokine measurement, and 20 L of induced sputum samples 
were used per reaction. All chemokines and cytokines measurements in induced sputum were 
performed in duplicates to account for variation within the assay and all of these assays were 
performed as batched runs with as many samples as practically achievable in each run to limit inter-
assay variation. 
 
2.8 Myeloperoxidase (MPO) activity assay  
Native MPO reacts with hydrogen peroxide to form the active redox and enzyme intermediate 
compound MPO-I, which oxidizes chloride (Cl
-
) to HOCl. MPO activity in BALF was measured by 
incubating BALF with H2O2 and Cl
-
, and detecting HOCl, the product from MPO chlorination 
activity, as per manufacturer’s instruction for the EnzCheck Myeloperoxidase Activity Assay Kit 
(Life Technologies, Carlsbad, CA).  
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2.9 Human neutrophil elastase activity assay  
Human neutrophil elastase activity was detected by measuring the signal intensity after addition of 
the substrate N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide (Sigma-Aldrich, St. Louis, MO). 
The assay was performed using 50 L diluted induced sputum without protease inhibitor. The 
lowest detection limit for this assay is 0.025 μg/mL. Human neutrophil elastase activity in induced 
sputum assays were performed in duplicate to account for variation within the assay and all of these 
assays were performed as batched runs with as many samples as practically achievable in each run 
to limit inter-assay variation. 
 
2.10 Matrix metalloproteinase activity assay  
SensoLyte Generic MMP detection kit (AnaSpec, Fremont, CA) is able to detect total enzyme 
activity of various matrix metalloproteinases including MMP-1, MMP-2, MMP-7, MMP-8, MMP-
9, MMP-10, MMP-12 using a fluorescent quenching sequence. The assay was performed as per the 
manufacturer’s instructions using 20 L concentrated BALF or 20 L diluted induced sputum 
without protease inhibitor. The lowest detection limit for this assay is 1.56 μM. 
 
2.11 Mucin protein detection 
In order to characterise and quantify the gel-forming mucins (MUC5AC and MUC5B) in induced 
sputum samples, frozen sputum was thawed and solubilised in 10 volumes of ice-cold Extraction 
Buffer (6 M guanidinium chloride with 0.1 M Tris, 5 mM EDTA and freshly added protease 
inhibitor cocktail and 5 mM N-ethylmelamide, pH 8.0) on a roller rotating gently overnight at 4C. 
2 mL solubilised sputum was dialysed vs Dialysis Buffer (6 M urea with 0.1 M Tris and 5 mM 
EDTA, pH 8.0) at 4C using a 10 kDa dialysis membrane (Sigma-Aldrich, St Louis, MO) for 4 h, 
and then overnight (with fresh Dialysis Buffer), followed by one more buffer change for 1 h the 
next morning. To reduce mucin polymers into individual subunit proteins, freshly made 
Dithiothreitol (DTT) was added to a final concentration of 50 mM, followed by incubation at 100C 
for 10 min, followed by alkylation by adding iodoacetamide to a final concentration of 125 mM, 
and then incubation in the dark at room temperature for 20 min.  
 
2.11.1 Agarose gel electrophoresis 
In order to semi-quantify mucin proteins in induced sputum, samples were subjected to 
electrophoresis on agarose gels, and then vacuum transferred onto nitrocellulose membrane 
(Kirkham et al., 2002). 60 µL (for Periodic acid/Shiff’s staining) or 40 µL (for mucin western 
blotting) of sample mixed with 10X Loading Buffer (40 mM Tris-acetate, 1 mM EDTA buffer, 1% 
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SDS, 30% glycerol and 0.002% bromophenol blue) was electrophoresed in a 0.7% agarose gel in 
0.1% SDS in TAE at 10 V overnight (or 16 h). Large format gels were used to maximise the 
number of samples on each gel, and individual inter-gel control samples were included on each gel. 
The agarose gel was vacuum transferred onto nitrocellulose membrane in 4x SSC buffer (0.6 M 
sodium chloride and 0.06 M sodium citrate).  
 
2.11.2 Periodic acid/Schiff’s (PAS) staining on nitrocellulose blots 
After proteins were vacuum transferred onto a nitrocellulose membrane (see Chapter 1.11.1), blots 
were rinsed in distilled water twice before incubating in 1% periodic acid in 3% acetic acid for 30 
min at room temperature. Freshly prepared Wash Buffer (0.1% sodium metabisulfite in 1 mM HCl) 
was used to wash the blot twice for 2 min, and then incubated in Schiff’s reagent for 15 min at room 
temperature, followed by 2 times 2 min washes in Wash Buffer. 
 
2.11.3 Mucin western blotting 
After proteins were vacuum transferred onto a nitrocellulose membrane (see Chapter 1.11.1), blots 
were rinsed in TBS with 0.05% Tween 20 before standard western blotting detection was carried 
out. Blots were blocked with 0.1% casein in TBS with 0.05% Tween 20 (Blocking Buffer). Primary 
antibodies were used at 1:2500 dilution in Blocking Buffer for MAN5AC primary antibody (a gift 
from Dr David Thornton, University of Manchester) and 1:5000 dilution in Blocking Buffer for 
EU-MUC5B primary antibody (Rousseau et al., 2003) were then completed together. Primary 
antibody incubation was carried out at 4⁰C overnight, followed by 4 x 5 min wash in TBST. Li-Cor 
secondary antibodies (a goat anti-rabbit and a goat anti-mouse secondary antibody were used to 
target each MAN5AC and EU-MUC5B antibody) were used at 1:10000 dilution in Blocking 
Buffer, incubated at room temperature for 1 h. Blots were washed 4 x 5 min each in TBST, and then 
2 x 5 min each in TBS. Detection of MUC5AC and MUC5B proteins using an Odyssey Li-Cor 
system (Li-Cor Biosciences, Lincoln, NE).  
 
2.11.4 Periodic acid/Schiff’s (PAS) and Alcian blue staining on histology slides 
Parafilm embedded histology sections were dewaxed in Solv21C twice for 5 min each, followed by 
100% ethanol twice for 5 min, 5 min in 90% ethanol, 5 min in 75% ethanol, and then rinsed in 
distilled water. Slides were first incubated in 3% acetic acid for 3 min, and then Alcian blue for 30 
min, followed by two washes in distilled water for 5 min each time. Slides were then incubated in 
1% periodic acid in 3% acetic acid for 30 min, and then washed with distilled water three times for 
5 min each. Schiff’s reagent was dropped onto the slides for 15 min incubation, and then washed 
with running distilled water for 5 min, followed by Haematoxylin incubation for 1 min. Running 
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distilled water was used to wash the slides for 5 min before dehydrating the slides in 70% ethanol 
for 5 min, 5 min in 90% ethanol, 100% ethanol twice for 5 min each, and then in xylene twice for 5 
min each. D.P.X. was used to mount the slides. 
 
2.11.5 MUC5AC and MUC5B immunohistochemistry staining 
Paraffin embedded histology sections (4 µm) were mounted on Super Frost Plus slides and dried at 
60⁰C for 1 h. Immunohistochemistry (IHC) was performed using a Ventana Benchmark Ultra 
staining system (Ventana Medical System, Oro Valley, AZ). Antigen retrieval was achieved using 
Ventana HIER with CC1 for 64 min at 95⁰C. The MAN5AC primary antibody and EU-MUC5B 
primary antibody were diluted 1/1000 and incubated at 37⁰C for 32 min. A score from 0 to 4 was 
given to each biopsy according to its number of mucin positive cells per goblet cell or sumbucosal 
gland. A score of “1” was given to biopsies with 1-25% mucin positive cells or glands, 26-50% was 
given a “2”, 51-75% was given a “3”, and 76-100% was given a “4”.  
 
2.12 Statistics analysis 
Data analysis for the BLESS study including sample size calculations are as described previously 
(Serisier et al., 2013). Data distribution was mostly non-parametric and Mann-Whitney U tests were 
used to test the significance of variance between control and disease groups, or Kruskal-Wallis test 
where 3 or more groups were compared. Correlations were calculated using Pearson’s correlation 
coefficient after log-transformation of continuous data or Spearman rank correlation coefficient for 
discrete variables. A multiple regression model incorporating various clinical measurements and 
inflammatory markers was not achievable due to limited sample size in the bronchoscopy subgroup. 
Statistical analyses were performed using SYSTAT software (version 3.1), were 2-sided and p 
values <0.05 were considered significant.  
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Chapter 3 Optimisation of specific methodology 
3.1 Overview 
Clinical samples are often difficult to analyse due to the large variations between individuals. To 
keep variation to a minimum, consistency in how the samples were stored and processed, and 
conduct of experiments using the optimal method, are particularly important to ensure reliable 
results. In this project, airway biopsy, BALF and induced sputum samples were collected from 
patients at the Mater Adults Hospital clinic, and stored at -80C until further use. This chapter will 
discuss analyses of the quality of these samples, and the development of protocols that were used to 
analyse the clinical samples. 
 
3.2 Biopsy 
Airway biopsy RNA extraction permits study of the epithelial cell gene expression that may be 
regulated by the disease inflammatory response or in response to the trial drug. From each 
bronchoscopy, two airway biopsies were immediately put into RNAlater solution at 4C for at least 
24 h, and then stored at -80C. RNAlater is a commercial product that is easy to use in clinical 
practice, which prevents RNA degradation in tissue and allows the samples to be stored for later 
use.  Two biopsies were pooled to increase our sampling area and obtain a more representative 
measure of the airway microenvironment. 
 
3.2.1 RNA yield and RNA quality from biopsy samples  
A commercial on-column RNA extraction kit was used to extract RNA from these frozen biopsy 
samples, and each sample was eluted in 20 µuL water. RNA concentration and RQI were measured 
to indicate the quantity and quality of RNA extracted from the biopsies. RQI measures the 18S and 
28S of eukaryotes RNA, and gives a score of 0 to 10. A RQI score of 10 indicates that the RNA 
sample is of high quality with minimal degradation or contamination. The lower the RQI score, the 
more degraded RNA may be contained in the sample.  
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Figure 3.1. BLESS biopsy RNA yield and quality. (A) Total RNA yield (B) RNA RQI scores 
 
Most of the biopsy samples did not have a high RNA yield, nor a high RQI score. As shown in 
Figure 3.1A, 37% of the samples had a total RNA of less than 400 ng, and only 21% of the samples 
had more than 1 µg total RNA. As shown in Figure 3.1b, 38% of the samples had a RQI score less 
than 4, and only 14% had a RQI score above 7. The low RNA yield and RQI score could be due to 
the size of each biopsy (ie ~1 mm
3
) or the nature of the diseased airway epithelium. As the 
bronchiectatic airway epithelium is constantly undergoing chronic inflammatory response, mucus 
layer turnover and potential wound repair, each biopsy could contain a mixed amount of healthy 
airway epithelial cells, apoptotic and necrotic airway epithelial cells, edema, immune cells, 
cartilage, and blood clots (in diseased airways), etc. These factors could affect the quality of the 
biopsy, and hence the RNA yield and RQI score. Besides the nature of the biopsy, the low RNA 
yield may also challenge the accuracy of Nano-drop RNA concentration reading and RQI 
measurements. Most molecular biology methods require sufficient sample to give accurate 
measurement, and measurements near the machine’s low and high boundaries should always be 
analysed carefully. The low RNA yield in these samples may have pushed Nano-drop to its lowest 
measuring capability, which may also affect the sensitivity for RQI measurements. I also tried to 
extract RNA using Trizol off-column method, but did not see an obvious increase in RNA yield. 
From this observation, we cannot conclude that the two RNA extraction methods have a difference 
in terms of RNA yield, due to the fact that we could not do a parallel comparison using the same 
piece of biopsy. Therefore, we continued to use the on-column RNA extraction method for this 
project as it is a more time-efficient protocol. The healthy control specimens had similar RNA yield 
and RQI compared to bronchiectasis biopsy specimens, suggesting that the inflamed tissue 
condition does not affect the quality of the specimen.  
 
(A) (B) 
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3.2.2 RNA amplification 
The low RNA yield from these biopsies is insufficient to analyse expression of many genes by 
PCR, so a RNA amplification step was necessary. The quality of the RNA amplified samples was 
checked by comparing the expression of three housekeeping genes using qRT-PCR. Figure 3.2 
shows that the expression levels of beta-2-microglobulin (B2M) and -actin (CTB) had similar 
patterns, but TATA-box-binding protein (TBP) was slightly off the pattern comparing to B2M and 
-actin. This indicates that RNA amplification step amplified RNA so that the relative expression of 
at least two housekeeping genes in each individual were consistent. The reason why TBP has a 
different pattern compared to B2M and -actin may be due to its low expression in these biopsies, 
or the expression may be altered with the disease in bronchiectatic airways.  
 
Figure 3.2. Housekeeping Gene comparison across a cohort of BLESS biopsies. Y-axis plots the Ct 
values.  
 
In order to determine whether the Ct values of the housekeeping genes are influenced by the RNA 
quality or yield, correlation analysis of B2M amplification versus RQI, starting RNA quantity and 
RNA concentration was performed. As can be seen in Figure 3.3, there are no clear correlations 
between B2M Ct and RNA quality or quantity. However, other factors such as the relative amounts 
of epithelial cells in the biopsy samples may also contribute to the different variation in Ct values. 
In this project, B2M and ACTB were used as househousekeepingkeeping genes, but not TBP.  
 
 
 
C
t
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Figure 3.3. Analysis of B2M gene expression Ct value versus RNA quality, starting total RNA 
quantity and starting RNA concentration in a cohort of BLESS biopsies. (A) B2M Ct versus RQI 
score (B) B2M Ct value versus starting total RNA quantity (C) B2M Ct versus starting RNA 
concentration.  
 
3.2.3 Preliminary gene expression study using microarray 
A preliminary microarray gene expression study was performed by analysing 8 controls and 12 
bronchiectasis biopsy RNA samples. The recommended RNA quality for microarray analysis 
requires high quality RNA (ie RQI > 8) in order to minimise all non-disease related factors that may 
contribute to the differences in gene expression and signal intensity. However, due to the 
compromised quality of biopsy RNA samples in this project, we set the threshold at RQI score of 6. 
Eight healthy controls and 12 Visit 1 BLESS bronchiectasis biopsy RNA samples with an RQI 
score >6 were selected to investigate the primary disease gene expression before macrolide 
treatment. The 12 bronchiectatic samples were carefully selected according to their clinical scores 
and histology scores to include a range of patients with mild disease symptoms to severe disease 
state.  
 
The microarray experiment was done in two batches in two laboratories due to availability of the 
facilities, and this fact has impacted on the signal intensity of the samples possibly due to the 
different settings in the two laboratories. Figure 3.4 shows the average signal intensity of each 
sample. The last 6 samples were done in one laboratory, and the rest of the samples in another 
laboratory. The raw data (Figure 3.4A) shows that the last 6 samples had relatively stronger signal 
intensity comparing to the rest of the samples, and this difference still existed after normalisation 
(Figure 3.4B). Therefore, analysis would be more accurate by analysing the two batches separately, 
and comparing the two analyses in parallel. 
 
 
(A) (B) (C) 
49 
 
From these microarray data, we selected genes that had a big difference between controls and 
bronchiectasis to further validate using qRT-PCR in a larger cohort. Within the genes that had large 
variances, genes with low signal intensities were also eliminated for RT-PCR, because the low 
intensity reading may potentially be background noise signals, and the results may not be 
biologically significant. 43 genes and four house-keeping genes were selected to put on the ABI 
TaqMan Microfluid Card for RT-PCR analysis. For house-keeping gene selection, He et al and 
Glare et al reported that the expression of commonly used housekeeping genes (eg -actin and 
GAPDH) may differ between healthy controls and disease airways (Glare et al., 2002; He et al., 
2008). Therefore, 12 commonly used housekeeping genes reported in other respiratory studies were 
analysed to identify potential housekeeping genes for this project. The average B2M, -actin, PPIA 
and TBP gene expression signal intensity between normal and bronchiectasis group were minimally 
different (< 0.2), therefore were selected to use as housekeeping genes in this project. 
 
 
Figure 3.4. Microarray signal intensity check. (A) Signal intensity of each biopsy RNA sample 
before normalisation (B) Signal intensity of each biopsy RNA after normalisation 
 
 
(A) 
(B) 
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3.3 Broncheoalveolar lavage 
Broncheoalveolar lavage fluids were immediately aliquoted and centrifuged at 500 g for 5 min at 
4C, followed by 10 min centrifugation at 16,000 g at 4C, and then stored at -80C upon 
collection. From these BALF, cell pellets spun at 500 g were used detect cytokine gene expressions, 
supernatants without protease inhibitor were used to detect MMP, and supernatants with protease 
inhibitor were used to detect cytokine and growth factor levels. 
 
3.3.1 BALF cell pellet (BAL-CP) RNA 
RNA was extracted from the BALF cell pellet for RT-PCR analysis of cytokines and other immune 
mediators. RNA concentration and RQI were measured to check the quantity and quality of RNA in 
these samples. The lower the RQI score, the more degraded RNA may be contained in the sample. 
In Figure 3.5, the last lane on the right is a typical RNA sample with good RNA quality which 
yielded a RQI score of 9. The third lane from the left after the ladder yielded a RQI score of 10, but 
with a smear between 18S and 28S, indicating potential DNA contamination in the RNA samples. 
Therefore, as long as the signals at 18S and 28S positions are strong enough, it will yield high RQI 
score regardless of the contaminants showing up on other locations. Hence, BAL-CP RQI could 
easily be overestimated due to possible DNA contaminations. This phenomenon is likely due to the 
neutrophil extracellular trap (NET) in these samples. NET is a DNA web released by the 
neutrophils to trap bacteria. As neutrophils play an important role in bronchiectasis, it is very likely 
that there are large amounts of NET in these patient airways. These NET are sticky DNAs, which 
may possibly stick onto the column that we used to extract RNA. Therefore, DNase-treatment on 
these samples was essential to yield high quality RNA.  
 
 
Figure 3.5. An example of RQI test results using a set of BALF cell pellet RNA 
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Figure 3.6 shows the total BAL-CP RNA yield and RNA quality after DNase treatment. 68% of the 
BAL-CP samples had a total RNA yield more than 1 g, and only 17% had a total RNA yield of 
less than 0.5 g. RNA quantity was therefore sufficient for RT-PCR analysis, therefore no RNA 
amplification was required for these samples. Although the RNA yield in these BAL-CP was 
acceptable, RQI scores were low in some samples with 54% of the samples having a RQI score less 
than 4. This could be due to the amount of dead cells washed off from the airway surface that 
contributed degraded RNA into the sampling pool.  
 
                   
Figure 3.6. BLESS BAL-CP RNA yield and quality. (A) Total RNA yield (B) RNA RQI scores 
 
3.3.2 BALF protein concentration 
Detection of cytokines and growth factors in BALF is currently widely used in respiratory research. 
BALF contains leukocytes, cytokines, growth factors, bacteria, and anti-microbial proteins. 
Infections, inflammation and disease stage may affect the amount of proteins detected in BALF. 
However, the amounts of measureable biological analytes in these samples may also be affected by 
which part of the lung lobe are flushed and how much BALF was used and withdrawn from the 
lung. We measured the protein concentration in BALF to get an estimate of how much total 
measureable biological analytes are contained in each samples. As shown in Figure 3.7, most 
samples had a protein concentration <200 g/mL (100% of the control samples and 71% of the 
bronchiectasis samples). 24% of the bronchiectasis samples had a protein concentration higher than 
double the median (242 g/mL). The protein concentration in BALF was negatively correlated with 
BALF volume aspirated (r=-0.45, and p=0.04) (Figure 3.8A), however there was no link to 
measures of airway obstruction (FEV1/FVC ratio) (Figure 3.8B). 
 
(B) (A) 
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Figure 3.7. BLESS bronchoalveolar lavage protein concentration 
 
 
 
 
Figure 3.8. Correlation of BLESS bronchoalveolar lavage protein concentration and clinical scores. 
(A) BALF volume aspirated (B) FEV1/FVC ratio. 
 
3.4 Sputum 
Sputum is viscous due to the presence of mucin glycoproteins and also often contains DNases, 
proteases and products released from microbes, and therefore are difficult to handle. In this project, 
mucin proteins, cytokines and MMP levels were measured in induced-sputum samples from 
patients with bronchiectasis and healthy controls.  
 
3.4.1 Protein concentration measurement 
Two biochemical protein assays, Bicinchoninic acid (BCA), Bradford kit, and Nano-drop A280 
spectrometer measurements, were compared to confirm reliability of protein concentration 
measurement in sputum samples. BCA measures cysteine, tryptophan and tyrosine, and Bradford 
kit and Nano-drop measure the aromatic rings of proteins. As shown in Figure 3.9, none of the 
results were replicable using another measuring method. Detection of protein using Bradford assay 
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was low in all 16 induced sputum samples, while high protein concentrations were detected in the 
same samples using the BCA assay. As sputum samples contain a large amount of mucin proteins, 
which have a cysteine-rich domain but are poor in tryptophan and tyrosine, BCA may overestimate 
the protein concentration in sputum samples by picking up all the cysteine-rich domain, while 
Bradford and Nano-drop may have underestimate the amount of mucin. Although Bradford and 
Nano-drop both measure the aromatic ring in proteins, the differences in protein concentration 
measurement between Bradford kit and Nano-drop A280 spectrometer measure may be due to the 
large difference in detection range, and that Nano-drop was a more sensitive and direct 
measurement. In summary, none of these three methods is good for measuring sputum protein 
concentration, therefore PAS staining, sputum dry weight and sputum wet weight measurements 
was selected as better approaches to normalise the amount of MUC5AC, MUC5B and cytokines in 
these induced-sputum samples.  
 
                 
Figure 3.9. Sputum protein assay comparison. (A) Nano-drop A280 spectrometer measurement 
versus Bradford kit (B) Nano-drop A280 spectrometer measurement versus BCA kit (C) Bradford 
kit versus BCA kit.  
 
3.4.2 Mucin western blotting 
Mucin protein detection using Western blotting was described by Kirkham et al (Kirkham et al., 
2002). In this project, semi-quantification of MUC5AC and MUC5B proteins in induced sputum 
was undertaken to provide further understanding of mucus hypersecretion disease phenotype in 
patients with bronchiectasis. In order to perform this experiment in a cost-efficient manner for over 
500 sputum samples, the mucin western blotting protocol was optimised for Li-Cor Odyssey 
detection, which allowed two fluorescent antibody labelling for two different proteins on one blot.  
 
(A) (B) (C) 
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3.4.2.1 Blocking buffer 
In order to obtain a clean blot with clear signal and a clean background, four different blocking 
buffers were tested. A serial diluted sputum sample was blotted on four nitrocellulose membranes, 
each incubated in 0.5% BSA in PBST, 0.1% casein in TBST, Odyssey blocking solution or 10% 
milk powder in PBST, followed by standard MUC5AC and MUC5B antibody staining, and then 
detection using Li-Cor Odyssey detection system. In Figure 3.10, 0.1% casein in TBST and 
Odyssey blocking solution both showed clear MUC5AC and MUC5B signal with a clean 
background, 0.5% BSA in PBST had more background, and the mucin protein signal on the 10% 
mild powder in PBST membrane was not very clear. A parallel comparison of 0.1% casein in PBST 
and 0.1% casein in TBST was done on two identical blots to further confirm the combination of 
casein and TBST was the optimal condition. Figure 3.11 showed a cleaner blot with minor 
background noise was obtained by using 0.1% casein in TBST as blocking buffer. As Odyssey 
blocking solution was more expensive, 0.1% casine in TBST was chosen to use as blocking buffer 
in the MUC5AC and MUC5B western blotting method using Li-Cor Odyssey detection system.  
 
                             
Figure 3.10. Comparison of blocking buffer used for MUC5AC and MUC5B antibody staining 
using the Li-Cor Odyssey detection system. Each nitrocellulose membrane was blotted with a 
serial-diluted sputum mucin sample from top to bottom. The yellow colour shows the overlay of 
MUC5AC (red) and MUC5B (green). (A) 0.5% BSA in PBST, (B) 0.1% casein in TBST, (C) 
Odyssey blocking solution, and (D) 10% milk powder in PBST. 
 
 
(A) (B) (C) (D) 
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Figure 3.11. Comparison of base buffer used for MUC5AC and MUC5B antibody staining using 
the Li-Cor Odyssey detection system. The yellow colour shows the overlay of MUC5AC (red) and 
MUC5B (green). (A) 0.1% casein in PBST (B) 0.1% casein TBST. 
 
3.4.2.2 Reduction and alkylation 
In order to analyse all the samples together, two samples were run on every blot to use as internal 
controls. However, a reduction in signal intensity was noticed in later blots (Figure 3.12). These 
samples had been stored at -20C, therefore the loss of signal intensity could possibly due to long-
term storage or a freeze-thawing fact.  
 
 
Figure 3.12. Diminished mucin protein signal intensity after storing at -20C for 3 months 
 
To test whether there was actual signal lost in these sputum samples after a period of time, the same 
samples were analysed using western blot three times on Day 0, Day 3, and Day 14. Samples were 
run fresh on Day 0 (Blot 3-1), and then 3 days after storing at -20C (Blot 3-2) and 2 weeks after 
storing at -20C (Blot 3-3). Data was normalised to the mean or median of the other two blots, and 
(A) (B) 
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then scatter graphs were plotted to compare the distribution of the data set. Figure 3.13 shows that 
MUC5AC raw data, MUC5AC normalised to the mean, and MUC5AC normalised to the median 
were quite consistent after 3 days and 2 weeks storage at -20C. MUC5B signals were consistent 
after 3 days storage at -20C, but a huge signal lost was detected after 2 weeks storage at -20C. 
These results indicate that MUC5AC could still be measured accurately after 2 weeks storage, but 
not MUC5B.  
 
  
Figure 3.13. Comparison of MUC5AC and MUC5B western blot protein signal intensity in sputum 
samples after storage at -20C for 3 days and 2 weeks. The same batch of samples were run on 
agarose-SDS gels using the same MUC5AC and MUC5B western blotting method three times with 
fresh samples (Blot 3-1), and then 3 days after storing at -20C (Blot 3-2) and 2 weeks after storing 
at -20C (Blot 3-3). Each blot was normalised to the mean or median of the other two blots, and 
then analysed using scatter plots. 
 
To further investigate the reason why signals were diminishing, two samples were re-
reduced/alkylated (reduction using 50 mM DTT at 100C for 10 min, and then 125 mM 
iodoacetamide in the dark for 20 min) just before loading on agarose gel to test if the diminishing 
signal was due to the re-formation of disulfide bonds in the mucin protein. Figure 3.14 showed that 
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re-reduction/alkylation of the sputum mucin samples did not increase the protein signal after -20C 
storage. Sputum mucin signal intensity was decreased even further after re-reduce/alkylate the 
samples, and the distance of how far the samples moved on an electrophoresis agarose-SDS gel was 
altered, indicating a possible change in size or charge of these mucin proteins after re-
reduce/alkylation. These results indicated that the signal lost after freeze-thawing and -20C storage 
is not likely to be due to disulfide bond reformation of the mucin proteins. 
 
 
Figure 3.14. Re-reducing/alkylate stored sputum samples for mucin detection. Lane 1: Sample #75 
stored at -20C for over a year, Lane 2: stored Sample #75 re-reduce/alkylate before loading on 
agarose-SDS gel, Lane 3: Sample #99 stored at -20C for over a year, Lane 4: stored Sample #99 
re-reduce/alkylate before loading on agarose-SDS gel. 
 
It is possible that 100C incubation was too harsh on the mucin proteins to undergo twice, and the 
epitopes could have been destroyed due to the high temperature denaturing the protein. To further 
determine if a different re-reduce/alkylation method could bring the mucin protein signals back 
after -20C storage and whether freeze-thawing was causing the lost mucin signal intensity in 
sputum samples, sputum samples were tested at several conditions as described in Figure 3.15. The 
results show that freeze-thaw did not make a big difference in signal intensity, and re-reducing the 
sample does not bring the signal back. These results indicated that freeze-thawing is not the major 
cause of mucin protein signal loss, and the length of time that the samples were stored in the freezer 
may be more critical than freeze-thawing. As re-reducing the samples could not bring the mucin 
protein signals back, there is no ideal method to store these clinical samples once the mucin proteins 
are extracted. Therefore, it was important to perform the mucin western blotting analysis as soon as 
the mucin proteins were extracted from the sputum samples. 
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Figure 3.15. Comparison of the impact on mucin protein signal intensity using different re-
reduction/alkylation methods. Condition 1:  fresh sample reduced with 50 mM DTT incubated at 
100C for 10 min. Condition 2:  fresh sample reduced with 50 mM DTT incubated at 100C for 10 
min, followed by 50 mM DTT incubation at 100C for 10 min. Condition 3:  fresh sample reduced 
with 50 mM DTT incubated at 100C for 10 min, followed by 50 mM DTT incubation at 37C for 
1.5 h. Condition 4:  fresh sample reduced with 50 mM DTT incubated at 100C for 10 min, and 
then freeze-thawed once. Condition 5:  fresh sample reduced with 50 mM DTT incubated at 100C 
for 10 min, freeze-thaw once, followed by 50 mM DTT incubation at 100C for 10 min. Condition 
6:  fresh sample reduced with 50 mM DTT incubated at 100C for 10 min, freeze-thaw once, 
followed by 50 mM DTT incubation at 37C for 1.5 h. 
 
In order to further investigate whether this phenomena is a mucin protein characteristic or an 
antibody specific effect, the same samples were blotted on the same nitrocellulose, which was then 
divided into two halves after blocking in 0.1% casein in TBST for 2 h. One half of the blot was 
incubated with EU-MUC5B antibody, and the other half was incubated with MAN5B antibody. 
Figure 3.16A shows that EU-MUC5B antibody worked better with DTT reduction at 37C for 1.5 
h, and MAN5B antibody worked better at 100C reduction for 10 min. This antibody-dependent 
factor was also shown in a MUC5AC and MUC5B western blot. Figure 3.16B shows that 
MUC5AC (MAN5AC) antibody worked better at 100C reduction for 10 min, and MUC5B (EU-
MUC5B) antibody worked better with DTT reduction at 37C for 1.5 h. These data show that 
mucin protein signal intensity is strongly influenced by the optimal reduction method that suits each 
particular primary antibody, indicating that the secondary structures of mucin proteins may open 
slightly differently between each reduction method to allow antibody binding. 
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Figure 3.16. Mucin protein signal intensity varied between different antibodies and different 
reduction methods. (A) Comparison of different reduction methods between two different MUC5B 
antibodies. (B) Comparison of different reduction methods between a MUC5AC and a MUC5B 
antibody. 
 
3.5 Bronchial epithelial cell culture 
Bronchial epithelial cell culture on transwells in a air-liquid interface allows differentiation of 
mucus producing cells and ciliated cells. The cells are in contact with the medium only on their 
basal surface, leaving the apical surface in contact with air, which this system mimics the real 
physiology in human airways. According to manufacturer’s instruction, differentiation of mucus 
producing cells can be observed from 10 days post air-lifting, and ciliated cells can be observed 20 
days post air-lifting. In this project, regulation of mucus production was tested using this cell 
culturing system. Successful expansion of bronchial epithelial cells from bronchiectasis patient 
airway brushings (Figure 3.17) allowed comparison of mucus production regulation between cells 
cultured from healthy individuals and patients with bronchiectasis. I successfully cultured HBEC 
from 3 out of 3 healthy donors from a commercial supplier (Lonza), 10 out of 10 brushings from 
healthy donors, and 7 out of 8 brushings from bronchiectatic subjects. The one bronchiectatic 
subject that I was not able to establish a culture for was due to the presence of Aspergilus fumigatus 
in the patient’s airway, which resulted in fungal growth in the culture. 
 
 
(A) (B) 
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Figure 3.17.  Expansion of bronchial epithelial cells from patient airway brushings. (A) Healthy 
control primary bronchial epithelial cells purchased from commercial supplier. (B) Bronchiectatic 
primary bronchial epithelial cells expanded from patient airway brushing.  
 
3.5.1 Medium 
The balance of growth factors and hormones used in HBEC culture is critical for the differentiation 
of airway epithelial cells. Yoon et al described the critical roles of retinoic acid and triiodothyronine 
in regulation of mucin gene expression and mucin secretion (Yoon et al., 1997), and the importance 
of retinoic acid and EGF in regulating ciliated cells and epithelial cell proliferation was also shown 
in swine airway epithelial cell culture (Bateman et al., 2012). In order to find out the optimal 
medium condition for HBEC to grow, different cell culture media combinations were tested using 
passage 2 (P2) and passage 3 (P3) HBEC (Table 3.1). As can be seen in Figure 3.18, MUC5AC 
gene expression was higher using 50% high glucose DMEM:50% LONZA BEGM with 50 nM 
retinoic acid and without triiodothyronine at Day 20 in both P2 and P3, but P2 has relatively higher 
levels comparing to P3. MUC5B gene expression level remained high at Day 20 and Day 32 in both 
P2 and P3 cells using 50% DMEM:50% LONZA BEGM with 50 nM retinoic acid and without 
triiodothyronine. The mucin western blot result further confirmed that 50% high glucose 
DMEM:50% LONZA BEGM with 50 nM retinoic acid and without triiodothyronine was the 
optimal condition for differentiation of mucus producing cells. Other than the level of mucus 
production, histology results showed no difference in the limited amount of ciliated-cell 
differentiation between each cell culture media combination (Figure 3.19). 
  
(A) (B) 
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Table 3.1. Different HBEC cell culture media combination 
 
 
 
 
Figure 3.18. Comparison of mucin gene and protein levels in different media combinations (as per 
Table 3.1). Five different culture media were tested with cells at passage 2 and 3. (A) MUC5AC 
and MUC5B RT-PCR of cells harvested on Day 20 and Day 32. Media combination 5, the media 
condition recommended by the supplier, was used as control, and the figure showed the fold change 
of each condition relative to the Ct of Media combination 5 at Day 20. Expression of MUC5AC and 
MUC5B were corrected to the expression of -actin. (B) MUC5AC (show in red) and MUC5B 
(show in green) western blot of mucus samples collected on the apical chamber on Day 32.  
(A) (B) 
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Figure 3.19. Histology of the HBEC in different media as per Table 3.1 
 
3.5.2 Growth duration 
A miminum of 20 days post air-lifting is thought to be required for ciliated cell differentiation in 
this cell culturing system. Currently, there are no published studies suggesting particular growth 
factors promote cilia growth in human airway epithelial cell cutures, and the air-lifting step is 
believed to initiate ciliated cell differentiation. In order to test if more ciliated cells can be seen after 
maintaining the culture for a longer period of time, HBEC was harvested at Day 33, Day 40 and 
Day 47 post air-lifting. Histology sections were stained with Alcian blue/PAS and -tubulin to 
identify mucus-producing cells and ciliated cells. In Figure 3.20, mucus producing cells could still 
be observed at Day 40 post-air-lifting, but no cilia was observed at Day 33, Day 40 or Day 47 post 
air-lifting. As described in Chapter 3.5.1, decreased MUC5AC gene expression was observed at 
Day 32 post air-lifting comparing to Day 20, therefore there may be a compromised MUC5AC gene 
expression at Day 40, Day 47 and later. Given the main focus of this project was to determine the 
regulation of mucus production in response to inflammatory cytokines and antibiotic treatment, 
compromising mucus producing characteristics to gain ciliated cell differentiation was considered 
to be neither ideal nor practical. 
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Figure 3.20. Histology of the HBEC on Day 33, 40 and 47 post air-lifting with H&E, Alcian 
blue/PAS and -tubulin staining. 
 
3.5.3 Fixation 
HBEC cultures are very fragile due to the delicate columnated cell layer and its water rich mucus 
layer. Various fixation solution may potentially distort the cell monolayer. Paraformaldehyde is 
widely used in many histology protocols, as it preserves the cell architecture nicely and is suitable 
for many antibody staining protocols. Carnoy’s solution preserves the mucus layer, however does 
not preserve tissue artitecture as well as paraformaldehyde. These two fixation solutions were tested 
to compare the quality of fixed cell monolyer architecture. Figure 3.21 shows that parafomaldehyde 
is more prone to change the shape of the transwell membrane, and a wavy cell section could often 
be observed, whilst this phenomena was not observed in cells fixed with Carnoy’s solution. 
Therefore, Carnoy’s solution may be a better fixation solution in HBEC culture experiments.  
 
                   
Figure 3.21. Comparison of HBEC histology sections fixed using Carnoy’s solution and PFA 
 
H&E 
H&E 
Alcian blue + PAS 
Alcian blue + PAS 
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3.6 Discussion 
This project involves a broad array of measurements using airway biopsy samples, BALF and 
induced sputum samples. In order to generate high-quality data, the methods for analysing these 
samples were tested and optimised to ensure reproducible results. This chapter characterised the 
nature of these clinical samples, and fully optimised all the protocols used for analyses.  
 
In summary, for the airway biopsies: 
 Low RNA yield and RQI scores were obtained from many airway biopsy samples, 
particularly in diseased samples.  
 RNA amplification was required for all biopsy samples, and was found to be a reliable 
method to increase final cDNA quantity for qRT-PCR. 
Despite the suboptimal samples, these samples were able produce reliable RT-PCR results after 
RNA amplification of house-keeping genes. 
 
In summary, for the BALF: 
 It is essential to treat BAL cell pellet RNA with DNase to obtain non-contaminated RNA  
 Protein concentrations in BALF vary considerably between individuals. 
BALF protein concentrations in the control group were lower than in bronchiectatic samples, and 
the BAL cell pellet RNA tended to have more DNA contamination, reflecting the inflammatory 
nature of the bronchiectatic airways.  
 
In summary, for the induced sputum samples: 
 MUC5AC and MUC5B western blot using Li-Cor Odyssey detection system is optimal 
using 0.1% casein in TBST buffer as blocking solution 
 Extracted mucin protein from the sputum samples should be analysed using western blot 
within a few days to avoid epitope loss 
 Different mucin primary antibodies have different optimal reduction/alkylation conditions 
MUC5AC and MUC5B proteins in induced sputum samples could be detected using western 
blotting, however, there is no optimal storage method to prevent epitope loss, and analysis should 
be carried out soon after mucin protein extraction.  Due to the limitation of mucin sample storage, 
use of internal controls between blots is not ideal. Mucin protein signal intensity should be 
corrected to the medians of other blots to allow normalisation between experiments, and each blot 
should have a large number of samples (80 samples per blot) including controls and disease samples 
on the same blot. 
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In summary, for the HBEC culture: 
 Optimal medium cocktail for mucus production is 50% high glucose DMEM:50% LONZA 
BEGM with 50nM retinoic acid, without triiodothyronine 
 Main gel-forming mucin gene expression in HBEC peaks at Day 20 
 Carnoy’s solution is a preferred fixation solution for HBEC culture  experiments 
HBEC cultured in 50% high glucose DMEM:50% LONZA BEGM with 50 nM retinoic acid and 
without triiodothyronine for 20 days was optimal for mucus secretion studies, however 
differentiated ciliated cells were not observed in these cultures. Successful RNA and mucin protein 
extractions from these HBEC cells have been demonstrated by RT-PCR and western bloting. As 
this project focuses on the regulation of mucus production in response to inflammatory cytokines 
and antibiotics, the currently optimised condition is suitable to carry out further experiments and 
analyses.  
 
Results from this chapter demonstrated the feasibility of the analysis planned for this project, and 
the methods are reliable and replicable. These methods will be used to analyse samples collected 
from patients with bronchiectasis and normal healthy controls.   
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Chapter 4 Inflammation in bronchiectasis 
4.1 Overview  
Many chronic respiratory conditions, including bronchiectasis, CF and COPD, are associated with 
long-term recurrent airway inflammation. While neutrophilic inflammation appears a central feature 
of non-CF bronchiectasis, there is evidence of involvement of other inflammatory pathways, such 
as the Th17 response (Tan et al., 2011) (see Chapter 1.6.2). The Th17 response produces cytokines 
that are involved in regulating both granulopoiesis and neutrophil recruitment, and is also involved 
in immune responses against extracellular bacteria such as P. aeruginosa (Tiringer et al., 2013; Ye 
et al., 2001). We hypothesised that the Th17 pathway will be strongly activated in bronchiectatic 
airways and contribute to the pathophysiology in bronchiectasis. To date in non-CF bronchiectasis 
there is a lack of comprehensive assessments of inflammation compared to healthy controls, 
longitudinal analyses within individuals, and studies large enough to associate features of 
inflammation with the clinical phenotype and specific microbial pathogens. In order to determine 
whether activation of the Th17 pathway contributes to the pathophysiology of bronchiectasis, we 
analysed inflammatory markers that are associated or independent from the Th17 pathway. We 
aimed to comprehensively characterize the airway inflammatory pattern in non-CF bronchiectasis, 
and how it could be associated with clinical measurements and disease severity markers (Aim 1).   
 
4.2 Methods 
Subjects and procedures  
All sample processing and evaluation was undertaken with complete blinding to disease state and 
study treatment assignment. At baseline, all 117 subjects enrolled in the BLESS study had induced 
sputum collected and a subgroup of 41 subjects with no evidence of additional (non-bronchiectasis) 
chronic respiratory disease underwent bronchoscopy with bronchoalveolar lavage (BAL). Twenty 
healthy control subjects also underwent sputum induction and bronchoscopy. Sputum and 
bronchoscopy procedures were repeated at week 48 with results from subjects in the placebo arm 
presented here. Full details of sputum induction and bronchoscopy procedures are in Chapter 2.3 
and Appendix 1. All control and bronchoscopy subgroup subjects were lifelong non-smokers (<2 
pack year history), aged 18-85 years, with no history of asthma or atopy, recent respiratory tract 
infection (within 4 weeks) or conditions with the potential to impact the safe performance of 
bronchoscopy. Full details of BALF, induced sputum and endobronchial biopsy sample processing 
are in Chapter 2.4. 
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Cytokine and chemokine ELISA (full details in Chapter 2.7) 
The Procarta Luminex cytokine and chemokine array which measures IL-1, IL-1, IL-4, IL6, IL-
8, IL-10, IL-13, IL-17A, IL-23, CXCL5, CXCL10, TNF-, IFN-, eotaxin and MPO was used to 
measure cytokine and chemokine concentrations in BALF (Affymetrix, Santa Clara, CA). IL-8, IL-
1, IL-17A, IFN- and TNF- concentrations in induced sputum samples were measured using 
Enzyme-linked immunosorbent assay (ELISA) as per the manufacturer’s instruction (BD 
Biosciences, San Jose, CA).  
 
Myeloperoxidase (MPO) activity assay (full details in Chapter 2.8) 
MPO activity in BALF was measured by detecting HOCl, the product from MPO chlorination 
activity, as per manufacturer’s instruction for the EnzCheck Myeloperoxidase Activity Assay Kit 
(Life Technologies, Carlsbad, CA).  
 
Microarray analyses for determination of genes of interest (full details in Chapter 2.6.5) 
A preliminary RNA expression microarray experiment was conducted to identify candidate genes 
differentially expressed in bronchiectasis using Illumina Human HT-12 V4 Expression Chip 
(Illumina, San Diego, CA). From these candidate genes, a selection of 20 genes (representing either 
the most consistently highly expressed genes in the microarray or genes thought to be important 
based upon preceding literature) were selected. 
 
Gene expression (full details in Chapter 2.6) 
TaqMan detection system was used to detect expression of selected genes from endobronchial 
biopsies (Microfluidic Cards, Life Technologies, Carlsbad, CA). RNA was amplified from all 
samples, prior to analysis by qRT-PCR. The average CT of three housekeeping genes (2-
microglobulin, -actin and Cyclophilin A) was used for standardization. 
 
Data analysis (full details in Chapter 2.12) 
Data analysis for the BLESS study including sample size calculations are as described previously 
(Serisier et al., 2013). Data distribution was mostly non-parametric and Mann-Whitney U tests were 
used to test the significance of variance between control and disease groups, or Kruskal-Wallis test 
where 3 or more groups were compared. Correlations were calculated using Pearson’s correlation 
coefficient after log-transformation of continuous data or Spearman rank correlation coefficient for 
discrete variables. Statistical analyses were performed using SYSTAT software (version 3.1), were 
2-sided and p values <0.05 were considered significant. 
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4.3 Results 
All 117 bronchiectasis subjects provided baseline sputum. BALF specimens were obtained from all 
41 bronchoscopy subgroup subjects and satisfactory biopsies from 34. Demographic details are 
shown in Table 4.1.  
 
Table 4.1. Subject demographics and disease characteristics 
  
Control (n=20) 
Non-CF Bronchiectasis 
(n=117) 
Non-CF Bronchiectasis 
bronchoscopy subgroup (n=41) 
Age (years) 36 (±11.8) 62 (±10) 63 (±6.9) 
Female - No (%) 12 (60) 71 (61) 28 (68) 
FEV1 (L) - pre-bronchodilator 3.52 (±0.83) 1.82 (±0.71) 1.87 (±0.61) 
FEV1 (L) - post-bronchodilator 3.61 (±0.83) 1.92 (±0.72) 1.97 (±0.64) 
FEV1 % predicted (pre-bronchodilator) 97.9 (±12.6) 68.5 (±18.77) 72.9 (±15.30) 
FEV1 % predicted (post-bronchodilator) 100.4 (±11.70) 71.9 (±18.77) 76.8 (±14.42) 
Pseudomonas aeruginosa - No (%) 0 41 (35) 11 (27) 
Other sputum pathogens - No (%)   
 
  
Normal flora (no pathogens) 20 53 (45) 17 (41) 
Haemophilus influenzae 0 23 (20) 12 (29) 
Stenotrophomonas maltophilia 0 3 (2.6) 1 (2) 
Others 0 5 (4.3) 3 (7) 
≥5 exacerbations in the prior year - No (%)   42 (36) 16 (39) 
24 hour sputum weight (g) - median (95% CI) - 17.1 (12 to 22) 16.4 (13 to 20) 
SGRQ total - 37.1 (±14.6) 39.4 (±14.4) 
Leicester cough questionnaire - 14.9 (±3.2) 14.2 (±4) 
6MWT - median (95% CI) - 510 (494 to 526) 510 (480 to 540) 
Medications -    
 
  
Inhaled corticosteroids 0 13 5 
Combination inhalers (ICS/LABA) 0 51 17 
Inhaled LABA 0 4 2 
Inhaled SABA 0 49 17 
Inhaled anticholinergics 0 18 4 
Prednisolone 0 3 0 
Nebulised saline 0 2 2 
Bromhexine 0 4  2  
Inhaled mannitol 0 1 0 
Nebulised colistin 0 1 0 
Comorbidities -   
 
  
Ischaemic heart disease 0 11 2 
Cerebrovascular disease 0 6 1 
Hypertension 0 37 9 
Diabetes mellitus 0 3 1 
 
 
4.3.1 Markers of innate and adaptive immune response are elevated in BALF  
Concentrations of all measured inflammatory markers were present in significantly higher 
concentrations in bronchiectasis than healthy BALF. These included innate (CXCL5, CXCL10, 
eotaxin, GM-CSF, MCP-1, IL-1 IL-1, IL-8), Th1 (IFN-, TNF-), Th2 (IL-4, IL-6, IL-13), Th17 
(IL-17A, IL-23), and regulatory (IL-10) immune mediators (all p<0.001 except CXCL10 <0.05; 
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Figure 4.1A). IL-1 had the greatest increase in median concentration in bronchiectasis compared 
to healthy individuals (120-fold), followed by IL-8 (34-fold). The remaining cytokines and 
chemokines were elevated between 3- and 10-fold in bronchiectasis. MPO concentration was 
increased 12-fold, and MPO activity was >2000 times greater in bronchiectasis (p<0.001; Figure 
4.1B) compared with healthy individuals.  
 
 
Figure 4.1. Inflammatory markers in respiratory fluids from subjects with bronchiectasis and 
normal healthy controls. (A) BALF chemokines and cytokines from bronchiectasis (n=41) and 
normal healthy control subjects (n=20). (B) BALF MPO activity and concentration as described in 
(A). (C) Induced sputum IL-1β and IL-8 concentrations from bronchiectasis (n=100) and control 
subjects (n=20). (D) Within-sample correlation between sputum IL-1β and IL-8 concentrations 
from bronchiectasis subjects. 
(Box and whisker plots display median, interquartile ranges, and range; *P<0.05, **P<0.01, 
***P<0.001 by Mann-Whitney U test (A-C) and unadjusted Pearson correlation coefficients (D).) 
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4.3.2 Markers of immune response are elevated in induced sputum  
Sputum contained very high concentrations of both IL-1 and IL-8 (p<0.001 compared to control; 
Figure 4.1C), and there was a strong correlation between IL-1 and IL-8 concentrations (r=0.76, 
p<0.001) (Figure 4.1D). However, the concentrations of IL-1 and IL-8 measured in BALF 
correlated less strongly with induced sputum measurements (IL-1 r=0.56, p<0.001, and IL-8 
r=0.45, p=0.004, Figure 4.2). Additionally, whereas the absolute concentrations of IL-1β in BALF 
and sputum were similar, the average concentration of IL-8 in sputum was >4000 times that in 
BALF. However, GM-CSF, IFN-, TNF- and IL-17A were not detectable in induced sputum 
samples using commercial ELISA kits (data not shown). 
 
 
Figure 4.2. Within-subject correlation of IL-1 and IL-8 concentrations measured in induced 
sputum and BALF in bronchiectasis. Unadjusted Pearson correlation coefficients and p-values are 
shown. 
 
4.3.3 BALF and sputum inflammatory markers are correlated 
Strong correlations were observed between many different chemokines and cytokines in 
bronchiectasis subjects, especially between eotaxin, GM-CSF and T-cell derived cytokines 
including IFN-γ, TNF-α, IL-4, IL-13, IL-17A, IL-23 and IL-10 (Figure 4.3). MPO activity was 
positively correlated with IL-8 concentration (r=0.6, p<0.001; Figure 4.4A). IL-1β and IL-6 
concentrations were positively correlated with total cell counts in BALF (r=0.70 and r=0.64, 
respectively, p<0.001 for both), although other cytokines and chemokines were not (Figure 4.4B) 
(cell count data in Supplementary Table S4.1).   
 
Figure 3 – Comparison of biomarkers in BE BALF and sputum (n = 39)
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Figure 4.3. Within-sample correlations of each measured cytokine and chemokine concentration in 
BALF in (A) healthy individuals, and (B) bronchiectasis. Unadjusted Pearson correlation 
coefficients are displayed and p-values shown by highlighting as per the key. 
 
4.3.4 BALF and sputum inflammatory markers are consistently elevated over time 
Longitudinal assessment of BALF inflammatory markers in the BLESS placebo arm showed 
unexpectedly strong correlations between baseline and 48 week samples for most measures (Figure 
4.4C). IL-1β, TNF-α, and IL-17A showed the strongest correlations (r>0.70, p<0.001 for all). 
Sputum concentrations of IL-1β and IL-8 at baseline and week 48 were highly correlated (IL-1β 
r=0.83, IL-8 r=0.71, p<0.001) (Figure 4.4D).  
 
(B) Correlation of each chemokine and cytokine concentration at bronchiectasis baseline
(A)                                Correlation of each chemokine and cytokine concentration in healthy controls
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Figure 4.4. Correlation of inflammatory markers in subjects with bronchiectasis. (A) Within-
sample correlation between BALF MPO activity and IL-8 concentrations. (B) Within-sample 
correlation between each of IL-1β and IL-6 concentrations and total cell counts in BALF. (C) 
Longitudinal, within-subject correlations for individual BALF inflammatory marker concentrations 
obtained at weeks 0 and 48 (placebo subjects only). (D) Within-subject correlations for induced 
sputum IL-1β and IL-8 concentrations obtained at weeks 0 and 48 (placebo arm).  
(Unadjusted Pearson correlation coefficients for all.)  
 
4.3.5 Inflammatory genes have elevated expression in bronchial tissue 
A preliminary RNA expression microarray experiment was conducted, in a subset of samples with 
the highest RNA quality, to identify candidate genes differentially expressed in BE. Due to the 
restricted availability of high quality RNA samples, we performed two batches of microarray 
experiments without an internal control. However, we ensured that we had similar proportions of 
healthy versus bronchiectatic samples in each batch, which allowed us to analyse the two batches 
separately. We acknowledge that inclusion of a quality control sample would have been beneficial, 
however it is not feasible to retrospectively perform this analysis owing to omission of an internal 
control sample. In order to overcome this limitation, we analysed the two batches separately as two 
independent experiments, and selected 43 genes that had the greatest difference between 
bronchiectatic and control in both batches for analysis in the larger sample set by qRT-PCR.  
 
Amongst the genes that were identified, many were related to infection response (Table 4.2). Within 
genes encoding inflammatory cytokines and chemokines, there was significantly higher expression 
of only IL-1β (5-fold) and IL-8 (20-fold) in bronchiectasis compared with control biopsies (p<0.05 
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and p<0.01, respectively), but not CXCL6, CXCL9, CXCL10, IFN-γ or IL-17A (Figure 4.5). In 
contrast, the majority of infection response genes (7 of 9) were significantly more highly expressed 
in bronchiectasis, with serine protease inhibitor A3 (SERPINA3) and prolactin-induced protein 
(PIP) demonstrating the greatest relative increases (24- and 27-fold, respectively, p<0.001). Genes 
of unknown function (noted to be highly expressed from the initial screening microarray), including 
Chromosome 6 open reading frame 58 (C6orf58; increased 43-fold, p<0.05) and 
microseminoprotein-β (MSMB; p<0.001) were also significantly higher in bronchiectasis. 
Expression of infection response genes and some unknown function genes were positively 
correlated, notably lysozyme (LYZ) was highly correlated with PIP and Zinc-α-2-glycoprotein 
(AZGP1) (r=0.88 and r=0.82, respectively, p<0.05) (Figure 4.6). SAA1 protein concentration in 
most BALF samples (85%) was below the detection range (<1.5 ng/mL BALF) (data not shown). 
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Table 4.2.  Preliminary microarray data. This table listed the function and expression sites of the top 
20 genes that had the greatest fold increase in expression in bronchiectasis comparing to normal 
healthy individuals. 
Target ID 
Fold 
change 
in BE 
Search key Function Expression Definition 
SERPINA3 8.78 NM_001085.4 
DNA binding / 
protein binding 
Pancreatic islet, 
liver, pancreas, 
trachea. 
Homo sapiens serpin peptidase inhibitor, 
clade A (alpha-1 antiproteinase, antitrypsin), 
member 3 (SERPINA3), mRNA. 
PIP 6.79 NM_002652.2 
Actin binding / 
protein binding 
Salivary gland, 
trachea. 
Homo sapiens prolactin-induced protein 
(PIP), mRNA. 
C6ORF58 6.15 NM_001010905.1 
Secreted / 
function 
unknown 
Trachea 
Homo sapiens chromosome 6 open reading 
frame 58 (C6orf58), mRNA. 
PRB1 6.14 NM_199354.1 
Function 
unknown 
Trachea, salivary 
gland. 
Homo sapiens proline-rich protein BstNI 
subfamily 1 (PRB1), transcript variant 3, 
mRNA. 
LYZ 4.72 NM_000239.1 
Anti-microbial 
agent 
Trachea, small 
intenstine, bone 
marrow. 
Homo sapiens lysozyme (renal amyloidosis) 
(LYZ), mRNA. 
PRB3 4.37 NM_006249.3 
Gram-negative 
bacterial cell 
surface binding 
Trachea, salivary 
gland. 
Homo sapiens proline-rich protein BstNI 
subfamily 3 (PRB3), mRNA. 
BPIFB2 3.98 NM_025227.1 Lipid transfer Trachea 
Homo sapiens bactericidal/permeability-
increasing protein-like 1 (BPIL1), mRNA. 
AZGP1 3.81 NM_001185.2 
Transmembrane 
transport / 
stimulates 
lipolysis 
Secretory cells of 
lung epithelium. 
Homo sapiens alpha-2-glycoprotein 1, zinc-
binding (AZGP1), mRNA. 
CXCL9 3.81 
NM_002416.1 
 
Immune 
response / cell-
cell signaling 
Endothelial cells, 
macrophage, 
salivary gland. 
Homo sapiens chemokine (C-X-C motif) 
ligand 9 (CXCL9), mRNA. 
IL8 3.50 NM_000584.2 Chemoattractant 
Smooth muscle, 
epithelial cells. 
Homo sapiens interleukin 8 (IL8), mRNA. 
CXCL10 3.42 NM_001565.1 
Immune 
response / cell-
cell signaling 
Monocytes, 
endothelial cells, 
fibroblasts. 
Homo sapiens chemokine (C-X-C motif) 
ligand 10 (CXCL10), mRNA. 
SAA1 3.21 NM_199161.1 
Transporter / G-
protein-coupled 
receptor binding 
Salivary gland, 
colon. 
Homo sapiens serum amyloid A1 (SAA1), 
transcript variant 2, mRNA. 
CXCL6 2.83 NM_002993.2 
Immune 
response / cell-
cell signaling 
Smooth muscle 
Homo sapiens chemokine (C-X-C motif) 
ligand 6 (granulocyte chemotactic protein 2) 
(CXCL6), mRNA. 
DEFB1 2.67 NM_005218.3 
Defense 
response to 
bacterium 
Salivary glands, 
kidney, pancreas. 
Homo sapiens defensin, beta 1 (DEFB1), 
mRNA. 
MSMB 2.63 NM_002443.2 
Function 
unknown 
Prostate, trachea. 
Homo sapiens microseminoprotein, beta- 
(MSMB), transcript variant PSP94, mRNA. 
BPIFA1 2.35 NM_016583.2 
Lipid binding / 
innate immune 
response 
Trachea, lung. 
Homo sapiens palate, lung and nasal 
epithelium carcinoma associated (PLUNC), 
transcript variant 2, mRNA. 
IL1B 1.76 NM_000576.2 
Immune 
response / cell-
cell signaling 
Bronchial 
epithelial cells, 
smooth muscle, 
myeloid cells. 
Homo sapiens interleukin 1, beta (IL1B), 
mRNA. 
IFNG 1.24 NM_000619.2 
Adaptive 
immune 
response 
NK cells, T cells, 
myeloid cells. 
Homo sapiens interferon, gamma (IFNG), 
mRNA. 
IL17A 0.97 NM_002190.2 
Immune 
response / cell-
cell signaling 
Lymphocytes, 
myeloid cells. 
Homo sapiens interleukin 17A (IL17A), 
mRNA. 
SERPINB2 0.29 NM_002575.1 
Serine protease 
inhibitor 
Placenta, 
bronchial 
epithelial cells, 
tonsil. 
Homo sapiens serpin peptidase inhibitor, 
clade B (ovalbumin), member 2 
(SERPINB2), mRNA. 
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Figure 4.5. Bronchial tissue gene expression in subjects with bronchiectasis (n=34) and normal 
healthy controls (n=20). Gene expression was assessed in amplified mRNA by qRT-PCR, corrected 
for three housekeeping genes, and expressed as fold-change of the median for the healthy control 
group.   
(Box and whisker plots display median, interquartile ranges, and range, and *P<0.05, **P<0.01, 
***P<0.001 by Mann-Whitney U test) 
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Figure 4.6. Within-sample correlations between the expression of each infection response and 
unknown function genes in bronchiectasis patient airways. Unadjusted Pearson correlation 
coefficients and p-value shown by highlighting as per the key. 
 
4.3.6 Inflammatory markers are elevated in subjects with airway microbial pathogens 
Bronchiectasis patients who cultured potentially pathogenic microorganisms (PPM’s) from 
respiratory secretions had significantly higher levels of inflammatory markers than ‘culture-
negative’ patients, including sputum IL-1β (p<0.001) and IL-8 (p<0.001) and BALF IL-8 (p<0.01) 
and total MPO activity (p<0.05) (Figure 4.7). Interestingly, the concentrations of these 
inflammatory markers were also significantly higher in bronchiectasis patients who were ‘culture-
negative’ compared to healthy controls (p<0.01 for sputum IL-1, and p<0.001 for sputum IL-8, 
BALF IL-8, and BALF total MPO activity). No relationships were seen between expression of any 
epithelial gene and the presence of PPM’s. P. aeruginosa infected subjects did not demonstrate 
increases in inflammatory markers compared to subjects culturing non-Pseudomonas bacteria 
(Supplementary Figure S4.1 and S4.2).  
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0.8 ≤ r (p < 0.05)
Bold = p < 0.001
Figure 2a – Gene expression of inflammatory cytokine genes from biopsy. Significantly higher expression of IL-
1b and IL-8 was shown in bronchiectatic airways. (Control n = 20, and BE n = 34)
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Figure 2b – Gene expression of infection response genes from biopsy (Control n = 20, and BE n = 34)
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Figure 2c – Gene expression of potential infection response genes from biopsy (Control n = 20, and BE n = 34)
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Figure 4.7. Sputum inflammatory marker concentrations according to airway microbiology by 
standard culture. Induced sputum from bronchiectasis (n=100) and control subjects (n=20) were 
cultured for pathogens and classified as ‘culture negative’ (only normal respiratory flora cultured; 
n=20 for all control subjects and n=36 for bronchiectasis subjects) or culture positive (any 
potentially pathogenic microorganism cultured).  
(Individual data points, median and interquartile ranges are shown. *P<0.05, **P<0.01 by Kruskal-
Wallis test comparing bronchiectasis subgroups.) 
 
4.3.7 Inflammatory markers are elevated in subjects with more severe disease phenotype 
Sputum, but not BALF, concentrations of IL-1β and IL-8 were significantly higher in patients with 
elevated serum CRP (p<0.001 and p<0.01, respectively; Figure 4.8A), and subjects with poorer 
lung function (p<0.01 for both; Figure 4.8B and Supplementary Figures S4.3 and S4.4). No 
significant differences in inflammatory markers were seen according to pulmonary exacerbation 
history, however interestingly the gene expression of -defensin (DEFB1) (Figure 4.8C and 
Supplementary Figure S4.5) was significantly lower in subjects reporting ≥5 pulmonary 
exacerbations ― however, this result must be considered cautiously given that it was an isolated 
result of significance and given the p value of only 0.048. No inflammatory marker predicted 
pulmonary exacerbation frequency in the subsequent 48 week clinical trial (placebo arm only). 
Combination corticosteroid (ICS)/ long-acting β-agonist (LABA) inhaler users had significantly 
lower concentrations of sputum and BALF inflammatory markers including IL-1β, IL-6 and IL-8 
(p<0.05 for all ; Figure 9 and Supplementary Figure S4.6). 
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Figure 4.8. Sputum inflammatory marker concentrations according to clinical markers of disease 
activity and severity. (A) Sputum IL-8, IL-1β concentrations and inflammatory cells according to 
serum CRP concentration. (B) Sputum IL-8 and IL-1β concentrations according to lung function. 
(C) Sputum IL-8 and IL-1β concentrations according to number of self-reported pulmonary 
exacerbations in the preceding 12 months.  
(Individual data points, median and interquartile ranges are shown. *P<0.05, **P<0.01, ***P<0.001 
by Mann-Whitney U test for (A) and (C) and by Kruskal-Wallis test for (B).) 
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Figure 4.9. Differences in inflammatory marker concentrations according to maintenance use of 
inhaled corticosteroid (ICS)/ long-acting β-agonist (LABA) inhalers.  
(Individual data points, median and interquartile ranges are shown; *P<0.05 by Mann-Whitney U 
test.)               
 
4.4 Discussion 
Bronchiectasis is characterized by prolonged inflammation and mucus hypersecretion, however, the 
definition of clinical bronchiectasis is vague, and the molecular characteristics of the disease are 
poorly understood. Bronchiectasis is therefore likely to be a common phenotype which originates 
via multiple differing aetiologies. In clinically stable non-CF bronchiectasis we identified a 
complex, basal level of airway inflammation involving both innate and adaptive immunity, 
consistent with a stable, rather than episodic, inflammatory process. Patients positive for recognized 
bacterial pathogens, higher serum CRP concentration and worse lung function had more 
inflammation. 
 
Neutrophilic inflammation is conventionally thought to be a key player in the pathogenesis of 
bronchiectasis. Patients with stable bronchiectasis display an increased percentage of neutrophils in 
BALF, and higher concentrations of elastase, myeloperoxidase, TNF-, IL-8, and IL-6 in BALF 
have been reported previously (Angrill et al., 2001). Bronchial biopsies also show significantly 
higher neutrophil, macrophage, IL-8 and TNF--positive cell densities in the lamina propria of 
bronchiectatic airways compared to control airways (Gaga et al., 1998; Zheng et al., 2001). Our data 
supports the previous findings that neutrophilic inflammation and innate immunity are important 
mediators in bronchiectatic airways, with IL-1, IL-8 and MPO, which are all associated with 
innate immunity and neutrophilic inflammation, having the greatest fold increase in both gene 
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expression and protein concentration in BALF and sputum from the BLESS cohort versus healthy 
individuals.  
  
Other than the innate immunity, adaptive immunity also plays a role in non-CF bronchiectasis. IL-
17A and IL-23 are Th17 related pro-inflammatory cytokines that regulate both granulopoiesis and 
recruitment of neutrophils into sites of inflammation through induction of CXC chemokines and 
regulation of the expression of G-CSF (Alcorn et al., 2010; Ye et al., 2001). Activation of Th17 
responses has been shown to initiate or suppress Th1 or Th2 response in infection (Alcorn et al., 
2010; Khader et al., 2007; Zelante et al., 2007). Elevated levels of IL-17A, IL-17F and IL-23 have 
previously been demonstrated in BALF, airway biopsies and sputum of CF patients undergoing 
pulmonary exacerbation, and a higher number of IL-17-positive cells were found in endobronchial 
biopsies of non-CF bronchiectasis children undergoing pulmonary exacerbation (McAllister et al., 
2005; Tan et al., 2011; Tiringer et al., 2013). Our results demonstrated not only a higher 
concentration of IL-17A and IL-23 in BALF, but also higher concentration of cytokines involved in 
Th1, Th2 and Treg responses.  
 
The longitudinal assessments were undertaken to investigate the progression of inflammation over 
time within individuals. We hypothesised that the inflammatory pattern in the bronchiectatic 
airways would be modulated by the microenvironment at the time of sampling, and that this 
microenvironment would vary with time.  If this hypothesis was correct the inflammatory pattern 
within each individual would not be consistent across different sampling times. We found that that 
the complex mixed inflammatory pattern in bronchiectatic subjects was surprisingly consistent, with 
individual inflammatory marker concentrations at week 0 and week 48 having very strong 
correlations. The data suggests that bronchiectasis subjects tend to have stably activated 
inflammatory profiles over time, which could be due to an intrinsic defect or a constant stimulus by 
mechanical factors promoting poor airway clearance in the bronchiectatic airways. 
 
Identification of a consistent, basal level of mixed inflammation in BE raises the possibility of 
functional polymorphisms in inflammatory pathways underlying genetic susceptibility, or 
mechanical factors leading to constant stimulus of poor airway clearance could also be contributing 
factor to the consistent, basal level of inflammation in BE. Genetic polymorphisms have been 
identified in other chronic respiratory diseases, but are yet to be demonstrated in bronchiectasis 
(Boyton et al., 2006; Seibold et al., 2011). A demonstration of differences in haplotype expression 
in natural killer cells in subjects with idiopathic bronchiectasis is the only genetic study so far 
(Boyton et al., 2006). Insights from other idiopathic pulmonary diseases like IPF also suggest their 
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may be a contribution from genetics (further discussed in Chapter 5) (Seibold et al., 2011). Future 
studies in bronchiectatic subjects linking genetic variations and their impact on inflammatory 
responses against infections would provide further understanding of the potential intrinsic immune 
defects. Genetic variations in toll-like receptors identified in asthma or COPD are potential 
candidates that may play a role in pathogenesis of bronchiectasis (Kanagaratham et al., 2011; Pabst 
et al., 2013).  
 
Potential biomarkers identified in BE include sputum elastase, IL-8 and TNF-, which have 
previously demonstrated positive correlation with predicted FEV1/FVC, leucocyte output, sputum 
purulence elastase, and bacteria load (Chalmers et al., 2012b; Richman-Eisenstat et al., 1993; Shum 
et al., 2000; Stockley et al., 1984; Tsang et al., 2000). Within the BLESS trial, clinical markers of 
disease severity significantly correlate with composition of the lower airways microbiota (Rogers et 
al., 2013). We show that none of the measured inflammatory markers were associated with 
measures of disease progression (increased number of exacerbations in the following 12 months, 
decline in lung function measured by FEV1, or increase in serum CRP concentration), sputum 
volume or quality of life, however sputum IL-8 and IL-1 were reliable indicators of disease 
severity, and correlated with H. influenzae and P. aeruginosa culture positivity, plasma CRP level, 
and poor lung function. Taken together our results indicate H. influenzae and P. aeruginosa 
influence the extent, but not necessarily the nature of the inflammatory response in BE. High 
cytokine levels in H. influenzae and P. aeruginosa culture negative patients may reflect carriage of 
non-cultured pathogens (eg. Veillonella and certain strains of Staphylococcus), low numbers of 
bacteria (< 10
4
 cfu/mL), respiratory viruses, yeasts (eg. Aspergilus fumigatus), or non-pathogen 
related stimulation of inflammation. Correlation of inflammatory marker concentrations with 
bacteria load determined by microbial species-specific PCR could be a more comprehensive way to 
evaluate links between composition of the microbial population and inflammatory patterns. Our 
inability to demonstrate a relationship between inflammatory markers in BALF and clinical features 
of disease may reflect lower subject numbers and statistical power (n=41 compared to n=117 for 
sputum samples). Alternative approaches to define disease progression which may inform further 
understanding of the links between disease progression and change in inflammatory patterns include 
analysing the pathological change show on HRCT scan, analysing the increase of colonising 
bacteria in the airways, and analysing the switch of dominant bacteria species in the airways (ie 
dominance of P. aeruginosa is an indicator of progression into a more severe bronchiectasis).  
 
We hypothesised that the Th17 pathway is an important inflammatory pathway in bronchiectatic 
airways that contributes to the pathophysiology of bronchiectasis. Although we have detected 
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increased concentration of Th17 pathway-related cytokines in BALF, there was no link between the 
concentration of these cytokines with the presence of pathogenic microbes. Together with the fact 
that the IL-17A concentration in BALF was one of the most consistent inflammatory mediators 
when re-measured after 48 weeks, it is likely that this immune pathway remains switched on once it 
is activated. Other than its role in host defence, its contribution in promoting fibrotic responses and 
airway tissue remodelling in bronchiectasis remains to be explored and warrants further analysis. 
Future studies investigating the roles of different IL17-producing cell types would inform further 
understanding in the interplay between Th-17-related host defence and remodelling of the airways, 
and may indicate whether IL-17 antagonism has any place in treatment of bronchiectasis. Specific 
immunomodulatory therapy such as targeting IL-17, whilst offering the prospect of reducing 
collateral tissue damage, has substantial risks in terms of reducing immune pressure on resident 
pathogens in the airways. 
 
Cytokine measurement in BALF is currently the most commonly used method in respiratory 
research, however, a less invasive sampling method such as induced sputum is preferred. Our 
results show strong correlations between BALF and sputum IL-8 and IL-1 concentrations, but 
many other cytokines detected in BALF were not measurable in induced sputum. This could be due 
to protease degradation of cytokines and regions where the samples were from. The fact that IL-8 
concentration in induced sputum was >4000 times that in BALF further suggests that chemokines 
and cytokines in BALF and induced sputum could be from different sources. IL-8 and IL-1 
detected in sputum samples may originate mainly from sputum neutrophils, whereas cytokines 
measured in BALF are more likely to include secretions from alveolar macrophages, mucosal 
lymphocytes and epithelial cells.  
 
To date, there have been no studies of expression of inflammation and host defense genes in BE. 
These studies have inherent difficulties due to the reliance on small biopsies that may not be 
representative, and that may include highly inflamed tissue with poor quality RNA. Sampling 
variation may also contribute to the wide scatter within groups and lack of significance between 
healthy and BE. Higher expression of IL-8 and IL-1 was detected in the bronchiectatic airways, 
but not other cytokine genes, possibly because epithelial cells are the main source of IL-8 and IL-
1, whereas other cytokines are mainly produced by leukocytes. Expression of inflammatory genes, 
including IL-17A, would be better measured in isolated immune cells than in airway biopsies where 
the immune cells are a minor component. 
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We acknowledge that network analysis has the potential to provide a deeper exploration of the gene 
expression data. However, considering our small sample size (n=8 for healthy control and n=12 for 
bronchiectatic subjects), the variability between individuals and disease status, the relatively poorer 
RNA quality, and the potential batch effect, the power of network analysis would not reach its 
greatest potential in this case. With the limited sample size, and compromised RNA quality, we 
decided to look for expression of genes that were consistently up- or downregulated in 
bronchiectatic airways compared to healthy airways in the two distinct microarray experiments. We 
also acknowledge that cluster analysis has the potential to provide more insights as to which groups 
of inflammatory markers are activated together or independently. The advice we were given by our 
biostatisticians is that, in order to have a reliable analysis, we were required to have 10 data points 
per analyte; suggesting that for 17 cytokines measured, we would need at least 170 samples to 
perform a reliable cluster analysis. Unfortunately, as we only had 41 BALF specimens, the cluster 
analysis approach was therefore deemed not feasible.  
 
We have comprehensively characterized the pattern of inflammation in non-CF bronchiectasis 
airways using sputum, BALF and bronchial biopsy specimens. We show a very complex and mixed 
inflammatory profile indicating activation of the Th17 immune response and multiple inflammatory 
pathways, which is relatively consistent over time. Levels of inflammatory markers correlated with 
airway bacterial infection and clinical markers of disease activity, but no individual marker was 
predictive of disease progression. The aetiology of most cases of BE remains uncertain. The 
complex inflammatory pattern may reflect the underlying heterogeneous origin of the disease, and 
makes it unlikely that a single, targeted, immunological treatment for BE would be effective. The 
impact of shifting the balance of inflammatory mediators on the ability of bronchiectatic airways to 
control recurrent infections is uncertain, and could disrupt the delicate balance between continued 
exposure to pulmonary pathogens and mucosal immune defence.  
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SUPPLEMTARY TABLES AND FIGURES 
 Table S4.1. Inflammatory cell counts in BALF and sputum in patients with bronchiectasis     
Sample 
Total count 
(x10
5 
cells) 
Macrophage 
(%) 
Neutrophil 
(%) 
Lymphocyte 
(%) 
Eosinophil 
(%) 
BALF 
(n = 35) 
13.7 ± 23.5 43.9 ± 34.0 45.2 ± 38.8 10.3 ± 11.0 0.53 ± 0.91 
Induced sputum 
(n = 40)  
13.4 ± 15.3 84.4 ± 15.0 1.52 ± 2.29 0.66 ± 0.69 
Spontaneous sputum 
(n = 94)  
4.70 ± 7.10 93.5 ± 7.91 1.06 ± 1.33 0.78 ± 1.20 
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Figure S4.1. Inflammatory marker levels according to airway microbiology by standard culture. 
Induced sputum from bronchiectasis (n=100) and controls subjects (n=20) were cultured for 
pathogens and classified as ‘culture negative’ (only normal respiratory flora cultured; n=36) or 
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culture positive (any potentially pathogenic microorganism cultured). (A) The relationship between 
inflammatory markers measured in BALF and airway cultured microbes. (B) The relationship 
between endobronchial biopsy gene expression and airway cultured microbes. (C) The relationship 
between MPO concentration and airway cultured microbes. (D) The relationship between neutrophil 
and macrophage counts and airway pathogens. BALF inflammatory marker concentrations and 
endobronchial biopsy gene expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown. *P<0.05, **P<0.01 by Kruskal-
Wallis test comparing bronchiectasis subgroups.) 
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Figure S4.2. Inflammatory marker levels according to pathogenic microbe by standard culture. 
Induced sputum from bronchiectasis (n=100) was cultured for pathogens and classified as ‘culture 
negative’ (only normal respiratory flora cultured; n=36) or ‘P. aeruginosa’ (P. aeruginosa cultured; 
n=36) or ‘other pathogen’ (any potentially pathogenic microorganism cultured; n=28). (A) The 
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relationship between inflammatory markers measured in BALF and airway pathogenic microbes. 
(B) The relationship between endobronchial biopsy gene expression and airway pathogenic 
microbes. (C) The relationship between MPO activity and concentration and airway pathogenic 
microbes. (D) The relationship between inflammatory markers measured in sputum and airway 
pathogenic microbes. Inflammatory marker concentrations and endobronchial biopsy gene 
expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown. Mann-Whitney non-parametric 
test comparing subjects with P. aeruginosa and subjects with other pathogens.) 
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Figure S4.3. Inflammatory marker levels according to serum CRP concentration. (A) The 
relationship between inflammatory markers measured in BALF and serum CRP concentration. (B) 
The relationship between MPO and serum CRP concentration. (C) The relationship between 
endobronchial biopsy gene expressions and serum CRP concentration. BALF inflammatory marker 
concentrations and endobronchial biopsy gene expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown.) 
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Figure S4.4. Inflammatory marker levels according to lung function measured by FEV1. (A) The 
relationship between inflammatory markers measured in BALF and lung function. (B) The 
relationship between endobronchial biopsy gene expressions and lung function. (C) The relationship 
between MPO and lung function. (D) The relationship between spontaneous sputum cell count and 
lung function. BALF inflammatory marker concentrations and endobronchial biopsy gene 
expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown.) 
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Figure S4.5. Inflammatory marker levels according to number of reported pulmonary exacerbations 
in the previous 12 months. (A) The relationship between inflammatory markers measured in BALF 
and number of pulmonary exacerbations. (B) The relationship between MPO and number of 
pulmonary exacerbations. (C) The relationship between induced sputum cell count and number of 
pulmonary exacerbations. (D) The relationship between endobronchial biopsy gene expressions and 
number of pulmonary exacerbations. BALF inflammatory marker concentrations and endobronchial 
biopsy gene expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown. *P<0.05 for Mann-Whitney 
non-parametric test comparing less severe versus severe.) 
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Figure S4.6. Differences in inflammatory marker levels according to maintenance use of inhaled 
corticosteroid (ICS)/ long-acting β-agonist (LABA) inhalers. (A) The relationship between 
inflammatory marker concentration measured in BALF and long-term use of ICS/LABA. (B) The 
relationship between MPO and long-term use of ICS/LABA. (C) The relationship between induced 
sputum cell count and long-term use of ICS/LABA. (D) The relationship between endobronchial 
biopsy gene expressions and long-term use of ICS/LABA. BALF inflammatory marker 
concentrations and endobronchial biopsy gene expressions as per Figures 4.1 and 4.3.  
(Individual data points, median and interquartile ranges are shown.) 
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Chapter 5 Mucin production in bronchiectasis 
5.1 Overview  
Idiopathic bronchiectasis is commonly seen in the middle and lower lobes, which may reflect 
failure of mucociliary clearance and gravity-dependent retention of inflammation related secretions 
(Whitwell, 1952). Airway inflammation in response to bacterial pathogens is assumed to play a 
significant role in bronchiectasis, however the mechanism of airway damage and the nature of the 
underlying mucus overproduction and inflammation are poorly understood. Maintenance therapies 
and physiotherapy to clear sputum from the airways may reduce exacerbation frequency, but 
specific therapies are lacking.  
 
The composition of airway mucus is altered in disease states, with increases in MUC5AC and a 
low-charge isoform of MUC5B reported in asthma and COPD (Kirkham et al., 2008; Kirkham et 
al., 2002) (see Chapter 1.5). These changes in mucin composition were correlated with lung 
function and airflow obstruction in COPD subjects and smokers (Innes et al., 2006; Kirkham et al., 
2008; Kirkham et al., 2002). Little is known about functional differences between MUC5AC and 
the two isoforms of MUC5B, which are likely to represent two differing glycosylation states of 
MUC5B possibly as a consequence of two different cells of origin (Schulz et al., 2007; Xia et al., 
2005). Studies in idiopathic pulmonary fibrosis (IPF) have identified a MUC5B promoter SNP 
(rs35705950) strongly associated with IPF, which is likely to contribute the dysregulated mucin 
production in the IPF airways in these individuals (Scholand et al., 2014; Seibold et al., 2013; 
Seibold et al., 2011). The dysregulated mucin production could potentially stress the protein 
biosynthesis machinery in the cells, and eventually lead to inflammatory signalling and/or apoptosis 
(see Chapter 1.7). 
 
Mucus hypersecretion is one of the hallmark features of non-CF bronchiectasis, however the 
relative abundance of different mucin glycoproteins in bronchiectatic airways has not been 
characterized. Even in CF, which has been much more comprehensively studied, there has been 
considerable debate about the nature of the mucin content of mucus. Recent studies have suggested 
that previous studies which led to a conclusion that CF mucus had a reduced mucin content were 
due to post-sampling mucin degradation, and that the mucin content of CF mucus is increased 
consistent with the increased mucus viscosity. We hypothesised that abnormal airway mucin 
production contributes to dysregulated mucociliary clearance in bronchiectatic airways. We also 
hypothesised that ER stress would occur in secretory cells in bronchiectasis due to increased mucin 
biosynthesis and oxidative stress, and lead to UPR activation and inflammatory signalling by 
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secretory cells. We aimed to comprehensively characterize the airway mucin content in non-CF 
bronchiectasis using induced sputum and endobronchial biopsies to better understand the mucin 
composition of bronchiectatic sputum and how differences in mucin composition may reflect the 
underlying bronchiectasis phenotype (Aim 2), and to characterise the potential role of ER stress in 
bronchiectatic epithelium (Aim 3). 
 
5.2 Methods 
Subjects and procedures 
All sample processing and evaluation was undertaken with complete blinding to disease state and 
study treatment assignment. At baseline, all 112 subjects enrolled in the BLESS study had induced 
sputum collected and a subgroup of 41 subjects with no evidence of additional (non-bronchiectasis) 
chronic respiratory disease underwent bronchoscopy with bronchoalveolar lavage (BAL). Twenty 
healthy control subjects also underwent sputum induction and bronchoscopy. Sputum and 
bronchoscopy procedures were repeated at week 48 with results from subjects in the placebo arm 
presented here. Full details of sputum induction and bronchoscopy procedures are in Chapter 2.3 
and Appendix 1. All control and bronchoscopy subgroup subjects were lifelong non-smokers (<2 
pack year history), aged 18-85 years, with no history of asthma or atopy, recent respiratory tract 
infection (within 4 weeks) or conditions with the potential to impact the safe performance of 
bronchoscopy. Full details of induced sputum and endobronchial biopsy sample processing are 
presented in Chapter 2.4. 
 
Mucin Protein Detection  
In order to characterise and quantify the gel-forming mucins (MUC5AC and MUC5B) in induced 
sputum samples, induced sputum was solubilised for mucin protein detection using Periodic 
Acid/Schiff’s (PAS) Staining and western blot. Full details of sputum solubilisation are in Chapter 
2.11. 
 
Periodic Acid/Schiff’s (PAS) Staining on Nitrocellulose Blots (full details in Chapter 2.11.1) 
In order to semi-quantify mucin proteins in induced sputum, samples were subjected to 
electrophoresis on agarose gels, and then vacuum transferred onto nitrocellulose membranes 
(Kirkham et al., 2002). After proteins were vacuum transferred onto a nitrocellulose membrane, 
Periodic Acid/Schiff’s Staining was carried out to detect and semi-quantify total glycosylated 
proteins on the nitrocellulose membrane.  
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MUC5AC and MUC5B Western Blot (full details in Chapter 2.11.2) 
In order to semi-quantify MUC5AC and MUC5B mucin proteins in induced sputum, samples were 
subjected to electrophoresis on agarose gels, and then vacuum transferred onto nitrocellulose 
membranes (Kirkham et al., 2002). After proteins were vacuum transferred onto a nitrocellulose 
membrane, western blotting detection was carried out using standard methods to detect MUC5AC 
and MUC5B mucin proteins on the nitrocellulose membrane using MAN5AC primary antibody and 
EU-MUC5B primary antibody. Detection of MUC5AC and MUC5B protein on the same blots was 
carried out using Odyssey Li-Cor system (Li-Cor Biosciences, Lincoln, NE).  
 
MUC5AC and MUC5B Immunohistochemistry Staining (full details in Chapter 2.11.4) 
Immunohistochemistry (IHC) was performed using a Ventana Benchmark Ultra staining system 
(Ventana Medical System, Oro Valley, AZ) on paraffin embedded histology sections (4 µm). 
MAN5AC primary antibody and EU-MUC5B primary antibody were used for MUC5AC and 
MUC5B detection. A score from 0 to 4 was given to each biopsy according to its number of mucin 
positive cells per goblet cell or sumbucosal gland. A score of “1” was given to biopsies with 1-25% 
mucin positive cells or glands, 26-50% was given a “2”, 51-75% was given a “3”, and 76-100% was 
given a “4”.  
 
Gene Expression (full details in Chapter 2.6) 
TaqMan detection system was used to detect expression of selected genes from endobronchial 
biopsies (Microfluidic Cards, Life Technologies, Carlsbad, CA). RNA was amplified from all 
samples, prior to analysis by qRT-PCR. The average CT of three housekeeping genes (2-
microglobulin, -actin and Cyclophilin A) was used for standardization. 
 
MUC5B Promoter SNP Genotyping Assay 
Genomic DNA extraction from whole blood was done using an on-column method as per 
manufacturer’s instruction for NucleoSpin Blood (Macherey-Nagel, Duren, Germany). MUC5B 
promoter SNP (rs35705950) genotype was detected using TaqMan detection system as per 
manufacturer’s instruction for TaqMan SNP Genotyping Assays (Life Technologies, Carlsbad, 
CA). 
 
Data Analysis 
Data analysis for the BLESS study including sample size calculations are as described previously 
(Serisier et al., 2013). Data distribution was mostly non-parametric and Mann-Whitney U tests were 
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used to test the significance of variance between control and disease groups, or Kruskal-Wallis test 
where 3 or more groups were compared. Correlations were calculated using Pearson’s correlation 
coefficient after log-transformation of continuous data or Spearman rank correlation coefficient for 
discrete variables. Statistical analyses were performed using SYSTAT software (version 3.1), were 
2-sided and p values <0.05 were considered significant. 
 
5.3 Results 
One hundred and twelve bronchiectasis subjects provided baseline sputum, and satisfactory biopsies 
were obtained from 34 subjects. Demographic details are shown in Table 4.1.  
 
5.3.1 Secreted mucin proteins are elevated in bronchiectatic airways 
Total mucin proteins in induced sputum were quantified using a PAS staining method which detects 
glycosylated proteins (Figure 5.1A), and also a western blotting method to quantify MUC5AC and 
each MUC5B isoform (Figure 5.1B). The total mucin concentration per volume in BE sputum 
(n=112) was 50% higher than in healthy control sputum (n=20, p<0.001) (Figure 5.1C). The 
concentrations of MUC5AC and the low-charge isoform (LCI) of MUC5B were 2-fold and 4-fold 
higher in BE than control sputum (p<0.01 and p<0.001, respectively) (Figure 5.1D) and the ratio of 
MUC5B LCI:high charge isoform (HCI) was 6-fold higher (p<0.001, Figure 5.1E). However, the 
concentration of total MUC5B did not differ between BE and healthy controls. The protein 
concentration of MUC2 in sputum was under the detection limit using our Western blotting method 
in both healthy and BE sputum, demonstrating negligible MUC2 contribution to mucus (data not 
shown). Longitudinal assessment of sputum mucin content in patients in the placebo arm of 
BLESS, showed significant positive correlations between measurements at the beginning of the trial 
and week 48 (r=0.41 and p<0.01 for total mucin) (Figure 5.2).  
 
In order to identify which cells produce these mucins, MUC5AC and MUC5B 
immunohistochemistry was performed. The amount of MUC5AC in bronchiectatic epithelium was 
significantly higher than in normal healthy epithelium, and no MUC5AC protein was detected in 
the submucosal glands of healthy controls or BE (p<0.05, Figure 5.1F). MUC5B was present in 
bronchial epithelium and submucosal glands, and the amount of MUC5B did not differ between 
healthy and bronchiectasis subjects. Figure 5.1G and Figure 5.1H show representative examples of 
MUC5AC and MUC5B protein localization in bronchiectatic airways. Figure 5.1G in particular 
shows representative goblet cells that produce both MUC5AC and MUC5B in bronchiectatic airway 
epithelium. 
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Figure 5.1. Relative quantity of sputum mucin proteins from subjects with bronchiectasis and 
normal healthy controls. (A) Semi-quantification of total mucins in induced sputum using PAS 
staining method. (B) Semi-quantification of MUC5AC and MUC5B protein in induced sputum 
using western blotting method. (C) Relative quantification of total mucin protein in induced sputum 
from BE patient airways (n=112) and normal healthy controls (n=20) measured as described in (A). 
(D) Relative quantification of MUC5AC and MUC5B protein in induced sputum from BE patient 
airways and normal healthy controls measured as described in (B). (E) MUC5B isoform ratio in 
induced sputum as described in (D). (F) Semi-quantification of MUC5AC and MUC5B protein in 
endobronchial biopsies from BE subjects (n=35) and normal healthy individuals (n=20) using 
immunohistochemistry method. (G) MUC5AC and MUC5B immunohistochemistry co-staining 
(MUC5AC shown in brown and MUC5B shown in pink) on epithelium of a BE endobronchial 
biopsy section. (magnification x60) (H) MUC5B immunohistochemistry staining (shown in pink) 
on submucosa of a BE endobronchial biopsy section. (magnification x60) 
(Box and whisker plots display median, interquartile ranges, and range; **P<0.01, ***P<0.001 by 
Mann-Whitney non-parametric test for (C), (D) and (E). Bar charts display mean±SD; *P<0.05, 
**P<0.01 by Mann-Whitney non-parametric test for (F).) 
 
 
Figure 5 – Immunohistochemistry stain of MUC5AC and MUC5B on bronchiectatic airway biopsies
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Figure 5.2. Within-subject correlations for (A) total mucin concentration and (B) MUC5B isoform 
ratio from placebo arm bronchiectasis samples obtained at weeks 0 and 48. Unadjusted Pearson 
correlation coefficients and p-value are shown. 
 
5.3.2 Expression of mucin-related genes are elevated in bronchial tissue in bronchiectasis 
In bronchial tissue from endobronchial biopsies gene expression of the main airway gel-forming 
mucins MUC5AC and MUC5B did not differ between healthy control (n=20) and BE (n=34) 
subjects. Interestingly, the gene expression of MUC2 was significantly reduced in bronchiectasis 
subjects (p<0.05) (Figure 5.3A), as was one of the cell surface mucins, MUC4 (p<0.01). There were 
no differences in expression of the other measured cell surface mucins MUC1 and MUC16. 
Amongst other genes involved in mucin processing pathway or mucus cells, TFF1, TFF3 and 
AGR2 were upregulated in BE subjects (7-fold, 3-fold and 2-fold, respectively), whilst TFF2, 
SPDEF or ZG16B were unchanged (Figure 5.3B). The expression of TFF1 and TFF3 were 
positively correlated (r=0.69, p<0.001, Figure 5.3C), as were ZG16B and MUC5B (r=0.72, 
p<0.001, Figure 5.3D). Both MUC5B and ZG16B expression were positively correlated with 
expression of genes encoding for infection response proteins: lysozyme (LYZ), serine protease 
inhibitor A3 (SERPINA3) and prolactin-induced protein (PIP) (Figure 5.3E).                             
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Figure 5.3. Bronchial tissue gene expression in subjects with bronchiectasis (BE) and normal 
healthy controls (CONT). (A) Expression of mucin genes in tissue from bronchial biopsies from BE 
patient airways (n=34) and normal healthy controls (n=20). (B) Expression of mucin-related genes 
from BE patient airways and normal healthy controls.  (C) Within-sample correlation between the 
expression of mucin related genes, TFF1 and TFF3, in BE patient airways. (D) Within-sample 
correlation between the expression of MUC5B and mucin-related gene, ZG16B, in BE patient 
airways. (E) Within-subject correlation between the expression of mucin-related genes and infection 
response genes in BE patient airways.  
(Box and whisker plots display median, interquartile ranges, and range, and *P<0.05, **P<0.01, 
***P<0.001 by Mann-Whitney non-parametric test for (A) and (B). Unadjusted Pearson correlation 
coefficients for (C-E), and *P<0.05, **P<0.01, ***P<0.001 for (E).)  
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5.3.3 Mucin concentrations do not reflect airway microbial pathogens and markers of 
inflammation 
There was no evidence of any relationships between the presence of cultured potentially pathogenic 
microorganisms (PPM’s) and sputum concentrations of either total mucin or subtypes, nor any 
evidence that the presence of specific cultured pathogens (eg Pseudomonas aeruginosa) influenced 
mucin levels (Figure 5.4 and Supplementary Figures S5.1 and S5.2). Similarly, no relationships 
were seen between cultured microorganisms and mucin or gene expression in endobronchial 
biopsies. Sputum concentrations of mucin proteins did not correlate with cytokines (Table 5.1), or 
inflammatory cell counts (Table 5.2). 
 
 
Figure 5.4. Total mucin concentration according to airway microbiology by standard culture. (A) 
Induced sputum from BE patients at enrolment in the BLESS trial (n=112) and from healthy 
controls (n=20) were cultured for pathogens and classified as ‘culture negative’ (only normal 
respiratory flora cultured; n=20 for all control subjects and n=39 for bronchiectasis subjects) or 
culture positive (any potentially pathogenic microorganism cultured).  (B) Induced sputum from BE 
patients were further classified as positive for P. aeruginosa (n=39), or other pathogen (n=34).  
(Individual data points, median and interquartile ranges are shown; Kruskal-Wallis non-parametric 
test comparing BE subgroups.) 
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Table 5.1. Within-subject correlations for sputum relative mucin concentration and inflammatory 
marker concentration. Unadjusted Pearson correlation coefficients are shown, and p>0.05 for all 
correlations. N=40 for BALF correlation, and n=100 for induced sputum correlation. 
 
 
 
Table 5.2. Within-subject correlations for sputum relative mucin concentration and inflammatory 
marker concentration. Unadjusted Pearson correlation coefficients are shown, and p>0.05 for all 
correlations.  
 
 
 
 
 
Table 2 – Correlation pattern of each mucin with airway cytokine level (n = 40 for BALF cytokine
correlation, and n = 100 for sputum cytokine correlation.)
Total mucin MUC5AC MUC5B(LCI) MUC5B(HCI)
CXCL5 0.37 0.13 0.15 0.16
CXCL10 0.16 0.15 -0.12 0.14
Eotaxin 0.31 0.23 0.24 -0.05
GM-CSF 0.35 0.21 0.24 -0.05
MCP-1 0.20 0.33 -0.13 -0.06
IL-1a 0.14 0.19 -0.02 -0.06
IL-1b 0.12 0.07 -0.01 -0.19
IL-8 0.24 0.24 0.11 -0.04
IFN-g 0.33 0.23 0.20 -0.12
TNF-a 0.28 0.21 0.20 -0.04
IL-4 0.29 0.23 0.15 0.01
IL-6 0.27 0.29 0.03 -0.06
IL-13 0.20 0.12 0.12 -0.08
IL-17A 0.37 0.25 0.28 -0.03
IL-23 0.30 0.28 0.20 -0.05
IL-10 0.26 0.16 0.20 -0.07
IL-1b 0.15 0.36 -0.11 -0.33
IL-8 0.35 0.44 0.15 -0.07
Measured
from BALF
Measured
from sputum
Total mucin MUC5AC MUC5B (LCI) MUC5B (HCI)
BALF total cell count 0.42 0.42 0.02 0.12
BALF macrophage % -0.34 -0.09 -0.13 0.06
BALF neutrophil % 0.28 0.25 0.14 -0.07
Induced sputum macrophage % 0.05 0.15 0.29 0.31
Induced sputum neutrophil % 0.03 -0.01 -0.29 -0.35
Spontaneous sputum macrophage % -0.01 0.01 0.09 0.17
Spontaneous sputum neutrophil % 0.31 0.17 0.24 0.15
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5.3.4 Mucin concentrations in sputum do not reflect clinical measures of disease activity and 
severity 
There were no significant relationships seen between sputum mucin concentrations and 24 hour 
sputum weight, FEV1, serum CRP, number of self-reported pulmonary exacerbations in the 
preceding 12 months, quality of life (St George’s Respiratory Questionnaire), cough symptoms 
(Leicester Cough Score) (Figure 5.5 and Supplementary Figures S5.3, S5.4, S5.5, S5.6). 
Furthermore, sputum mucin concentrations were not predictive of the number of pulmonary 
exacerbations in placebo subjects in the subsequent 12 months. 
 
 
Figure 5.5. Sputum total mucin relative concentration according to clinical markers of disease 
activity and severity. (A) Within-subject correlation between the total mucin and 24 h sputum 
volume in BE patient airways. (B) Total mucin concentrations according to lung function. (C) Total 
mucin concentrations according to serum CRP concentration. (D) Total mucin concentrations 
according to number of self-reported pulmonary exacerbations in the preceding 12 months.           
(Unadjusted Pearson correlation coefficients for (A). Individual data points, median and 
interquartile ranges are shown; Kruskal-Wallis non-parametric test comparing BE subgroups for 
(B), and Mann-Whitney non-parametric test for (C) and (D).)  
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5.3.5 The IPF-associated MUC5B promoter SNP allele frequency in bronchiectasis does not 
differ from population controls 
Out of the 117 bronchiectasis subjects, 103 patients consented for analysis of the MUC5B 
polymorphism recently linked to idiopathic pulmonary fibrosis (IPF) (Seibold et al., 2011; Zhang et 
al., 2011), and adequate samples were available from 101 patients (86%). The allele frequency of 
the MUC5B promoter SNP rs35705950 minor allele in BE subjects did not differ from 575 
population controls (10.90 and 10.95%, respectively, p>0.05) (Table 5.3). Within the bronchiectasis 
cohort, carriage of the minor allele was not associated with sputum mucin concentration, 24-hour 
sputum volume, lung function, or number of self-reported pulmonary exacerbations in the preceding 
12 months. Thus is highly unlikely this polymorphism predisposes to bronchiectasis or affects the 
relative abundance of mucins in mucus. 
 
Table 5.3. MUC5B promoter SNP genotype in bronchiectasis subjects 
 
Wild type SNP carrier 
Bronchiectasis (n=84) 79% (80/101) 21% (21/101) 
   Total mucin 267 ± 62 270 ± 102 
MUC5AC 544 ± 311 547 ± 348 
MUC5B (LCI) 114 ± 104 145 ± 166 
MUC5B (HCI) 59 ± 57 74 ± 74 
MUC5B isoform ratio 3.5 ± 4.4 2.9 ± 2.4 
Sputum volume (g) 21.3 ± 33.2 21.0 ± 12.0 
FEV1 % predicted (pre-bronchodilator) 68.1 ± 19.1 68.3 ± 19.1 
Exacerbations (last 12 months) 4.7 ± 2.9 4.8 ± 3.6 
   
 
5.3.6 ER stress marker gene expression is not elevated in endobronchial biopsies 
The mucin hypersecretion in BE, together with oxidative stress induced by the immune response, 
could cause ER stress, which has been reported in CF and IPF (Bartoszewski et al., 2008; Korfei et 
al., 2008). Amongst a group of ER stress marker genes, in the BE airway there was a 2-fold 
decrease in expression of the ER stress chaperone, GRP78, which is typically increased during ER 
stress, and a 1.6-fold increase in the transcription factor, CHOP, which is associated with ER stress-
induced apoptosis (p<0.05 for both) (Figure 5.6). However, there was no significant difference in 
splicing of the XBP1 mRNA (a direct measure of activation of the unfolded protein response) or 
changes in expression of other ER stress markers including calnexin, calreticulin, EDEM1, EDEM2 
and VCP-1. These data provide little support for ER stress being an important phenomenon in 
bronchiectasis pathophysiology. 
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Figure 5.6. Expression of ER stress marker genes in endobronchial biopsies from BE patient 
airways (n=34) and normal healthy controls (n=20). Box and whisker plots display median, 
interquartile ranges, and range, and *P<0.05 by Mann-Whitney non-parametric test. 
 
5.4 Discussion 
Bronchiectatic airways are characterised by copious mucus hypersecretion with patients producing 
large volumes of sputum daily. Mucus hypersecretion and inadequate ciliary clearance in the 
bronchiectatic airways prevent clearance of micro-organisms from the bronchial lumen, hence 
triggering prolonged inflammation and ongoing mucus hypersecretion (Cole, 1986). No report so 
far has comprehensively analyzed the relationship between sputum mucin quantity and clinical 
features of non-CF bronchiectasis.  In order to further understand the mucin composition of 
bronchiectatic sputum and how the mucin composition could affect disease phenotype, this study 
described the relative abundance of the major mucin glycoproteins constituents of mucus in 
bronchiectatic airways and the expression of mucin-related genes. We demonstrate increased mucin 
content in bronchiectatic sputum, particularly of the low charge glycoform of MUC5B. However, 
surprisingly the mucin composition did not correlate with sputum volume, the presence of 
inflammatory airway bacterial pathogens, poor lung function, serum CRP concentrations or 
frequency of pulmonary exacerbations. 
 
Mucins are major contributors to the viscosity of airway secretions, with an optimal balance 
required for mucus to effectively sequester particulate matter in the airway and yet still be 
efficiently cleared by the mucociliary escalator.  Both the total quantity of mucin secretion and the 
relative abundance of cell surface and secreted mucins can change in chronic respiratory disease, 
Figure 1 – Gene expression of ER stress mark rs in airway biopsies. (Controls n = 20, and non-CF BE n = 34)
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and our data did not contradict these findings. Altered sputum mucin content has previously been 
shown in chronic respiratory diseases including asthma and COPD. The increase in intracellular 
mucin storage and shift in the ratio of MUC5B to MUC5AC were linked to lung function and 
airflow obstruction in smokers and COPD subjects (Innes et al., 2006; Kirkham et al., 2008; 
Kirkham et al., 2002). Although there is an increase in mucin-producing cells in pathological 
conditions, no evidence of major change in the distribution of MUC5AC and MUC5B secreting 
cells has been shown, and no major change in the macromolecular properties of the mucins 
including barrier function and rheological properties has been identified in respiratory diseases so 
far (Thornton et al., 2008; Thornton et al., 1991). Our data show increased total quantity of mucin, 
particularly an increased relative abundance of the low charge isoform of MUC5B, and MUC5AC 
producing cells in the epithelium. And if this data were to be viewed as amount of mucin per day, 
the difference between healthy individuals and controls is amplified as the bronchiectatic subjects 
constantly produce sputum whereas healthy individuals do not.  
 
In CF airways,  Henke et al reported a lower mucin content in CF sputum compared to normal 
sputum, which they suggested that highly polymerized DNA from polymorphonuclear leukocyte 
necrosis and net formation may have greater impact on mucus viscosity than mucins (Henke et al., 
2004). In contrast, others have found increased mucin content and a greater partial osmotic pressure 
in CF sputum compared to normal sputum (Davies et al., 1999; Henderson et al., 2014). The recent 
studies have shown that proteolytic activities contributed by host immune responses and bacteria in 
the CF airways have been identified as contributor to loss of sputum elasticity and loss of epitopes 
for detection of mucins using immunological techniques (Davies et al., 1999; Henderson et al., 
2014; Horsley et al., 2014). These recent studies suggested that the earlier studies in CF sputum 
were likely compromised by post-sampling degradation of mucins by proteases, and that in fact 
mucin content is increased, not decreased, in CF sputum. In our bronchiectatic sputum, even though 
we froze induced sputum samples soon after collection, the absolute quantity of mucin protein 
could have been underestimated as bronchiectatic sputum also contains vast amounts of proteases 
and the mucins may have been subject toproteolytic degradation in the airways (see Chapter 6).  
 
In subjects with bronchiectasis, daily sputum volume and serum CRP level had a positive 
correlation (unpublished data), but the specific mucin concentration did not link to sputum volume, 
or clinical measures of disease activity and severity. Little is known about functional differences 
between MUC5AC and the two isoforms of MUC5B. It is not clear if MUC5AC and the different 
variants of MUC5B form gels with different transport properties or other functional properties, or 
whether the mucins are mixed within a single gel versus forming distinct layers within the gel. 
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Transgenic mice overexpressing Muc5ac do not develop luminal mucus plugging, airway 
inflammation or goblet cell hyperplasia (Ehre et al., 2012), and Muc5b -/- mice had impaired 
mucociliary clearance (Roy et al., 2013), suggest that MUC5B is necessary for healthy airway 
function. However, cell types that produce airway mucins in mouse are different from the human, 
and lacking the second Muc5b glycoform in mouse airway secretions lessens the relevance of these 
murine studies for human airway diseases. In human airway diseases, there are many interacting 
factors and the contributions of mucins to mucus plugging is still unclear. The data we presented in 
this chapter were measures of how much mucin there was in the mucus, not how much mucus the 
bronchiectatic subjects made. The sputum volume measurements are the measure of mucus 
hypersecretion, which is different from what we have measured, the mucin content of sputum. 
Mucus hypersecretion (24 h sputum weight) is an indicator of disease severity and is decreased in 
the BLESS erythromycin arm. Our data show that the relative mucin content in sputum is 
differentially regulated by mucus secretion.  
 
Post-transcriptional modifications of mucins could contribute to pathogenesis of bronchiectasis. 
SPDEF is expressed in epithelial cells in various tissues, and is highly involved in regulating a 
transcriptional network mediating the goblet cell differentiation and mucus hyper-production 
associated with chronic pulmonary disorders (Chen et al., 2009; Park et al., 2007). Our data show 
increased production of gel-forming mucin proteins, but the expression of MUC5AC, MUC5B or 
SPDEF genes did not differ from healthy controls, suggesting that mucus overproduction in 
bronchiectasis involves change in post-transcriptional regulation of mucin biosynthesis. 
Furthermore, we have also shown that expression of TFF1, TFF3 and AGR2, which are involved in 
modulation of mucus viscosity and mucin production in the ER (Schroeder et al., 2012; Wright et 
al., 1997), is increased in bronchiectatic airways. Interestingly, the biopsies in our studies were only 
obtained from proximal airways, hence whether dysregulated mucin gene expression in distal 
airways or alveolar epithelium could contribute to mucus hypersecretion remains unknown. Further 
investigations of the regulation of mucin production in different cell types and different areas along 
the respiratory tract would assist understanding as to whether dysregulated local mucin production 
contributes to mucus retention in the lower lobes and small airway inflammation, which could result 
in bronchiectasis (Whitwell, 1952).  
 
We did not observe a correlation between sputum mucin content with the expression of mucin-
related genes with inflammatory markers or the major airway microbial pathogens. This is 
somewhat surprising as the expression of cell surface and gel-forming mucins have been shown to 
be regulated by inflammatory mediators and microbes in cell culture or mouse models (Chen et al., 
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2009; Dabbagh et al., 1999; Delmotte et al., 2001; Gray et al., 2004; Neveu et al., 2009; Reader et 
al., 2003; Song et al., 2007; Zhen et al., 2007). In particular, Muc5ac has been shown to upregulated 
in influenza virus infection and promotes clearing of nematode infection (Floyd et al., 2012; 
Hasnain et al., 2011). A Muc5b knockout murine model has been shown to be lethally predisposed 
to S. auerus infection (Roy et al., 2013). 
 
Given that other studies only measured single inflammatory markers or were done in cultured cells, 
our study is the first study to comprehensively analyse a panel of cytokines and chemokines 
together with the mucin content, and we quite unexpectedly show no correlation between mucin 
content and specific individual inflammatory factors. These results further highlighted the 
complexity of chronic airway diseases, that the effect of each cytokine or chemokine could be 
potentiating or attenuating one another, therefore multiple effects should be taken into consideration 
when reviewing these results. Bacteria missed by culturing techniques (non-culturable bacteria or 
bacteria that exist in low numbers) could have also contributed to the inflammatory response, 
therefore a comprehensive analysis using molecular techniques to quantify the bacteria would give 
further insights as to how the airway microbiota influences mucin production. 
 
The longitudinal results were reported to investigate whether the activation of mucin production is 
consistent over time. We hypothesised that mucin content in bronchiectatic airways are modulated 
by the microenvironment at the time of sampling, hence the sputum mucin content would not be 
consistent at different sampling times. The surprisingly high correlation of sputum mucin content 
between baseline and 48 weeks suggests that the microenvironment in bronchiectatic airways is 
relatively consistent and stable.  
 
A common polymorphism in the promoter of MUC5B has been linked to IPF and its clinical 
symptoms (Hunninghake et al., 2013; Peljto et al., 2013; Scholand et al., 2014; Seibold et al., 2013; 
Seibold et al., 2011), and therefore we explored whether dysregulated MUC5B expression could be 
involved in the pathogenesis of bronchiectasis. Our data showed no difference in frequency of this 
specific allele between bronchiectasis subjects and healthy controls. In fact, we could find no 
significant difference in mucin MUC5B content of sputum in carriers of the IPF-associated allele. 
Furthermore, no phenotype was identified in subjects carrying the polymorphism, suggesting that 
this MUC5B polymorphism and dysregulated MUC5B production do not contribute to either the 
development of BE or to disease severity or phenotype. We acknowledge this genetic study is 
underpowered due to the small number of bronchiectatic samples, and it was effectively a pilot 
study to see if a larger more comprehensively powered study was warranted. 
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We hypothesised that mucus hypersecretion could lead to ER stress in the mucus-producing cells in 
bronchiectatic airways. However, we did not find evidence that ER stress is a significant feature of 
bronchiectasis. The validity of this negative finding could be compromised by the mixed cell 
populations in the endobronchial biopsies. Detection of ER stress using in situ staining techniques 
or by using mRNA from ex vivo airway epithelial cells from airway brushings would be a better 
approach to understand whether the mucus-producing cells in the bronchiectatic airways are in 
normal healthy condition or experiencing ER stress due to the local environment and the demands 
of chronically increased mucin biosynthesis. The intrinsic features of bronchiectatic airway 
epithelium will be further discussed in Chapter 8. 
 
We believe that we have used the most suitable specimens to measure markers that help to prove 
our hypotheses. For the detection of mucin proteins, other than measurements from induced sputum 
samples, we have also analysed a subset of BAL fluids. Mucin protein was undetectable in only 
~50% BALF. This was likely because the BALF was filtered through gauze when it was collected, 
which is likely to remove most of the mucus from the BALF. Also, considering we had 100 induced 
sputum samples compared to 41 BALF specimens, focusing on the results from induced sputum 
gave us more statistical power in the analyses. Our mucin detection using immunologic method was 
consistent with mucin detection using an antibody-free method, therefore we are confident that 
sampling variations due to proteolytic activity (Henderson et al., 2014; Horsley et al., 2014) are 
minimal due to strict and consistent sample processing methods with rapid freezing of induced 
sputum.  This is supported by our finding of high mucin content, consistent with the studies in CF 
which have minimised proteolytic degradation. 
 
The major limitation in this clinical study is the potential discrepancy between the actual sampling 
sites and where the pathology lies. In order to obtain samples representing a larger area of the lung, 
we chose to analyse induced sputum as induced sputum is believed to be a heterogeneous mix of 
mucus secreted from different areas of the lung. One can argue that induced sputum does not come 
from distal airways where bacteria could be colonising. However, compared to BAL which only 
samples one lobe of the lung and spontaneous sputum which is expectorated upon certain stimuli, 
induced sputum is likely to be more representative of the whole lung, and it would sample fairly 
distally in non-obstructed lungs. Nonetheless, the local microenvironment in different areas of the 
lung could vary, hence could contribute to the lack of correlations between our sputum, biopsy and 
BALF data. Furthermore, pathological mucin secretion may be happening lower in the lung than 
where endobronchial biopsies could reach (Seibold et al., 2013).  
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This report is the first comprehensive study exploring linkages between mucin quantity/quality and 
clinical, inflammatory and microbial factors in a large number of bronchiectasis subjects. However, 
we did not find any link between mucin content and inflammatory markers or pathogenic microbial 
species. We observed an increase in total mucin content and an alteration in the glycoform of the 
MUC5B mucin in bronchiectatic sputum. Furthermore, an increase in other goblet cell products was 
also observed in the BE patients compared to controls which in combination is likely to contribute 
to the poor mucociliary clearance in bronchiectasis. Future studies identifying the activator of 
mucin production and secretion by different cell types, and linking the potential roles of each gel-
forming mucin glycoform in mucus plugging may give insights into new treatments for 
bronchiectasis and other chronic airway diseases.  
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SUPPLEMENTARY TABLES AND FIGURES 
 
Figure S5.1. Relative sputum mucin concentration and mucin gene expression according to airway 
microbiology by standard culture. Induced sputum from BE patients at enrolment in the BLESS 
trial (n=112) and from healthy controls (n=20) were cultured for pathogens and classified as 
‘culture negative’ (only normal respiratory flora cultured; n=20 for all control subjects and n=39 for 
bronchiectasis subjects) or culture positive (any potentially pathogenic microorganism cultured). 
(A) The relationship between relative mucin concentration measured in sputum and airway cultured 
microbes. (B) The relationship between endobronchial biopsy gene expression and airway cultured 
microbes.     
(Individual data points, median and interquartile ranges are shown; Kruskal-Wallis non-parametric 
test comparing BE subgroups.) 
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Figure S5.2. Relative sputum mucin concentration and mucin gene expression according to airway 
P. aeruginosa colonisation by standard culture. Induced sputum from BE patients were further 
classified as positive for P. aeruginosa (n=39), or other pathogen (n=34). (A) The relationship 
between relative mucin concentration measured in sputum and airway P. aeruginosa colonisation. 
(B) The relationship between endobronchial biopsy gene expression and airway P. aeruginosa 
colonisation.     
(Individual data points, median and interquartile ranges are shown; Kruskal-Wallis non-parametric 
test comparing BE subgroups.) 
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Figure S5.3. Within-subject correlation between relative sputum mucin concentration and 24 h 
sputum volume in BE patient airways.  
(Unadjusted Pearson correlation coefficients are shown.) 
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Figure S5.4. Relative sputum mucin concentration and mucin gene expression according to lung 
function. (A) The relationship between relative mucin concentration measured in sputum and lung 
function. (B) The relationship between endobronchial biopsy gene expression and lung function. 
(Individual data points, median and interquartile ranges are shown; Kruskal-Wallis non-parametric 
test comparing BE subgroups.) 
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Figure S5.5. Relative sputum mucin concentration and mucin gene expression according serum 
CRP concentration. (A) The relationship between relative mucin concentration measured in sputum 
and serum CRP concentration. (B) The relationship between endobronchial biopsy gene expression 
and serum CRP concentration. 
(Individual data points, median and interquartile ranges are shown, and Mann-Whitney non-
parametric test comparing subjects with serum CRP concentration <5 versus subjects with serum 
CRP concentration ≥5.) 
 
 
< 5 > 5
0.1
1
10
T
F
F
3
< 5 > 5
10
100
1000
M
U
C
5
A
C
< 5 > 5
1
10
100
M
U
C
5
B
 L
C
I
< 5 > 5
1
10
100
M
U
C
5
B
 H
C
I
< 5 > 5
10
100
1000
M
U
C
5
B
 t
o
ta
l
< 5 > 5
0.1
1
10
M
U
C
5
B
 r
a
ti
o
< 5 > 5
1
10
A
G
R
2
< 5 > 5
0.1
1
10
M
U
C
1
< 5 > 5
0.1
1
M
U
C
1
6
< 5 > 5
0.0001
0.001
0.01
0.1
1
10
M
U
C
2
< 5 > 5
0.001
0.01
0.1
1
M
U
C
4
< 5 > 5
0.01
0.1
1
10
100
M
U
C
5
A
C
< 5 > 5
0.01
0.1
1
10
100
M
U
C
5
B
< 5 > 5
0.1
1
10
Z
G
1
6
B
< 5 > 5
0.01
0.1
1
10
100
S
P
E
D
F
< 5 > 5
0.1
1
10
100
T
F
F
1
< 5 > 5
0.01
0.1
1
10
100
T
F
F
2
MUC5AC           MUC5B total         MUC5B (LCI)       MUC5B (HCI)        MUC5B ratio           MUC5AC                  MUC5B MUC2                   MUC1 
MUC4                   MUC16                 SPEDF                   TFF1                    TFF2           TFF3                      AGR2       ZG16B
CRP
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 m
e
d
ia
n
s
 o
f 
c
o
n
tr
o
ls
S
ig
n
a
l 
in
te
n
s
it
y
 p
e
r 
m
L
 o
f 
in
d
u
c
e
d
 s
p
u
tu
m
F
o
ld
 c
h
a
n
g
e
 r
e
la
ti
v
e
 t
o
 m
e
d
ia
n
s
 o
f 
c
o
n
tr
o
ls
< 5        ≥ 5 < 5        ≥ 5 < 5        ≥ 5          ≥   5        ≥ 5 < 5        ≥ 5 < 5        ≥ 5 < 5        ≥ 5 
         ≥  
Serum CRP (mg/L)
(A) (B)
123 
 
 
Figure S5.6. Relative sputum mucin concentration and mucin gene expression according to number 
of reported pulmonary exacerbations in the previous 12 months. (A) The relationship between 
relative mucin concentration measured in sputum and number of reported pulmonary exacerbations. 
(B) The relationship between endobronchial biopsy gene expression and number of reported 
pulmonary exacerbations. 
(Individual data points, median and interquartile ranges are shown, and Mann-Whitney non-
parametric test comparing less severe versus severe.) 
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Chapter 6 Tissue remodelling in bronchiectasis 
6.1 Overview 
Airway scarring that is secondary to chronic inflammation is a key feature in bronchiectasis. The 
scarred airway wall is characterised by the loss of elasticity and smooth muscle hyperplasia and 
hypertrophy, as seen in patients with chronic inflammatory lung diseases that include CF, asthma, 
and bronchiectasis (Regamey et al., 2008). The remodelling process involves excess matrix 
synthesis along with distorted deposition of that matrix, which leads to lost elasticity of the tissue 
and reduced clearance of airway insults (see Chapter 1.6). Protease activities in the airways have 
been linked to bronchiectasis disease progression, specifically the onset of bronchiectasis in 
children with CF (Bergin et al., 2013; Sly et al., 2013). Matrix metalloproteinases (MMPs) that 
mediate the major part of the tissue destruction in chronic inflammatory diseases, and human 
neutrophil elastase (NE) which modulates neutrophilic inflammation, are important proteases 
involved in bronchiectasis tissue remodelling. Specific MMPs that have been shown to be 
associated with bronchiectasis include MMP-1, MMP-2, MMP-8 and MMP-9 (Bergin et al., 2013; 
Hsieh et al., 2013; Zheng et al., 2002). However, the process and the specific cells involved in the 
destruction of airway extracellular matrix (ECM) and development of bronchiectasis are still yet to 
be clarified.  
 
In chronic tissue injury, the control mechanisms of repair process are lost and continued repair 
results in change of normal airway structure (Jeffery, 2001, 2004). Many growth factors can induce 
ECM synthesis (Parameswaran et al., 2006; Postma and Timens, 2006). However, increased growth 
factor expression/concentration and activation of tissue repair processes does not prevent or reverse 
structural remodelling in the airways in CF (Shute et al., 2003). In bronchiectasis, growth factors 
involved in regulation of epithelial repair (epithelial growth factor, EGF), cell-cycle progression, 
cell growth and differentiation (fibroblast growth factor, FGF), and angiogenesis and vascular 
permeability (platelet-derived growth factor, PDGF, and vascular endothelial growth factor, VEGF) 
are potential markers that could affect airway remodelling and influence disease progression.  
 
While tissue remodelling seems to play a major role in progression of bronchiectasis, the interplay 
between tissue remodelling markers and other inflammatory responses are poorly defined. We do 
not know which aspects of inflammation initiate remodelling, which aspects are damaging or which 
lead to appropriate repair processes in bronchiectasis. Therefore, we hypothesised that continuous 
activation of tissue remodelling in bronchiectasis promotes disease progression. This study aims to 
characterize the tissue remodelling pattern in non-CF bronchiectasis, and to identify the potential 
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role of tissue remodelling in bronchiectasis pathophysiology and progression by linking levels of 
protease activities with clinical measurements and histology scores in clinical specimens from 
bronchiectatic airways (Aim 4). 
 
6.2 Methods 
Subjects and procedures  
All sample processing and evaluation was undertaken with complete blinding to disease state and 
study treatment assignment. At baseline, all 117 subjects enrolled in the BLESS study had induced 
sputum collected and a subgroup of 41 subjects with no evidence of additional (non-bronchiectasis) 
chronic respiratory disease underwent bronchoscopy with bronchoalveolar lavage (BAL). Twenty 
healthy control subjects also underwent sputum induction and bronchoscopy. Sputum and 
bronchoscopy procedures were repeated at week 48 with results from subjects in the placebo arm 
presented here. Full details of sputum induction and bronchoscopy procedures are in Chapter 2.3 
and Appendix 1. All control and bronchoscopy subgroup subjects were lifelong non-smokers (<2 
pack year history), aged 18-85 years, with no history of asthma or atopy, recent respiratory tract 
infection (within 4 weeks) or conditions with the potential to impact the safe performance of 
bronchoscopy. Full details of BALF, induced sputum and endobronchial biopsy sample processing 
are described in Chapter 2.4. 
 
Human neutrophil elastase (NE) activity assay (full details in Chapter 2.9) 
Human neutrophil elastase activity in induced sputum was detected by measuring the signal 
intensity after addition of the substrate N-methoxysuccinyl-ala-ala-pro-val p-nitroanilide (Sigma-
Aldrich, St. Louis, MO).  
 
Matrix metalloproteinase (MMP) activity assay (full details in Chapter 2.10) 
Total MMP activity in BALF and induced sputum was detected using SensoLyte Generic MMP 
detection kit (AnaSpec, Fremont, CA). 
 
Gene expression (full details in Chapter 2.6) 
The TaqMan detection system was used to detect expression of selected genes from endobronchial 
biopsies (Microfluidic Cards, Life Technologies, Carlsbad, CA). RNA was amplified from all 
samples, prior to analysis by qRT-PCR. The average CT of three housekeeping genes (2-
microglobulin, -actin and Cyclophilin A) was used for standardization. 
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Luminex assay for growth factors (full details in Chapter 2.7) 
The Procarta Luminex array which measures EGF, bFGF, PDGF-BB and VEGF-A was used to 
measure growth factors concentration in BALF (Affymetrix, Santa Clara, CA).  
 
Data analysis 
Data analysis for the BLESS study including sample size calculations are as described previously 
(Serisier et al., 2013). Data distribution was mostly non-parametric and Mann-Whitney U tests were 
used to test the significance of variance between control and disease groups, or Kruskal-Wallis test 
where 3 or more groups were compared. Correlations were calculated using Pearson’s correlation 
coefficient after log-transformation of continuous data or Spearman rank correlation coefficient for 
discrete variables. Statistical analyses were performed using SYSTAT software (version 3.1), were 
2-sided and p values <0.05 were considered significant. 
 
6.3 Results 
Induced sputum samples were obtained from 100 subjects, BALF specimens were obtained from all 
41 bronchoscopy subgroup subjects, and endobronchial biopsy samples obtained from 34 subjects. 
All control subjects provided samples. Demographic details of the participants are shown in Chapter 
4 Table 4.1.  
 
6.3.1 Protease activities are elevated in BALF and induced sputum 
Human neutrophil elastase activity was highly elevated in bronchiectatic sputum (Figure 6.1A). All 
the healthy controls were beneath the limit of detection (<0.1 g/mL sputum), while bronchiectatic 
sputum had an average human neutrophil elastase activity of 21.5 g/mL. Total MMP activity was 
also highly elevated in bronchiectatic sputum and BALF compared to healthy controls (Figure 
6.1B). Compared to healthy controls, bronchiectatic subjects demonstrated a ~140-fold increase in 
total MMP activity in sputum and >1000-fold increase in BALF. In bronchiectasis, a ~2-fold 
difference in total MMP activity was detected in sputum compared to BALF, and a positive 
correlation was seen between the two sample types (r = 0.43, p = 0.006) (Figure 6.1C). A strong 
positive correlation was also observed between NE activity and total MMP activity in 
bronchiectatic sputum samples (r = 0.89, p < 0.001) (Figure 6.1D). Longitudinal assessment of 
protease activity in placebo arm BE, showed that NE and total MMP activity in induced sputum 
remained at similar levels with significant correlations between samples at the beginning of the trial 
and 48 weeks later (r = 0.74 and r = 0.68, respectively, p < 0.001) (Figure 6.1E and 6.1F).  
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6.3.2 MMP gene expression is elevated in bronchial tissue in bronchiectasis 
We undertook to compare RNA expression in two pooled pinch biopsies from the 34 BE patients in 
the BLESS bronchoscopy substudy and in the 20 healthy controls. Due to low yields of RNA, RNA 
had to be amplified prior to analysis by qRT-PCR, and all qRT-PCR results were corrected for a 
group of three house-keeping genes. A significantly higher expression of MMP7 (~5-fold) was 
observed in bronchiectasis subjects, but not MMP9 or MMP10 (Figure 6.1G).  
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Figure 6.1. Human neutrophil elastase and matrix metalloproteinase in airway samples from 
subjects with bronchiectasis and normal healthy controls. (A) Human neutrophil elastase activity 
measured in induced sputum from BE patient airways (n=100) and normal healthy controls (n=20). 
The dotted line shows the lower detection limit of the assay. (B) Total MMP activity measured in 
induced sputum (as described in (A)) and BALF from BE patient airways (n=41) and normal 
healthy controls (n=20). (C) Within-subject correlations between total MMP activity in 
bronchiectasis induced sputum and BALF. (D) Within-sample correlation between NE activity and 
total MMP activity in bronchiectasis sputum. (E) Within-subject correlations for NE activity from 
placebo arm bronchiectasis induced sputum samples obtained at weeks 0 and 48. (F) Within-subject 
correlations for total MMP activity from placebo arm bronchiectasis induced sputum samples 
obtained at weeks 0 and 48. (G) Expression of MMP genes in endobronchial biopsies from BE 
patient airways (n=34) and normal healthy controls (n=20).  
(Box and whisker plots display median, interquartile ranges, and range; **P<0.01, ***P<0.001 by 
Mann-Whitney non-parametric test for (A), (B) and (G). Unadjusted Pearson correlation 
coefficients and p-values for (C)-(F).) 
 
Figure 2 – Gene expression of MMP and MMP activity in bronchiectatic airway. (Controls n = 20. Non-CF BE 
n = 41 for MMP activity, and n = 34 for gene expression.)
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Figure 2 – Gene expression of P and  activity i  r i t ti  ir . ( t l   
n = 41 f r MMP acti ity, and n = 34 for gene expressio .)
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Figure 2 – Gene expression of MMP and MMP activity in bronchiectatic airway. (Controls n = 20. Non-CF BE 
n = 41 for MMP activity, and n = 34 for gene expression.)
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6.3.3 Protease activities are elevated in subjects with profound inflammation and subjects with 
airway microbial pathogens   
We further assessed the link between protease activity and inflammatory cells and inflammatory 
marker concentrations. Positive correlations were observed between protease activity in sputum and 
BALF with pro-inflammatory chemokine (IL-8) and cytokine (IL-1) concentrations in sputum 
(p<0.001) (Table 6.1). Protease activity was also positively correlated with neutrophil percentage in 
the airway lumen and negatively correlated with macrophage percentage.  
 
We next addressed whether the presence of culturable pathogens in sputum altered the nature or 
extent of the protease activities. NE activity and MMP activity in sputum were significantly higher 
in subjects with cultured PPM’s than those without culturable PPM’s (Figure 6.2A). However, no 
significant difference in protease activity was seen when subjects were separated according to the 
presence or absence of culturable P. aeruginosa in their airways (Figure 6.2B). Expression of MMP 
genes did not differ between subjects with or without cultured PPM’s (Figure 6.2A). 
 
Table 6.1. Within-sample correlation between protease activities and inflammatory marker 
concentrations in bronchiectasis induced sputum and BALF. Unadjusted Pearson correlation 
coefficients and **P<0.05, **P<0.01, and ***P<0.001. 
 
 
6.3.4 Protease activities are elevated in subjects with more severe disease phenotype 
Protease activity was also linked with some clinical assessments of disease severity. Higher 
protease activity was observed in subjects with poorer lung function (lower FEV1 % predicted) 
(Figure 6.2C). Elevated MMP activity in induced sputum was also observed for subjects with 
higher serum CRP concentration (p<0.05) (Figure 6.2D). However, there were no links between 
protease activities and number of reported pulmonary exacerbations in the prior 12 months (Figure 
6.2E), number of protocol defined pulmonary exacerbations occurring in the following 12 months 
in the placebo arm, sputum volume, bronchiectasis duration (years), or quality of life (6MWT, 
SGRQ and Leicester cough score) (data not shown). Histology scores assessing the level of acute 
inflammation, chronic inflammation, and fibrosis also showed no statistically significant association 
with protease activities (Figure 6.3).  
Figure 2 – Gene expression of MMP and MMP activity in bronchiectatic airway. (Controls n = 20. Non-CF BE 
n = 41 for MMP activity, and n = 34 for gene expression.)
*** ** ControlBronchiectasis
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Figure 2 – Gene xpr ssion of MMP and MMP activity in bronchie tati  irw y. (Contr ls n = 20. Non-CF BE 
n = 41 for MMP activity, and n = 34 for gene xpr ssion.)
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Figure 2 – Gene expression of MMP and MMP activity in bronchiectatic airw y. (Controls n = 20. Non-CF BE 
n = 41 for MMP activity, and n = 34 for gene expression.)
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Figure 6.2. Protease activity in sputum or BALF and expression of MMP genes in endobronchial 
biopsies from BE patient airways according to airway microbiology by standard culture and 
markers of disease activity and severity. (A) Protease activity and expression of MMP genes in 
endobronchial biopsies from BE patient airways according to airway microbiology by standard 
culture. Induced sputum from BE patients at enrolment in the BLESS trial and from healthy 
controls were cultured for pathogens and classified as ‘culture negative’ (only normal respiratory 
flora cultured; n=17) or culture positive (any potentially pathogenic microorganism cultured; n=24). 
(B) Protease activity and expression of MMP genes in endobronchial biopsies from BE patient 
airways according to pathogenic microbe by standard culture. Induced sputum from bronchiectasis 
was cultured for pathogens and classified as ‘culture negative’ or ‘P. aeruginosa’ (P. aeruginosa 
cultured; n=11) or ‘other pathogen’ (any potentially pathogenic microorganism cultured; n=13) (C) 
Protease activity and expression of MMP genes in endobronchial biopsies from BE patient airways 
according to lung function measured by FEV1. (D) Protease activity and expression of MMP genes 
in endobronchial biopsies from BE patient airways according to serum CRP concentration. (E) 
Protease activity and expression of MMP genes in endobronchial biopsies from BE patient airways 
according to number of self-reported pulmonary exacerbations in the last 12 months.  
 (Individual data points, median and interquartile ranges are shown; *P<0.05, **P<0.01 by Kruskal-
Wallis non-parametric test comparing BE subgroups for (A)-(C), and Mann-Whitney non-
parametric test for (C) and (D).) 
 
 
Figure 6.3. Protease activity according to histology scores from endobronchial biopsies. (A) 
Protease activity according to normal epithelium (n=5), dominance of acute inflammation (n=5), 
chronic inflammation (n=16) or fibrosis (n=10). (B) Protease activity according to normal 
epithelium (n=5), dominance of inflammation (n=7), fibrosis (n=9) or a mix of inflammation and 
fibrosis (n=15). (Individual data points, median and interquartile ranges are shown) 
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6.3.5 Growth factor concentrations are altered in BALF 
Measurement of a range of growth factors in BALF showed highly significant increases in EGF 
(10-fold), bFGF (10-fold) and PDGF-BB (7-fold) in the BE airways compared to healthy 
individuals (all p<0.001) (Figure 6.4A). A lower concentration of VEGF-A was detected in the BE 
airway compared to healthy individuals (p<0.05). Longitudinal assessment of growth factor 
concentrations in bronchiectasis patients in the BLESS placebo arm, showed that bFGF in BALF 
remained at similar levels with significant correlations between samples at the beginning of the trial 
and 48 weeks later (Figure 6.4B). However, this was not seen for EGF and VEGF. In BE BALF, a 
significant positive correlation was also observed between EGF and PDGF-BB (p<0.001) (Figure 
6.4C).  
 
 
Figure 6.4. Growth factors in subjects with bronchiectasis and normal healthy controls. (A) Growth 
factors concentrations measured in BALF from BE patient airways (n=41) and normal healthy 
controls (n=20). (B) Within-subject correlations for individual growth factor concentrations from 
placebo arm bronchiectasis BALF samples obtained at weeks 0 and 48. (C) Within-sample 
correlation between EGF and PDGF concentrations in bronchiectasis BALF. 
(Box and whisker plots display median, interquartile ranges, and range;*P<0.05, ***P<0.001 by 
Mann-Whitney non-parametric test for (A). Unadjusted Pearson correlation coefficients for (B) and 
(C), and bold letters show p<0.001 in (B).) 
 
 
Figure 3 – Correlation pattern each growth factor and MMP with cytokine level
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6.3.6 Growth factor concentrations are elevated in subjects with more profound inflammation and 
subjects with airway microbial pathogens 
To assess whether there is a link between growth factor concentrations and inflammation, we 
analysed the concentration of growth factors and inflammatory markers. Positive correlations were 
observed between many growth factors and inflammatory markers (Table 6.2). Amongst the growth 
factors we measured, bFGF showed strong positive correlations with many inflammatory markers 
including eotaxin, GM-CSF, IFN-, TNF-, IL-4, IL-13, IL-17A, IL-23, IL-10 and MPO. EGF also 
showed positive correlations with IL-8 and IL-4 concentrations. PDGF-BB concentration was 
positively correlated with IL-1, IL-4 and IL-6 concentrations. Aside from these links between 
growth factor concentrations and inflammatory marker concentrations, VEGF-A concentration in 
BALF had no correlation with any inflammatory marker. We next addressed whether the presence 
cultured potentially pathogenic microorganisms (PPM’s) in sputum altered the concentration of the 
growth factors. None of the growth factor concentrations were significantly different between 
subjects with or without PPM’s (Figure 6.5A). Most of the growth factor concentrations fell in a 
similar range when comparing subjects with or without PPM’s. Furthermore, no significant 
difference in growth factor concentration was seen between subjects with or without culturable P. 
aeruginosa in their airways (Figure 6.5B).  
 
Table 6.2. Within-subject correlation between growth factor concentrations and inflammatory 
marker concentrations in bronchiectasis BALF. Unadjusted Pearson correlation coefficients and p-
values shown by highlighting. 
 
 
EGF bFGF PDGF-BB VEGF-A
CXCL5 0.63 0.43 0.62 0.48
CXCL10 0.33 0.12 0.65 0.24
EOTAXIN 0.51 0.93 0.58 0.12
GM-CSF 0.55 0.94 0.58 0.11
MCP-1 0.44 0.27 0.64 0.26
IL-1 0.64 0.50 0.74 0.28
IL-1 0.62 0.55 0.48 0.34
IL-8 0.72 0.68 0.66 0.33
IFN- 0.55 0.94 0.54 0.07
TNF- 0.62 0.85 0.60 0.23
IL-4 0.70 0.89 0.71 0.10
IL-6 0.66 0.65 0.77 0.36
IL-13 0.61 0.86 0.61 0.11
IL-17A 0.54 0.95 0.56 0.05
IL-23 0.63 0.92 0.61 0.17
IL-10 0.53 0.89 0.55 0.05
MPO 0.12 0.71 0.20 -0.03
0.7 ≤ r < 0.8 (p < 0.05)
0.8 ≤ r < 0.9 (p < 0.05)
0.9 ≤ r < (p < 0.05)
Bold = p < 0.001
EGF bFGF PDGF-BB VEGF-A
CXCL5 0.63 0.43 0.62 0.48
CXCL10 0.33 0.12 0.65 0.24
EOTAXIN 0.51 0.93 0.58 0.12
GM-CSF 0.55 0.94 0.58 0.11
MCP-1 0.44 0.27 0.64 0.26
IL-1 0.64 0.50 0.74 0.28
IL-1 0.62 0.55 0.48 0.34
IL-8 0.72 0.68 0.66 0.33
IFN- 0.55 0.94 0.54 0.07
TNF- 0.62 0.85 0.60 0.23
IL-4 0.70 0.89 0.71 0.10
IL-6 0.66 0.65 0.77 0.36
IL-13 0.61 0.86 0.61 0.11
IL-17A 0.54 0.95 0.56 0.05
IL-23 0.63 0.92 0.61 0.17
IL-10 0.53 0.89 0.55 0.05
MPO 0.12 0.71 0.20 -0.03
0.7 ≤ r < 0.8 (p < 0.05)
0.8 ≤ r < 0.9 (p < 0.05)
0.9 ≤ r < (p < 0.05)
Bold = p < 0.001
134 
 
6.3.7 Growth factor concentrations are elevated in subjects with more severe disease phenotype 
Concentrations of growth factors were also linked to some clinical measures of disease severity. 
Although there were no links between the concentration of growth factors and lung function (FEV1 
% predicted (Figure 6.5C), serum CRP concentration (Figure 6.5D), number of protocol defined 
pulmonary exacerbations occurring in the following 12 months in the placebo arm, sputum volume, 
bronchiectasis duration (years), or quality of life (6MWT, SGRQ and Leicester cough score) (data 
not shown), lower concentrations of VEGF-A were detected in subjects reporting more than 4 
exacerbations in the previous 12 months (p<0.01)(Figure 6.5E). A negative correlation between 
VEGF-A concentration and number of all exacerbations in the proceeding 12 months was observed 
(r=-0.33, and p<0.05) (Figure 6.5F). Histology scores assessing the degree of acute inflammation, 
chronic inflammation, and fibrosis also showed no statistically significant association with 
concentration of growth factors (Figure 6.6).  
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Figure 6.5. Growth factor concentrations according to airway microbiology by standard culture and 
markers of disease activity and severity. (A) Growth factor concentrations according to airway 
microbiology by standard culture. Induced sputum from BE patients at enrolment in the BLESS 
trial and from healthy controls were cultured for pathogens and classified as ‘culture negative’ (only 
normal respiratory flora cultured; n=17) or culture positive (any potentially pathogenic 
microorganism cultured; n=24). (B) Growth factor concentrations according to pathogenic microbe 
by standard culture. Induced sputum from bronchiectasis was cultured for pathogens and classified 
as ‘culture negative’ or ‘P. aeruginosa’ (P. aeruginosa cultured; n=11) or ‘other pathogen’ (any 
potentially pathogenic microorganism cultured; n=13) (C) Growth factor concentrations according 
to lung function measure by FEV1. (D) Growth factor concentrations according to serum CRP 
concentration. (E) Growth factor concentrations according to number of self-reported pulmonary 
exacerbations in the last 12 months. (F) Within-subject correlation between VEGF concentrations in 
bronchiectasis BALF and number of total exacerbations in the preceding 12 months. 
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(Individual data points, median and interquartile ranges are shown; *P<0.05, **P<0.01 by Kruskal-
Wallis non-parametric test comparing BE subgroups for (A)-(C), and Mann-Whitney non-
parametric test for (C) and (D). Unadjusted Spearman correlation coefficients for (F).) 
 
 
Figure 6.6. Growth factor concentrations according to histology scores from endobronchial 
biopsies. (A) Growth factor concentrations according to normal epithelium (n=5), dominance of 
acute inflammation (n=5), chronic inflammation (n=16) or fibrosis (n=12). (B) Growth factor 
concentrations according to normal epithelium (n=5), dominance of inflammation (n=7), fibrosis 
(n=11) or a mix of inflammation and fibrosis (n=15).  
(Individual data points, median and interquartile ranges are shown) 
 
6.4 Discussion 
Bronchiectasis is characterised by irreversible dilation of the airway wall which could be a result of 
uncontrolled tissue remodelling following chronic inflammation. However, the molecular 
characteristics of the tissue remodelling factors in bronchiectasis are poorly understood. Here we 
have demonstrated elevated NE and MMP activities in bronchiectatic subjects compared to healthy 
individuals, and patients positive for potential pathogenic microbes and worse lung function had 
much elevated protease activities. Concentrations of several growth factors were also increased in 
bronchiectatic airways, while VEGF-A concentrations in BALF were negatively correlated with 
number of pulmonary exacerbations in the past 12 months and in the preceding 12 months. 
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Protease activities in bronchiectatic airways are consistent over 48 weeks and are strongly 
associated with neutrophil activity and culturable PPM’s, indicating that the vicious cycle of 
ongoing protease activity, unresolved neutrophilic inflammation and presence of PPM’s are the key 
contributors in bronchiectatic airway remodelling. Activated neutrophils in the airway wall 
stimulate release of elastase and recruitment of macrophages and lymphocytes into the airway 
lumen, which slows cilial beat frequency, disrupts mucus secretion and causes structural changes in 
the airway wall (Amitani et al., 1991). Failure to resolve neutrophilic inflammation by apoptosis of 
neutrophils or phagocytosis of macrophages leads to removal of neutrophils by mucociliary 
clearance, which further results in release of protease and chemoattractants that eventually cause 
structural change in the airway wall (Cox et al., 1995).  
 
NE activity has been identified as a marker to predict onset of bronchiectasis in CF children (Sly et 
al., 2013). In this study, although higher NE activity was linked to culturable PPM’s and poorer 
lung function, we did not see a link between NE activity and other disease progression 
measurements, including histological airway fibrosis and the number of pulmonary exacerbations in 
the following 12 months. This is likely due to the contribution of elastase from P. aeruginosa, 
which can also cleave elastin, collagen and proteoglycans (Suter et al., 1984; Tingpej et al., 2007). 
As our current method only detects neutrophil elastase from human, the contribution of elastase 
from P. aeruginosa remains unclear. Determining the ratio of NE and the elastase inhibitor, alpha 1-
antitrypsin, in the airways could inform further understanding of the progression of tissue 
remodelling in bronchiectasis.   
 
MMPs mediate the major part of the tissue destruction in chronic inflammatory diseases. That the 
progressive bronchial dilatation in bronchiectasis is most likely due to continued airway matrix 
destruction is evident by the consistently high level of MMP activity in the BLESS cohort. MMPs 
are secreted by many different cell types including macrophages, neutrophils, epithelial cells and 
fibroblasts (Oikonomidi et al., 2009). They are capable of degrading almost all extracellular matrix 
and basement membrane components, and can influence the progression of inflammatory process 
(Parks and Shapiro, 2001; Parks et al., 2004). In bronchiectatic subjects, elevated MMP 
concentrations have been reported, and an MMP1 polymorphism has been shown to influence lung 
function and airway destruction (Hsieh et al., 2013). Subjects carrying the MMP-1 polymorphism 
were more vulnerable to permanent lung fibrosis due to the enhanced MMP-1 and TGF-1 activity, 
which further points out the role of MMPs in bronchiectasis pathogenesis and disease progression. 
In the BLESS cohort, a higher expression of MMP7 was measured in bronchiectasis subjects 
compared to healthy controls. MMP-7 knockout mice had impaired re-epithelialisation on airway 
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epithelium and they also have reduced neutrophil influx in injured lung (Dunsmore et al., 1998; Li 
et al., 2002), illustrating that MMP-7 is crucial for wound healing. Future studies assessing the roles 
of specific MMPs and tissue inhibitors of the metalloproteinase (TIMPs) from specific cell types 
will provide more insights in understanding bronchiectatic airway destruction and progression of 
bronchiectasis.    
 
Clinically stable bronchiectatic subjects demonstrated an altered level of growth factor 
concentrations, however the altered levels of growth factors seem to be insufficient to prevent 
structural remodelling of the airways or change the course of the disease. bFGF concentration in 
particular was strongly associated with the concentration of several pro-inflammatory cytokines, 
with the strongest correlation with IL-17A, IFN- and GM-CSF concentrations, suggesting that they 
could be produced by the same cells or regulated by the same pathways. However, while IFN- is 
regarded as a potential anti-fibrotic factor (Narayanan et al., 1992; Okada et al., 1993), levels were 
high in bronchiectasis suggesting it was not able to achieve normal repair without extensive 
fibrosis. Further investigation is needed to identify the mechanism of early tissue damage in 
bronchiectasis, and what causes the repair mechanism to be misdirected with a switch to scarring 
rather than appropriate mucosal healing.   
 
In normal airways, VEGF-A in the airway is mainly produced by alveolar epithelial cells. In the 
BLESS cohort, low VEGF-A concentrations were associated with an increased number of 
pulmonary exacerbations in the 12 months prior to recruitment and during the 12 months of 
BLESS, suggesting the potential of using VEGF-A as a diagnostic marker to predict likelihood of 
exacerbation. However, as VEGF-A concentration was not linked to pulmonary function, 
inflammation or cultured PPMs from sputum, the mechanistic ink between VEGF-A concentrations 
and risk of pulmonary exacerbations is not clear. In the airways, other than its roles in stimulating 
angiogenesis, VEGF-A is also involved in multiple mechanisms affecting various inflammatory 
responses and wound repair pathways, which could further affect risk of pulmonary exacerbations 
in bronchiectasis (Lee et al., 2011; Voelkel et al., 2006). VEGF-A is released during pro-
inflammatory response by alveolar epithelium, and can be induced by IL-1, PDGF, TGF-, TGF- 
and P. aeruginosa infection (Jung et al., 2001; Martin et al., 2011; Willems-Widyastuti et al., 2011). 
Upon infection, VEGF-A can induce eosinophilic inflammation (Lee et al., 2004), macrophage 
recruitment (Cursiefen et al., 2004), dendritic cell activation (Lee et al., 2004), increase innate 
immunity in epithelial cells (Olivier et al., 2011), and promote T cell priming (Kim et al., 2009). 
Therefore, insufficient VEGF-A could potentially lead to inefficient inflammatory responses, 
ineffective bacterial clearance, and inefficient repair which further result in prolonged 
139 
 
inflammation. A study in asthma subjects also demonstrated that a VEGF SNP is associated with 
asthma treatment outcomes using inhaled corticosteroid and leukotriene receptor antagonist, 
emphasising the importance of VEGF function in responding to inflammation (Balantic et al., 
2012).  
 
Activated protease activities and unresolved neutrophilic inflammation in bronchiectasis are 
strongly associated with disease severity. These inflammatory features are also observed in subjects 
with COPD and in some forms of asthma, however, COPD and neutrophilic asthmatic subjects do 
not often develop bronchiectasis. We know that the COPD and asthmatic sputum share similar 
features with bronchiectatic sputum in terms of mucin content (Kirkham et al., 2008), and the 
altered ratio of mucin glycoforms in these sputum could potentially impact on mucociliary 
clearance in a similar manner. However, bronchiectatic airways are less efficient in clearing 
bacteria compare to asthmatic airways, suggesting that although the quality of the sputum may have 
all changed in similar ways, mucociliary clearance of pathogens between these diseases is an 
important point of difference. With our knowledge on the cause of bronchiectasis, most known 
causes are associated with impaired mucociliary clearance, including CF, pink disease, and primary 
ciliary dyskinesia. Therefore, it is likely that impaired mucociliary clearance and epithelial damage 
resulted from ongoing inflammation and activated protease activities together are critical elements 
of the development of bronchiectasis pathology.  
 
In the Australian population, approximately 25% of patients between 45 and 69 years of age with an 
obstructive disease received more than one diagnosis (Abromson et al., 2002). In subjects with 
chronic respiratory conditions, the more frequent use of antibiotics may contribute to the selection 
for the more aggressive strains of bacteria, leading to more severe inflammatory responses that can 
damage the airway epithelium. This could potentially lead to development of bronchiectasis in 
subjects with other respiratory diseases.  
 
In clinically stable non-CF bronchiectasis, we have demonstrated that increased NE activity and 
MMP activity were strongly associated with disease severity and neutrophilic inflammation. 
However, we did not identify any individual   marker that was associated with histological chronic 
inflammation or fibrosis scores. Lower VEGF-A concentrations in bronchiectatic subjects were 
associated with more pulmonary exacerbations, however, were independent of the concentration of 
the pro-inflammatory cytokines that were measured in BALF. This is the first comprehensive 
analysis linking tissue remodelling factors and clinical measurements, inflammatory markers and 
infection responses in bronchiectasis, which provide further understanding of the progression of this 
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permanent damage. Future studies measuring the concentration of VEGF-A in BLESS sputum 
would give us stronger statistical power for subgroup analyses to identify whether VEGF-A 
concentration was driven by a specific inflammatory marker or a type of infection. Measuring the 
concentration of different MMPs and TIMPs in BLESS sputum samples would provide further 
information on which specific MMPs are driving the remodelling in bronchiectatic airways or 
preventing destruction of bronchiectatic airway walls. Determining the link between airway luminal 
TGF-1/TGF-3 ratio, key growth factors in inducing tissue fibrosis, and inflammatory marker 
concentrations and clinical measurements would inform further understanding of the remodelling 
network in bronchiectasis.   
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Chapter 7 Effect of erythromycin on inflammation, tissue remodelling 
and mucin production 
7.1 Overview 
Macrolide antibiotics, including azithromycin, clarithromycin and erythromycin, have been used 
worldwide to treat pulmonary infections for more than 50 years. Erythromycin, a 14-membered 
lactone ring macrolide antibiotic, is commonly used in respiratory tract infections. Emerging 
evidence shows that macrolide antibiotics have a diverse range of anti-inflammatory and 
immunomodulatory effects in respiratory diseases (see Chapter 1.8). Erythromycin, in vitro, 
inhibits neutrophil migration (Kadota et al., 1993) and oxidative burst (Abdelghaffar et al., 1997), 
inhibits neutrophil elastase activity (Gorrini et al., 2001), modulates inflammatory cytokine release 
from epithelial cells (importantly reducing IL-8 expression and release) (Takizawa et al., 1997), and 
reduces goblet cell mucus hypersecretion (Khair et al., 1995). Long-term low-dose erythromycin 
treatment was first tested as a therapy for inflammatory airway disease by Kudoh et al. in 1987, 
showing improved clinical symptoms in diffuse panbronchiolitis. Recently, three large randomised 
controlled trials reported on the clinical benefits of macrolides in non-CF bronchiectasis subjects, 
including reduced numbers of protocol defined pulmonary exacerbations, improved lung function, 
reduced 24 hour sputum volume, reduced serum CRP, reduced white blood cell count, and 
improved quality of life scores (Altenburg J and et al., 2013; Serisier et al., 2013; Wong et al., 
2012).  
 
So far, no mechanistic studies have been published from the BAT or the EMBRACE trials to help 
demonstrate the mechanisn of actions of long-term, low-dose macrolides in non-CF bronchiectasis. 
We hypothesised that long-term low-dose oral erythromycin reduces inflammation, alters the 
volume of mucus production, and the relative abundance of secreted mucins in sputum in patients 
with bronchiectasis. As part of the recently completed BLESS trial (Serisier et al., 2013), we aimed 
to comprehensively investigate the effect of long-term low dose erythromycin in non-CF 
bronchiectasis (Aim 5). The potential modulation of inflammation and mucus production was 
assessed using induced sputum, BALF and endobronchial biopsies to better understand the change 
in inflammatory markers and mucus production markers in bronchiectasis subjects after 
erythromycin treatment.  
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7.2 Methods 
Subjects and procedures  
All sample processing and evaluation was undertaken with complete blinding to disease state and 
study treatment assignment. At baseline, all 117 subjects enrolled in the BLESS study had induced 
sputum collected and a subgroup of 41 subjects with no evidence of additional (non-bronchiectasis) 
chronic respiratory disease underwent bronchoscopy with bronchoalveolar lavage (BAL) and 
endobronchial biopsy. Twenty healthy control subjects also underwent sputum induction and 
bronchoscopy. Sputum and bronchoscopy procedures were repeated at week 4 and 48. Full details 
of sputum induction and bronchoscopy procedures are in Chapter 2.3 and Appendix 1.  
 
Molecular marker measurements 
A broad range of measurements were generated within this trial, including chemokine and cytokine 
concentrations, expression of inflammatory response genes, sputum mucin content, protease 
activities, and growth factor concentrations in relation to long-term low-dose erythromycin 
treatment. Experiment set ups for assessing inflammation, mucins and tissue remodelling are in 
Chapters 4, 5 and 6, respectively. Full details of each specific method are in Chapter 2. 
 
Data analysis 
Data analysis for the BLESS study including sample size calculations are as described previously 
(Serisier et al., 2013). Data distribution was mostly non-parametric and Mann-Whitney U tests were 
used to test the significance of variance between the placebo and erythromycin arms. Statistical 
analyses were performed using SYSTAT software (version 3.1), were 2-sided and p values <0.05 
were considered significant. 
 
7.3 Results 
This project randomized 117 patients with bronchiectasis into either a long term low dose 
erythromycin treatment group or a control group given a placebo. The level of inflammatory 
markers at baseline in each treatment arm are shown in Table 7.1. All inflammatory markers 
including IL-8 and IL-1 concentrations were at similar levels at baseline in the erythromycin 
treated group compared to the placebo group, except for a higher concentration of IL-23 in BALF 
(p=0.049) observed in the erythromycin treated group at baseline. Mucin proteins and protease 
activities measured in induced sputum and gene expression detected from endobronchial biopsies 
were all at similar levels in the erythromycin and placebo groups at baseline.  
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Table 7.1. Concentrations of inflammation related molecules in BALF and induced sputum and 
gene expression in airway biopsies at baseline in the BLESS placebo and erythromycin groups. 
Protein concentrations measured in BALF samples unless specified. Mean ± SD, *p<0.05 by Mann-
Whitney non-parametric U test. 
 
 
Placebo Erythromycin 
Inflammation related molecules   
CXCL5 (pg/mL) 8.7 ± 13.0 9.3 ± 20.9 
CXCL10 (pg/mL) 226 ± 401 269 ± 347 
Eotaxin (pg/mL) 16.6 ± 9.0 18.0 ± 7.4 
GM-CSF (pg/mL) 1.3 ± 1.0 1.4 ± 0.8 
MCP-1 (pg/mL) 13.8 ± 17.1 9.5 ± 10.4 
IL-1a (pg/mL) 5.3 ± 5.9 6.3 ± 5.7 
IL-1b (pg/mL) 28.1 ± 61.3 35.3 ± 54.6 
IL-1b (ng/mL sputum) 7.9 ± 17.9 6.1 ± 10.5 
IL-8 (pg/mL) 44.0 ± 46.6 49.2 ± 44.5 
IL-8 (ng/mL sputum) 267 ± 329 174 ± 246 
IFNg (pg/mL) 2.8 ± 3.6 3.1 ± 2.2 
TNF-a (pg/mL) 1.1 ± 1.3 1.5 ± 1.5 
IL-4 (pg/mL) 1.7 ± 1.6 2.2 ± 1.4 
IL-6 (pg/mL) 3.9 ± 5.5 2.6 ± 1.7 
IL-13 (pg/mL) 0.5 ± 0.6 0.7 ± 0.7 
IL-17A (pg/mL) 2.2 ± 2.2 2.7 ± 1.9 
IL-23 (pg/mL) 9.0 ± 8.3 16.9 ± 14.2 * 
IL-10 (pg/mL) 0.18 ± 0.12 0.20 ± 0.10 
MPO (pg/mL) 2574 ± 2526 2675 ± 1811 
MPO activity (ng/mL) 9215 ± 17533 8300 ± 11600 
   Infection response genes from biopsies 
  IL1B 28 ± 58 6.3 ± 6.7 
IL8 8.6 ± 11 6.4 ± 5.8 
DEFB1 21 ± 30 14 ± 15 
LYZ 12 ± 15 10 ± 13 
PRB3 25 ± 48 26 ± 34 
SAA1 13 ± 21 3.7 ± 3.9 
SERPINA3 71 ± 92 39 ± 54 
BPIFB2 11 ± 21 13 ± 18 
PIP 32 ± 53 27 ± 31 
C6orf58 132 ± 307 64 ± 88 
MSMB 6.0 ± 7.5 5.8 ± 6.2 
   Tissue remodelling 
  EGF (pg/mL) 0.57 ± 0.79 0.91 ± 1.39 
bFGF (pg/mL) 5.6 ± 4.5 6.4 ± 3.8 
PDGF-BB (pg/mL) 10.2 ± 18.7 6.7 ± 7.2 
VEGF-A (pg/mL) 124 ± 80 98 ± 80 
NE activity (ug/mL sputum) 20 ± 29 23 ± 34 
MMP activity (au/mL sputum) 267 ± 360 234 ± 295 
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MMP activity (au/mL) 61 ± 193 180 ± 721 
MMP7 gene expression from biopsies 24 ± 48 9.3 ± 11 
   Mucin 
  Total mucin (au/mL sputum) 27.2 ± 7.4 25.2 ± 7.1 
MUC5AC (au/mL sputum) 5.3 ± 3.1 5.2 ± 3.2 
MUC5B low-charge isoform (au/mL sputum) 1.1 ± 1.3 1.0 ± 1.1 
   Mucin and mucin-related genes from biopsies 
 MUC5AC 6.0 ± 18 3.0 ± 6.2 
MUC5B 7.9 ± 19 3.7 ± 4.5 
MUC2 1.0 ± 1.4 0.8 ± 1.7 
MUC4 1.1 ± 2.0 9.2 ± 36 
TFF1 12 ± 14 17 ± 26 
TFF3 3.0 ± 2.7 2.7 ± 2.6 
AGR2 2.6 ± 2.5 2.3 ± 1.1 
 
7.3.1 Long-term low-dose erythromycin treatment therapy appears to alter the pattern of 
inflammation 
The effect of erythromycin treatment on inflammation was measured by comparing the change in 
concentration or expression of each inflammatory marker after 48 weeks of drug treatment from 
baseline. As discussed in Chapter 4, many chemokines and cytokines involved in the innate and 
adaptive immunity were highly elevated in the patients with bronchiectasis. However, the 
concentration of these individual chemokines and cytokines measured in BALF and sputum did not 
alter after 48 weeks of erythromycin treatment (Figure 7.1A). Concentrations of inflammatory 
markers including IL-1, IL-8, IFN-, IL-13, IL-17A, and MPO were slightly decreased in both the 
placebo arm and the erythromycin arm, however the differences between the placebo and 
erythromycin arm were not statistically significant. Expression of IL-1, IL-8 and other infection 
response genes including DEFB1 and LYZ that were elevated in bronchiectasis (see Chapter 4) did 
not alter after 48 weeks erythromycin treatment (Figure 7.1B). As described fully in Chapter 4, 
strong correlations were observed between many different chemokines and cytokines at baseline, 
especially between eotaxin, GM-CSF and T-cell derived cytokines including IFN-, TNF-, IL-4, 
IL-13, IL-17A, IL-23 and IL-10 (Figure 7.2A and B). This correlation pattern remained consistent 
after 48 weeks in the placebo arm (Figure 7.2C), however erythromycin treatment uncoupled these 
correlations between selected chemokines and cytokines (Figure 7.2D). The correlation pattern in 
the erythromycin-treated group was more similar to what was observed in our healthy individuals 
(Figure 4.3). The strongest shifts after erythromycin treatment were in the correlations between 
between GM-CSF, eotaxin, IL-17A, and IL-23 concentrations. In contrast, the correlation between 
IL-8 and IL-1 remained very high in the erythromycin-treated arm. 
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Figure 7.1. Relative change in inflammatory marker levels after erythromycin treatment. (A) 
Relative change in chemokine and cytokine concentrations in BALF and induced sputum at the end 
of the trial in the placebo arm (n=17 for BALF; n=37 for induced sputum) and in the erythromycin 
arm (n=14 for BALF; n=35 for induced sputum). All measures were performed using BALF unless 
specified. Symbol and bars display mean and SEM. (B) Relative change in expression of IL-1, IL-
8 and infection response genes in endobronchial biopsies at end of the trial in placebo arm (n=13) 
and in erythromycin arm (n=12). Median expression of each genes at baseline is 1, and the figure 
shows the relative fold change of each gene relative to median of all bronchiectatic subjects at 
baseline. Box and whisker plots display median, interquartile ranges, and range. 
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Figure 7.2. Within-sample correlations of concentrations of each measured cytokine and 
chemokine in BALF in bronchiectasis before and after 48 weeks placebo or erythromycin treatment. 
(A) Correlations of each chemokine and cytokine concentration in the placebo arm at baseline 
(n=21). (B) Correlations of each chemokine and cytokine concentration in the erythromycin arm at 
baseline (n=20). (C) Correlations of each chemokine and cytokine concentration in the placebo arm 
after 48 weeks (n=17). (D) Correlations of each chemokine and cytokine concentration after 48 
weeks erythromycin treatment (n=14). 
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(Unadjusted Pearson correlation coefficients are displayed and p-values shown by highlighting as 
per the key.) 
 
7.3.2 Long-term low-dose erythromycin treatment therapy does not modulate markers involved in 
tissue remodelling 
Protease activities and growth factor concentrations measured in induced sputum and BALF 
samples were also significantly altered in bronchiectatic subjects at baseline compared to controls 
(see Chapter 6). Erythromycin treatment did not change NE or total MMP activity in bronchiectatic 
airways (Figure 7.3A). Although there were changes in growth factor concentrations and MMP7 
gene expression after erythromycin treatment trending towards the base levels of healthy 
individuals, the differences were not statistically significant (Figure 7.3B and Figure 7.3C). 
 
7.3.3 Long-term low-dose erythromycin treatment therapy does not modulate mucin production 
Mucin proteins measured in induced sputum were elevated in bronchiectasis subjects at baseline 
compared to normal controls with a shift in the proportion of a specific isoform of MUC5B. 
Erythromycin treatment did not change mucin protein concentration in induced sputum (Figure 
7.3D) or expression of mucin and mucin-related genes including TFF1, TFF3 and AGR2 (Figure 
7.3E). 
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Figure 7.3. Relative change in tissue remodelling marker levels and mucin production after 
erythromycin treatment. (A) Relative change in protease activities measured in induced sputum at 
the end of the trial in the placebo arm (n=37) and in the erythromycin arm (n=35). (B) Relative 
change in growth factor concentrations measured in BALF at the end of the trial in the placebo arm 
(n=17) and in the erythromycin arm (n=14). (C) Relative change in expression of the MMP7 gene at 
the end of the trial in the placebo arm (n=13) and in the erythromycin arm (n=12). (D) Relative 
change in mucin protein concentrations measured in induced sputum at the end of the trial in the 
placebo arm (n=45) and in the erythromycin arm (n=48). (E) Relative change in expression of 
mucin and mucin-related genes at the end of the trial in the placebo arm (n=13) and in the 
erythromycin arm (n=12). 
(Symbol and bars display mean and SEM for (A), (B) and (D). Box and whisker plots display 
median, interquartile ranges, and range for (C) and (E)) 
 
7.3.4 Human neutrophil elastase activity is reduced in erythromycin treatment responders 
Erythromycin treatment significantly reduced 24 hour sputum production in patients with 
bronchiectasis. Here the erythromycin-treated subjects only were grouped according to the 
percentage of reduction in 24 hour sputum volume at week 48. Subjects with more than 46% 
sputum volume reduction were considered as “responders”, and others “non-responders”. As the 
sample size became much smaller in these subgroups, only measurements performed in induced 
sputum are reported here. Human neutrophil elastase activity was significantly reduced in the EM-
responders compared to non-responders (p<0.05) (Figure 7.4B), however, relative change in 
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inflammatory marker concentration, total MMP activity and mucin protein concentration in EM-
responders were not significantly different compared to non-responders (Figure 7.4). 
 
 
Figure 7.4. Relative change in molecular markers between non-responders and responders within 
the erythromycin arm and within the placebo arm as reference. (A) Relative change in IL-1 and 
IL-8 concentrations at end of 48 weeks erythromycin treatment in non-responders (n=27 and n=22 
in placebo and erythromycin arm, respectively) and in responders (n=10 and n=13 in the placebo 
and erythromycin arms, respectively) grouped according to their percentage of 24 hour sputum 
volume reduction at end of the trial. (B) Relative change in protease activities measured in non-
responders (n=27 and n=22 in the placebo and erythromycin arms, respectively) and in responders 
(n=10 and n=13 in placebo and erythromycin arm, respectively). (C) Relative change in mucin 
protein concentration measured in non-responders (n=33 and n=27 in the placebo and erythromycin 
arms, respectively) and in responders (n=12 and n=21 in placebo and erythromycin arm, 
respectively).  
(Symbol and bars display mean and SEM, and *P<0.05 by Mann-Whitney U test) 
 
7.3.5 No erythromycin treated subgroup shows changes in markers of inflammation, tissue 
remodelling or sputum mucin content 
In the BLESS trial, subjects with P. aeruginosa cultured in their sputum at baseline and subjects 
with more reported pulmonary exacerbations in the prior 12 months showed most clinical benefit 
after erythromycin treatment. We further analysed these subgroups in the erythromycin arm 
according to the presence of P. aeruginosa at baseline and number of reported pulmonary 
exacerbations in the prior 12 months. No significant differences in the relative change of 
inflammatory marker concentrations, protease activities or mucin production were observed 
between subjects with P. aeruginosa cultured in their sputum and subjects without P. aeruginosa 
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cultured from sputum (Figure 7.5A, 7.5B and 7.5C). Subjects with more than four pulmonary 
exacerbations in the prior 12 months did not have significant changes in inflammatory marker 
concentrations, protease activity or mucin production compared to subjects with less than four 
pulmonary exacerbations in the prior 12 months (Figure 7.6A, 7.6B and 7.6C). Other exploratory 
subgroups including subjects with H. influenzae cultured in their sputum at baseline, subjects with 
poor lung function, subjects with improved Leicester cough score, and subjects currently on 
combination therapy of LABA and ICS also showed no specific changes in molecular marker 
concentrations at end of the 48 weeks treatment. 
 
 
Figure 7.5. Relative change in molecular markers in subgroups based on culture of P. aeruginosa. 
(A) Relative change in sputum IL-1 and IL-8 concentrations (n=27 and n=21 in the placebo and 
erythromycin arms, respectively) and in P. aeruginosa culture positive subjects (n=10 and n=14 in 
the placebo and erythromycin arms, respectively). (B) Relative change in protease activities 
measured in P. aeruginosa culture negative subjects (n=27 and n=21 in the placebo and 
erythromycin arms, respectively) and in P. aeruginosa culture positive subjects (n=10 and n=14 in 
the placebo and erythromycin arms, respectively). (C) Relative change in mucin protein 
concentration measured in P. aeruginosa culture negative subjects (n=31 and n=28 in the placebo 
and erythromycin arms, respectively) and in P. aeruginosa culture positive subjects (n=14 and n=20 
in the placebo and erythromycin arms, respectively).  
(Symbol and bars display mean and SEM) 
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Figure 7.6. Relative change in molecular markers in subgroups based on the frequency of 
exacerbations in the year before the trial. (A) Relative change in sputum IL-1 and IL-8 
concentrations at end of 48 weeks erythromycin treatment in subjects with less than 5 reported 
pulmonary exacerbations in the prior 12 months (n=25 and n=30 in the placebo and erythromycin 
arms, respectively) and in subjects with more than 5 reported pulmonary exacerbations in the prior 
12 months (n=12 and n=18 in the placebo and erythromycin arms, respectively). (B) Relative 
change in protease activities measured in subjects with less than 5 reported pulmonary 
exacerbations in the prior 12 months (n=25 and n=30 in the placebo and erythromycin arms, 
respectively) and in subjects with more than 5 reported pulmonary exacerbations in the prior 12 
months (n=12 and n=18 in the placebo and erythromycin arms, respectively). (C) Relative change 
in mucin protein concentration measured in subjects with less than 5 reported pulmonary 
exacerbations in the prior 12 months (n=29 and n=21 in the placebo and erythromycin arms, 
respectively) and in subjects with more than 5 reported pulmonary exacerbations in the prior 12 
months (n=16 and n=14 in the placebo and erythromycin arms, respectively). 
(Symbol and bars display mean and SEM) 
 
7.3.6 No short-term effect of erythromycin treatment therapy on inflammation, tissue remodelling 
or sputum mucin content 
All observations and analyses were also performed using BALF, induced sputum and endobronchial 
biopsy samples collected at 4 weeks after starting the trial. No significant changes in inflammatory 
marker concentrations, protease activity or mucin production were observed at that timepoint (data 
not shown). Clinical outcomes (PDPE, 24 hour sputum volume and FEV1 % predicted) at the end of 
the 48 week trial were not associated with increases or decreases in molecular marker 
concentrations at 4 weeks after starting the trial (data not shown).  
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7.4 Discussion 
Long-term, low-dose erythromycin treatment in non-CF bronchiectasis subjects improves clinical 
outcomes including frequency of pulmonary exacerbations, lung function decline and daily sputum 
volume (Serisier et al., 2013). The mechanism of action of macrolides has been unable to be 
determined in previous in vivo studies. We show a shift in inflammatory pattern after erythromycin 
treatment towards that observed in our healthy individuals, in which many strong correlations 
between cytokine and chemokine concentrations were uncoupled. Surprisingly, no significant 
reduction in the concentration of any individual inflammatory marker or mucin was seen. 
Erythromycin-treated subjects who responded to the treatment in terms of sputum production, 
defined as at least a 46% reduction in 24 hour sputum volume, had a significant reduction in human 
neutrophil elastase activity. Subgroup analysis failed to identify any subgroup with significant 
benefit from erythromycin treatment. 
 
Several immunomodulatory effects of erythromycin have been demonstrated in vitro, illustrating 
multiple possible mechanisms of action on various immune pathways including inhibition of 
neutrophilic inflammation (Abdelghaffar et al., 1997; Kadota et al., 1993), modulation of  
inflammatory cytokine release from epithelial cells (Takizawa et al., 1997), inhibition of eosinophil 
recruitment (Sato et al., 2001), and shifts in production of Th1 to Th2 cytokine production (Park et 
al., 2004). The change in cytokine correlation pattern in our study raises the possibility that 
erythromycin may be acting on multiple immune pathways, the combined effects of which lead to 
improved clinical outcomes. Disease phenotype and aetiology of the disease are likely to contribute 
to the method of action and efficacy of erythromycin treatment in any individual. As bronchiectasis 
is a heterogeneous disease representing a pathological phenotype resulting from varying insults to 
the airway (Whitwell, 1952), the inflammatory profile may be dissimilar in subjects with different 
underlying causes of disease. Hence different mechanisms of erythromycin dependent 
immunomodulatory effects may result in different clinical outcomes for any individual.  
 
Some prior in vitro studies suggest an early, acute increase in neutrophilic inflammation in response 
to macrolides. An acute increase in neutrophilic inflammation after azithromycin treatment has been 
shown in healthy human subjects and COPD subjects by demonstration of an increase in the release 
of neutrophil granular enzymes, oxidative burst and oxidative protective mechanisms (Culic et al., 
2002; Parnham et al., 2005). In vitro mouse epithelial cell studies also demonstrate macrolide 
potentiation of the LPS response, and stimulation of cytokine expression in airway epithelial cells 
(Gavilanes et al., 2009). In the BLESS study, clinical outcomes (PDPE, 24 hour sputum volume and 
FEV1 % predicted) after 48 weeks treatment were not associated with increases or decreases in 
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molecular marker concentrations at 4 weeks, suggesting that the clinical benefits of low-dose 
erythromycin treatment in bronchiectasis are not achieved by acute enhancement of neutrophilic 
inflammation. 
 
Although the dose of erythromycin used in BLESS is not considered microbicidal, non-typical 
antimicrobial functions such as inhibition of bacterial adherence (Tsang et al., 2003), inhibition of 
virulence factors (Tanaka et al., 1994), inhibition of quorum sensing and biofilm formation (Tateda 
et al., 2004; Yanagihara et al., 2002) have been demonstrated with erythromycin and other 
macrolides. These anti-microbial properties could contribute to the clinical outcomes in BLESS. 
Previously we have shown that inflammatory markers and protease activities in bronchiectasis (see 
Chapter 4 and 6) are highly correlated with bacterial load in the airway. However, there is still no 
evidence to address whether bacteria are primary drivers of the inflammatory response, or whether a 
pre-existing chronic inflammatory microenvironment provides a niche for certain bacterial species 
to colonise the airway. Therefore, the subtle shift in inflammatory marker concentrations could be a 
response to reductions in bacterial load or shifts in bacterial community composition or 
pathogenicity.  
 
Neutrophil elastase induces mucus production (Fischer and Voynow, 2002; Shao and Nadel, 2005; 
Zhou et al., 2013), but also degrades airway mucins (Henke et al., 2011). In in vitro study and a 
cohort study, inhibition of neutrophil elastase activity by erythromycin has been shown in patients 
with bronchitis (Gorrini et al., 2001; Ichikawa et al., 1992). In the BLESS trial, we have also shown 
reduction in neutrophil elastase activity in erythromycin treatment responders with more than 46% 
24 h sputum volume reduction. This reduction in sputum volume could be attained by direct 
modulation of the epithelial ion channel by the macrolide (Tarran et al., 2013) or by the downstream 
effects of neutrophil elastase, including modulation of mucus production (Shao and Nadel, 2005), 
decreasing neutrophilic inflammation, and improvement of ciliary function (Amitani et al., 1991).  
 
Prophylactic antibiotics are associated with a reduction in purulent sputum production in 
bronchiectasis (Evans et al., 2007) and reduction  in  mucin production in cell culture systems and 
animal models (Araki et al., 2010; Tanabe et al., 2011). We did not see modulation in mucin content 
or expression of mucin-related genes after erythromycin treatment, suggesting that sputum volume 
reduction is achieved by alternative mechanisms such as modulation of the ion channels which 
changes the quality of the sputum rather than reducing mucin production (Tamaoki et al., 1992; 
Tamaoki et al., 1995a; Tamaoki et al., 1995b). Production of mucin proteins in the airway is 
modulated by the combined effect of inflammatory mediators and bacteria (Thornton et al., 2008), 
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but as discussed in Chapter 5, we did not see any link between mucin content and clinical 
measurements or inflammatory mediator concentrations in this study. This surprising outcome 
further emphasises the complexity of chronic inflammation in bronchiectasis, and the potential 
multi-pathway actions of macrolide therapy.  
 
Long-term low-dose erythromycin treatment appeared to uncouple the strong cytokine correlation 
patterns that we observed in non-CF bronchiectasis subjects, suggesting a subtle change in 
inflammatory profile. The major limitation of this project is that BLESS was powered to determine 
effects on the number of exacerbations rather than changes in molecular markers. Hence, statistical 
power was lost in many subgroup analyses, especially in the bronchoscopy substudy. This study is 
the first study in non-CF bronchiectasis that comprehensively analyses a broad range of 
inflammatory markers in a large cohort. Future studies concentrating on the changes in 
inflammatory pattern and microbe composition may be informative as to whether the clinical 
benefits of long term low dose EM are due to immunomodulatory or non-typical antibiotic effects, 
or a combination of the two. Alternative inflammatory modulation pathways that have been shown 
in other macrolide antibiotics including modulation of macrophage phagocytosis, regulation of 
immune cell differentiation and autophagy are also worth investigating (Hodge et al., 2006; 
Polancec et al., 2012; Renna et al., 2011). 
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Chapter 8 Response of normal and bronchiectatic airway epithelial 
cells to inflammatory stimuli 
8.1 Overview 
The inflammatory profile of non-CF bronchiectasis is addressed in Chapters 4, 5 and 6 and shows  
increased concentrations of inflammatory markers and elevated protease activity are strongly 
associated with disease severity and the presence of potential pathogenic microbes (PPM’s) in 
sputum. However, whether these characteristics are infection driven or due to primary defects in 
epithelial cells or immune cells is unclear. Human bronchial epithelial cells (HBEC) can be grown 
on transwells, which the cells are in contact with the medium only at their basal surface, leaving the 
apical surface in contact with air. This culture setup mimics the physiology in human airways and 
allows differentiation of mucus producing cells and ciliated cells. Differentiation of mucus 
producing cells can be observed from 10 days post air-lifting, and ciliated cells can be observed 
from 20 days post air-lifting. We aimed to characterise important functional characteristics of 
bronchial epithelial cells delivered from individuals with non-CF bronchiectasis, and to characterise 
their reaction to inflammatory stimuli compared to bronchial epithelial cells cultured from healthy 
individuals (Aim 6). These experiments aimed to provide preliminary exploration of the hypothesis 
that primary defects in bronchial epithelial cells contribute to non-CF bronchiectasis pathogenesis.  
 
8.2 Method 
Subjects and procedure 
Human bronchial epithelial cells established from airway brushings from five healthy individuals 
and five patients with bronchiectasis were brought back into culture from frozen aliquots. Bronchial 
brushings were obtained using a nylon cytology brush, from segmental bronchi, usually from the 
right or left upper lobe. Bronchial epithelial cells were expanded in Bronchial Epithelial cell 
Growth Media (BEGM) (LONZA, Basel, Switzerland). Full details of the bronchial brushing and 
bronchial epithelial cell expansion methods are in Appendix 1 and Chapter 2.5.1, respectively. 
 
Human bronchial epithelial cell (HBEC) culture (full details in Chapter 2.5.2) 
HBECs were expanded in BEGM at 37C, 5% CO2, in a humidified incubator. Passage 2 cells were 
seeded onto transwell inserts at 1.5x10
5
 cells/cm
2
 for all experiments. Cells were maintained at 
confluence for 3 days before introducing an air-liquid interface by removing media in the apical 
chamber and replacing basal chamber media with Differentiation Medium (LONZA, Basel, 
Switzerland), supplemented with BPE, insulin, hydrocortisone, GA-1000, transferrin, epinephrine, 
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hEGF, inducer from the SingleQuote kit, and 50 nM fresh retinoic acid (Sigma-Aldrich, St Louis, 
MO). Cells were maintained in the air-liquid interface for 20 days before harvest. 
 
Inflammatory mediator treatment 
Inflammatory mediators were administered to HBEC on day 20 post air-lifting. 10 ng/mL of 
cytokines were added to the basal chamber, or 60 μL of pooled concentrated BALF from 
bronchiectatic patients (from the BLESS cohort) were added to the basal chamber or dispersed 
gently on the apical chamber. BALF from three BLESS subjects sampled at the beginning of the 
trial with Pseudomonas cultured from their sputum were pooled to make “BALF (Pa +ve)”, and 
BALF from eight BLESS subjects sampled at the beginning of the trial without Pseudomonas 
cultured from their sputum were pooled to make “BALF (Pa -ve)”. These two pools of BALF were 
prepared to represent the luminal inflammatory environment in milder bronchiectasis (BALF (Pa -
ve)), and more severe bronchiectasis (BALF (Pa +ve)). Pooled BALF was concentrated down to 
1/5 of its original volume using a 3,000 Mr cutoff centrifugal filter device (PALL, Port Washington, 
NY). Cells were harvested at 24 h post treatment. Transepithelial voltage and resistance (TEER) 
was measured by placing the electrodes in the basal chamber and apical chamber. IL-8 
concentration in the medium was measured by standard IL-8 ELISA (BD Biosciences, San Jose, 
CA). RNA was extracted from the HBECs, and expression of selected genes was determined using 
the TaqMan detection system as per the manufacturer’s instructions (Microfluidic Cards, Life 
Technologies, Carlsbad, CA) or using the SYBR green detection system (Takara, Shiga, Japan) (full 
details in Chapter 2.6). Full details of primer sequences used is listed in Table 8.1. qRT-PCR results 
generated from the TaqMan detection system were corrected for a group of three house-keeping 
genes (2-microglobulin, -actin and Cyclophilin A), and qRT-PCR results generated from the 
SYBR green detection system were corrected to expression of -actin. 
 
Data analysis   
Data analysis for the BLESS study including sample size calculations are as described previously. 
Data distribution was mostly non-parametric and Mann-Whitney U tests were used to test the 
significance of variance between control and disease groups or non-treated and treated groups. 
Statistical analyses were performed using PRISM software (version 5), were 2-sided and p values 
<0.05 were considered significant. 
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Table 8.1. List of primer sequences 
Gene Search key Sequence 
Product size 
(bp) 
IL-8 NM_000584.3 
For - ACTCCAAACCTTTCCACCC 
Rev - CCCTCTTCAAAAACTTCTCCAC 
439 
IL-1b NM_000576.2 
For - CACGCTCCGGGACTCACAGC 
Rev - GGAGAACACCACTTGTTGCTCCA 
106 
SERPINA3 NM_001085.4 
For - CCTGAACGACATACTTCTCCAGC 
Rev - CATCAAGCACAGCCTTATGGACC 
125 
DEFB1 NM_005218.3 
For - GGTAACTTTCTCACAGGCCTTGG 
Rev - TCCCTCTGTAACAGGTGCCTTG 
124 
LYZ NM_000239.1 
For - ACTACAATGCTGGAGACAGAAGC 
Rev - GCACAAGCTACAGCATCAGCGA 
157 
MMP7 NM_002423 
For - TCGGAGGAGATGCTCACTTCGA 
Rev - GGATCAGAGGAATGTCCCATACC 
127 
sXBP1 NM_001079539.1 
For - GAGTCCGCAGCAGGTGC 
Rev - CAAAAGGATATCAGACTCAGAATCTGAA 
107 
 
8.3 Results 
In order to characterise the important functional characteristics of bronchiectatic bronchial epithelial 
cells, HBECs cultured from bronchial brushings of 5 healthy individuals and 5 patients with 
bronchiectasis were grown at air-liquid interface to compare their baseline characteristics and their 
degree of response to inflammatory stimuli. Cells from 2 out of the 5 bronchiectatic donors 
gradually died off from day 9 post air-lifting, therefore the healthiest 2 wells from these 2 
bronchiectatic donors were harvested on day 17 without inflammatory stimuli for the baseline gene 
expression study, leaving cultures from only 3 subjects for the functional assessments. 
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8.3.1 Comparison of baseline characteristics between bronchiectatic bronchial epithelial cells 
and healthy bronchial epithelial cells 
First, we characterised the function of bronchiectatic bronchial epithelial cells by assessing 
epithelial integrity, IL-8 production and expression of inflammatory response genes as reported in 
previous chapters. In comparison with bronchial epithelial cells from healthy donors, bronchiectatic 
cells had lower TEER, however this observation was not statistically significant (Fig. 8.1A). There 
were no baseline differences in expression of selected keratin genes or IL-8 concentration between 
healthy and bronchiectatic epithelial cells (Fig. 8.1B and C). However, higher expression of 
CXCL10 (34-fold, p<0.01) and SERPINB2 gene (3-fold, p<0.01) and a trend toward higher IL-1 
and DEFB1 expression was observed in bronchiectatic HBECs compared to healthy controls (Fig. 
8.1D and E). There were no differences in base level expression of IL-8, other infection response 
genes, MMP genes, mucin genes, mucin related genes, ER stress marker genes and other unknown 
function genes we previously linked with disease (see Chapter 4 for further details) between healthy 
and bronchiectasis bronchial epithelial cells (Fig. 8.1D, E, F, G, H, I and J). 
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Figure 8.1. Baseline differences between normal and bronchiectatic airway epithelial cells without 
stimulation at day 20 post air-lifting. (A) Transepithelial electrical resistance, (B) Keratin gene 
expression, (C) IL-8 protein concentration, (D) Chemokine and cytokine gene expression, (E) 
Infection response gene expression, (F) MMP gene expression, (G) Mucin gene expression, (H) 
Mucin-related gene expression, (I) ER stress marker gene expression, (J) Unknown function gene 
expression. 
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(Individual data points, mean and SEM are shown, and **P<0.01 by Mann-Whitney non-parametric 
test comparing Controls and bronchiectasis.) 
 
8.3.2 The response of healthy bronchial epithelial cells to stimulation with bronchiectatic BALF 
Next we stimulated the healthy cells using BALF pooled from bronchiectatic subjects with 
Pseudomonas aeruginosa cultured from their sputum as a cocktail containing all the inflammatory 
mediators in bronchiectatic airways. HBECs from healthy donors only were analysed using the 
same panel of outcome markers as in Figure 8.1. No change in TEER was detected after BALF (Pa 
+ve) stimulation (Figure 8.2A). KRT13 expression was decreased after BALF (Pa +ve) stimulation 
(-2.5-fold, p<0.05), but not KRT4 or KRT6C (Figure 8.2B). BALF (Pa +ve) stimulation did not 
change IL-8 protein concentration (Figure 8.2C), however it increased IL-8 and CXCL10 gene 
expression 18-fold and 1.5-fold, respectively (p<0.05, Figure 8.2D). Expression of infection 
response genes and MMP genes did not alter after BALF (Pa +ve) stimulation (Figure 8.2E and F). 
Amongst all the mucin and mucin-related genes, MUC1 gene expression was decreased after BALF 
(Pa +ve) stimuli (-1.2-fold, p<0.05), but not the others (Figure 8.2G and H). There were no 
differences in expression of ER stress marker genes or unknown function genes after BALF (Pa 
+ve) stimulation (Figure 8.2I and J). 
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Figure 8.2. Response of healthy HBECs stimulated for 24 hours with pooled BALF from 
bronchiectatic subjects with P. aeruginosa cultured from their sputum. (A) Transepithelial electrical 
resistance, (B) Keratin gene expression,  (C) IL-8 protein concentration, (D) Chemokine and 
cytokine gene expression, (E) Infection response gene expression, (F) MMP gene expression, (G) 
Mucin gene expression, (H) Mucin-related gene expression, (I) ER stress marker gene expression, 
(J) Unknown function gene expression. 
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(Individual data points, mean and SEM are shown, and *P<0.05 by Mann-Whitney non-parametric 
test comparing Controls and Controls stimulated with BALF.) 
 
8.3.3 Comparison of the response between healthy and bronchiectatic epithelial cells to 
inflammatory stimulation  
In order to address whether bronchiectatic bronchial epithelial cells are more responsive to 
inflammatory stimuli, HBECs from healthy donors and bronchiectatic donors were stimulated with 
selected chemokines and cytokines or BALF from bronchiectasis subjects with or without P. 
aeruginosa cultured in their sputum. After 24 hours stimulation with BALF (Pa +ve), lower TEER 
was detected in bronchiectatic HBECs compared to HBECs from healthy donors (-2.5-fold, p<0.01) 
(Fig. 8.3A). A trend of lower TEER in bronchiectatic compared to healthy HBECs was also 
detected after other inflammatory stimulants including IL-1 and BALF (Pa -ve). IL-8 gene 
expression in both healthy and bronchiectatic HBECs was significantly upregulated by IL-1 and 
TNF- stimulation (p<0.01 for Controls, and p<0.05 for BE) (Fig. 8.3C). However, the degree of 
upregulation in IL-8 expression after stimulation was similar between healthy and bronchiectatic 
HBECs. An increase in IL-8 gene expression after stimulation by IL-17A was seen in healthy 
HBECs (2-fold, p<0.05), but not in bronchiectatic HBECs. These patterns were also observed for 
IL-8 protein concentration, however the increase in IL-8 concentration was not statistically 
significant (Fig. 8.3B). Expression of IL-1β, the other key inflammatory cytokine highly elevated in 
bronchiectasis and potentially produced by epithelial cells, was unaltered at the mRNA level by any 
of the inflammatory stimuli used (Fig. 8.3D). Expression of SERPINA3 was increased to similar 
degrees in healthy and bronchiectatic cells after IL-1 and TNF- stimulation (p<0.01 for Controls, 
and p<0.05 for BE) (Fig. 8.3E). SERPINA3 expression was also upregulated by stimulation with 
BALF (Pa +ve), but only in the cells from bronchiectatic subjects (2-fold, p<0.05). Expression of 
DEFB1, LYZ and MMP7 were not altered by any of the inflammatory stimulation (Fig. 8.3F, G and 
H).  
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Figure 8.3. Response of healthy and bronchiectatic HBECs to various inflammatory stimuli for 24 
hours. (A) Transepithelial electrical resistance, (B) IL-8 protein concentration, (C) IL-8 gene 
expression, (D) IL-1 gene expression, (E) SERPINA3 gene expression, (F) DEFB1 gene 
expression, (G) LYZ gene expression, (H) MMP7 gene expression. 
(Individual data points, mean and SEM are shown, and *P<0.05, **P<0.01 by Mann-Whitney non-
parametric test comparing non-treated and treated or controls versus bronchiectatic.) 
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8.3.4 Comparison of the responses of healthy bronchial epithelial cells to basal vs apical 
exposure to bronchiectatic BALF  
Stimulation of inflammatory mediators from the basal chamber and the apical surface of the cell 
culture system mimics different physiologically relevant scenarios in the airways. Stimulation from 
the basal chamber mimics inflammatory mediators fed from the blood stream or underlying 
leukocytes, and stimulation from the apical surface can be viewed as stimulation from inflammatory 
mediators which have leaked into the airway lumen or released by luminal leukocytes. We tested 
the effect of stimulation by BALF (Pa -ve) versus BALF (Pa +ve), by adding BALF in the basal 
chamber or dropping onto the apical surface of HBECs from healthy donors. As shown in Figure 
8.4, BALF (Pa -ve) and (Pa +ve) did not change TEER, IL-8 protein concentration or expression of 
inflammatory markers, except a trend of increase in IL-8 gene expression (Fig. 8.4C). Regardless of 
whether the stimuli were added in the basal chamber or apical surface, the effect on the expression 
of inflammatory markers was similar. 
 
 
Figure 8.4. Response of healthy HBECs stimulated with pooled BALF from bronchiectatic subjects 
with or without P. aeruginosa cultured from their sputum in the basal chamber or dropped on the 
apical surface for 24 hours. (A) Transepithelial electrical resistance, (B) IL-8 protein concentration, 
(C) IL-8 gene expression, (D) IL-1 gene expression, (E) SERPINA3 gene expression, (F) DEFB1 
gene expression, (G) LYZ gene expression, (H) MMP7 gene expression. 
(Individual data points, mean and SEM are shown.) 
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8.4 Discussion  
Bronchiectatic subjects have a mixed and consistent activation of both innate and adaptive immune 
responses (Chapter 4), which is accompanied by mucus hypersecretion (Chapter 5) and increased 
protease activity (Chapter 6). Bronchial epithelial cells play an important role in mucosal barrier 
functions including maintaining a tight cell layer to prevent microbial invasion, responding to 
stimuli, and creating an optimal mucus layer to protect the epithelium. A question to be addressed in 
bronchiectasis is whether the phenotype is due to an inherited defect that made the individual more 
susceptible to infection and its sequelae, or whether the disease represents an expected infection 
driven response. The preliminary experiments presented in this chapter are the first reported 
experiments with bronchiectatic HBEC and showed that these inflammatory characteristics of 
bronchiectasis are not due to primary epithelial defects in mucus production or IL-8 production. The 
level of increase in IL-8 expression after inflammatory stimuli was similar between bronchiectatic 
and healthy HBECs. However, bronchiectatic HBEC cell integrity appeared more susceptible to 
inflammatory stimuli compared to healthy HBECs. Higher expression of CXCL10 and SERPINB2 
genes in bronchiectatic HBECs could be a signature of an underlying predisposition to 
bronchiectasis.  
 
CXCL10 is an important chemokine in responding to viral infection. It is mainly produced by 
macrophages, and epithelial cells to a less extent in healthy airways. However, whether CXCL10 
produced by immune cells and epithelial cells have similar function and similar potential to trigger 
downstream immune responses is still not clear. We have shown an increased expression of 
CXCL10 in bronchiectatic HBECs suggesting that higher levels of CXCL10 produced by airway 
epithelial cells could lead to different immune responses upon infection. Long-term exposure to 
CXCL10 in the lung can lead to a bronchiolitis-like inflammation in mice (Jiang et al., 2012). With 
a high level of CXCL10, a more active IFN regulatory factor-1-dependent innate response could be 
triggered when undergoing a rhinovirus infection (Dufour et al., 2002; Spurrell et al., 2005; Zaheer 
and Proud, 2010). CXCL10’s roles in regulating angiogenesis and fibrosis further highlight its 
potential role in bronchiectasis pathogenesis (Angiolillo et al., 1995; Pociask et al., 2011; Tager et 
al., 2004). The role of CXCL10 in bronchiectasis airway biology requires further investigation. 
Comparing the expression and function of CXCL10 produced by macrophages and epithelial cells 
from healthy and bronchiectatic subjects upon inflammatory stimuli will assist further 
understanding of the roles of CXCL10 in bronchiectasis. 
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SERPINB2 is a member of the serine protease inhibitor, which is induced during many 
inflammatory processes and infections. It is involved in the control of multiple inflammatory 
processes including inhibition of IL-1 converting enzyme (Greten et al., 2007), priming of IFN-
/ responses (Antalis et al., 1998), regulation of monocyte proliferation and differentiation (Yu et 
al., 2002), and it is one of the most upregulated proteins in activated monocytes/macrophages. 
SerpinB2
-/-
 mice generate increased Th1 responses by stimulated macrophages (Schroder et al., 
2010), suggesting that high expression of SERPINB2 in bronchiectatic airway epithelial cells could 
result in a disturbed balance of the normal immune response. Excessive SERPINB2 expression in 
bronchiectatic airways could also reduce activation of plasmin, leading to less plasmin mediated 
activation of matrix metalloproteinases, resulting in less matrix metalloproteinase-mediated 
degradation of the extracellular matrix, and further lead to increased fibrosis. The expression of 
SERPINB2 was shown to be increased in asthmatic airways (Woodruff et al., 2007), further 
suggested its potential roles in other chronic respiratory diseases such as bronchiectasis. 
Overexpressing SERPINB2 in HBECs co-cultured with immune cells and fibroblasts will help to 
understand the roles of SERPINB2 in bronchiectasis. 
 
BALF is a mixture of inflammatory mediators which is most representative of what is in the 
bronchiectatic airway. In the BLESS cohort, we did not see much difference in inflammatory 
profiles between subjects with Pseudomonas cultured in their sputum, and subjects without 
Pseudomonas cultured in their sputum (Chapters 4, 5 and 6). However, here we have shown that 
epithelial cell integrity in bronchiectatic HBECs was broken by BALF from subjects with cultured 
Pseudomonas in their sputum, but not BALF from subjects without cultured Pseudomonas in their 
sputum. This data suggested that there are still undetermined differences between the Pseudomonas 
infection response and the non-Pseudomonas infection response. Further understanding can be 
achieved by comprehensive analysis of inflammatory patterns according to airway dominant species 
and Pseudomonas bacteria load (Rogers et al., 2013). And in order to understand whether the 
healing ability of bronchiectatic epithelial cells are weaker than healthy epithelial cells, future 
studies characterising tight junctions and integrins in bronchiectatic epithelial cells will provide 
additional insights as to whether bronchiectatic epithelial cells are less capable of combating 
external stimulant or infections.    
 
In conclusion, experiments performed in this chapter need to be repeated with a larger sample size 
to further confirm the findings. However, data generated in this chapter have provided preliminary 
findings for future follow up studies, including: 
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 Are there more baselevel differences between healthy and bronchiectatic HBECs other than 
CXCL10 and SERPINB2 expression? 
- Tight junction proteins, integrins, apoptosis-related genes and autophagy-related genes 
are potential candidates for examination. 
- An unbiased microarray or RNASeq approach would help to provide a more thorough 
examination of gene expression. 
 Are the unknown function genes regulated by infection or inflammatory stimuli? 
- Measuring the expression of AZGP1, C6orf58 or MSMB using cDNAs from this 
experiment would provide insights as to whether these genes are regulated by 
inflammatory cytokines or BALF stimuli, which could potentially result in unresolvable 
inflammation and bronchiectasis.  
- Adenovirus knockdown of AZGP1, C6orf58 and MSMB in healthy and bronchiectatic 
HBECs will help to identify the functional roles of these genes. 
 What are the different effects between Pseudomonas and non-Pseudomonas mediated 
immune responses in the airways? 
- Stimulating HBECs with Pseudomonas and non-Pseudomonas bacteria exoproducts 
would further determine the difference between Pseudomonas and non-Pseudomonas 
mediated immune responses. This will inform futher understanding as to why 
Pseudomonas positive subjects have more frequent exacerbations, and perhaps we could 
prevent the frequent exacerbation by targeting specific immune responses. 
 What are the network effects between epithelial cells and other cells types? 
- Many chemokines and cytokines are produced by epithelial cells and various immune 
cells. Therefore, the interactions between different cells types could be crucial in 
triggering and resolving an immune response. Co-culturing HBECs and immune cells 
using healthy and bronchiectatic cells will provide further understanding of the net 
effects of an immune response upon infection, and how an immune response is resolved. 
- Epithelial cells and fibroblasts are tight regulators of each other, and fibrosis is a key 
phenotype in bronchiectatic airways that is heavily controlled by the interactions 
between fibroblasts and epithelial cells. Co-culturing HBECs and fibroblasts using 
healthy and bronchiectatic cells will provide further understanding in the progress of 
fibrosis in bronchiectasis. 
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Chapter 9 Discussion 
9.1 Discussion 
Non-CF bronchiectasis is a debilitating, incurable chronic airway disease which imposes high costs 
upon the individual patient and the community. Subjects with bronchiectasis suffer from chronic 
productive cough, and are susceptible to infections. Progression of bronchiectasis varies between 
individuals with some being stable with minimum symptoms for years, while others have frequent 
pulmonary exacerbations and progressively deteriorating lung function. Maintenance therapy such 
as long-term low-dose macrolide therapy has shown clinical benefits in non-CF bronchiectasis. It is 
generally understood that neutrophilic inflammation plays a major role in bronchiectatic airways, 
however the underlying nature of the chronic inflammation and the roles of respiratory mucins and 
cellular responses to environmental stimuli have not been previously examined in detail. In 
addition, how macrolide therapy benefits subjects with bronchiectasis has not been clearly 
explained. 
 
This project aimed to characterise the inflammatory cytokine milieu and mucin content of 
bronchiectatic airways by assessing bronchoscopic biopsies, BALF and sputum samples obtained in 
the context of a randomised controlled trial. By examining the specimens from study baseline and 
by comparing these specimens to samples obtained at end of the trial, we aimed to test the following 
hypotheses: 
1. The Th17 pathway is an important inflammatory pathway in bronchiectatic airways that 
contributes to the pathophysiology of bronchiectasis. 
2. Abnormal airway mucin production contributes to dysregulated mucociliary clearance in 
bronchiectatic airways. 
3. ER stress occurs in epithelial secretory cells in bronchiectatic airways. 
4. Activation of proteases involved in tissue remodelling is associated with disease progression 
in bronchiectasis. 
5. Long-term low-dose oral erythromycin reduces inflammation, alters the volume of mucus 
production, and the relative abundance of secreted mucins in sputum in patients with 
bronchiectasis. 
 
The results generated from this project have provided substantial insights into the potential roles 
respiratory mucins and innate and adaptive immunity play in the pathogenesis, perpetuation and 
progression of this disease and an exploration of the influence of low dose erythromycin, which is 
effective in disease management, on these parameters. In summary, we have demonstrated: 
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 Bronchiectatic airways typically have a strongly activated Th17 immune response and 
exhibit a complex, airway inflammatory profile that is consistent longitudinally within 
individuals. 
We accept our hypothesis that Th17 pathway is an important inflammatory pathway in 
bronchiectatic airways that contributes to the pathophysiology of bronchiectasis. However, 
whether activation of the Th17 pathway in bronchiectatic airways is beneficial for the host 
to combat extracellular microbes, and/or worsens neutrophilic inflammation and tissue 
remodelling in the airways still requires further investigation.  
 Bronchiectasis sputum has a high mucin content and an increase in a specific glycoform of 
the MUC5B mucin. 
We accept our hypothesis that abnormal airway mucin production is apparent in 
bronchiectatic sputum. However, whether the abnormal airway mucin production 
contributes to dysregulated mucociliary clearance in bronchiectatic airways still requires 
further research aimed to understand whether the quality of sputum changes with the 
altered ratio of mucin glycoforms in the sputum. 
 ER stress is not activated in the bronchiectatic epithelium. 
We reject our hypothesis that ER stress is present in bronchiectatic airways based on the 
normal expression of ER stress/UPR genes in the endobronchial biopsies and the 
bronchiectatic primary bronchial epithelial cells. However, detection of ER stress in ex vivo 
bronchial epithelial cells will help to further confirm this finding.  
 Ongoing tissue remodelling demonstrated by elevated protease activity in bronchiectasis is 
strongly associated with disease severity and the presence of pathogenic microbes. 
We accept our hypothesis that continuous activation of tissue remodelling markers in 
bronchiectasis may promote disease progression. However, the lack of association between 
tissue remodelling marker concentration and histology scores suggest that although tissue 
remodelling markers may play a substantial role in the bronchiectatic airways, the 
bronchiectasis pathophysiology is also determined by other factors.   
 Long-term low-dose erythromycin treatment results in subtle shifts in the inflammatory 
pattern in bronchiectasis subjects.  
We reject our hypothesis that long-term low-dose oral erythromycin reduces inflammation, 
and alters the relative abundance of secreted mucins in sputum in patients with 
bronchiectasis. The significant decrease in sputum volume and subtle shifts in the 
inflammatory pattern after the treatment is more likely to be a result of the anti-bacterial 
effect of erythromycin.   
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What more do we know about chronic inflammation in bronchiectasis now? 
Bronchiectasis has a complex disease phenotype demonstrated by upregulation of multiple immune 
pathways, tissue remodelling markers, and altered mucin content in sputum (Chapter 4, 5, and 6). 
We have shown not only that the Th17 pathway is an important inflammatory pathway in 
bronchiectatic airways, but also almost every inflammatory factor we measured was increased 
consistent with an assault on the chronic microbial infection by multiple arms of immunity. Our 
data supports previous reports that many of the inflammatory markers and tissue remodelling 
markers are concurrently activated in bronchiectasis (Angrill et al., 2001; Chalmers et al., 2012; 
Regamey et al., 2012), but so were immune factors involved in resolution of inflammation, such as 
IL-10. Therefore, inflammation resolving mechanisms in bronchiectasis are not absent, but could be 
deficient or insufficient due to the continuous microbial stimulation of immunity. Previous studies 
have been restricted to limited individual inflammatory markers, whereas our study suggests that 
assessment of the inflammation network as a whole is required to understand immunopathology in 
this disease. We have further emphasised that the loss of balance in various pro- and anti-
inflammatory responses is what differentiates a chronic inflammatory disease from the more simple 
normal healthy immune response against a transient infectious agent successfully cleared by 
immunity.   
 
Activation of the pro-inflammatory responses in bronchiectatic airways are consistent through time 
(Chapter 4 and 6), suggesting that they could be due to an inherited immune phenotype, loss of 
immune regulation, persistence of particular microbial communities in bronchiectatic airways, or 
structural damage from repeated viral infections. We have shown consistently activated pro-
inflammatory responses and anti-microbial responses, however the mechanisms to completely clear 
the infections and to switch these immune responses off once the infection is cleared could be lost 
or deficient. The balance between classically activated macrophage and the alternatively activated 
could play an important role in maintaining the homeostasis in the airways. In addition, the concept 
of endotoxin tolerance has been described in macrophages and airway epithelial cells (Pena 2014), a 
deficiency of which could provide a potential mechanism of ongoing chronic inflammation. Under 
normal circumstances, when the immune signalling pathway is activated the second time, the cells 
produce more wound healing and anti-inflammatory cytokines than pro-inflammatory cytokines to 
restrain inflammation in a manageable manner. However, in some conditions like allergic airway 
inflammation and inflammatory bowel disease, this regulatory mechanism is distorted, and hence 
the development of non-resolving inflammation. Therefore it is plausible that the consistently 
activated inflammation and remodelling we observed in bronchiectatic airways could be due to 
dysregulated inflammation resolving mechanisms.  
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Are bacteria driving the disease? 
Positive correlations between inflammatory marker concentrations and the presence of potential 
pathogenic microbes in sputum (Chapter 4 and 6) may support Cole’s hypothesis that the 
inflammatory processes are driven by infection (Cole, 1986), or alternatively that inflammatory 
activation in the airway provides a suitable environment for bacterial infection. Emerging data from 
our laboratory suggest further associations between these inflammatory markers and airway 
microbiology assessed by molecular techniques (unpublished). Normal mucociliary clearance 
together with appropriate immune responses in healthy airways would have cleared the bacteria 
before they trigger an uncontrolled inflammatory response. However, goblet cell hyperplasia and 
increased mucin glycoprotein production may have contributed to defective mucociliary clearance 
that retained microbes in the bronchiectatic airways (Chapter 5).  It remains unclear whether the 
inflammatory pattern is the result of infection or if the inflammatory environment determines the 
niche for specific bacterial species.  
 
Is bronchiectasis genetic? 
The potential of an inherited immune phenotype in bronchiectasis has been addressed in this project 
by a pilot study characterising the immune functions of airway epithelial cells and by an analysis of 
the MUC5B polymorphisms that have been linked with IPF. We have shown that epithelial defects 
may predispose individuals to bronchiectasis. The high expression of CXCL10 and SERPINB2 
genes in bronchiectatic epithelial cells may reflect an underlying functional predisposition to 
bronchiectasis (Chapter 8), which could potentially lead to abnormal and exaggerated immune 
responses when responding to airway insults, including infection. This could further trigger 
unresolvable downstream immune activation setting up a cycle of epithelial damage and chronic 
inflammation and infection (Schroder et al., 2010; Spurrell et al., 2005; Zaheer and Proud, 2010). 
Inherited predisposition related to immunoglobulin production and NK cell function have been 
shown to be risk factors for bronchiectasis (Boyton et al., 2006), and our data further stressed that 
genetic polymorphisms or epigenetic modulations could be involved in bronchiectasis disease 
pathogenesis. However, we found that the MUC5B promoter SNP which has been linked to IPF 
(Seibold et al., 2011) was not associated with bronchiectasis (Chapter 5), and ER stress is not 
activated to contribute to inflammation signaling (Chapter 8).  Therefore, mucus hypersecretion in 
bronchiectasis is more likely to be a result of infection, inflammation and mucosal damage, rather 
than being the trigger which initiates disease. 
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Do we have a biomarker yet? 
Amongst over 50 inflammatory markers that we detected in BALF, sputum and endobronchial 
biopsies, low VEGF-A concentration in BALF was identified as a potential marker to predict the 
number of exacerbations (Chapter 6). However, how low VEGF-A concentration is associated with 
the number of pulmonary exacerbations in bronchiectatic subjects is still not clear. Other than 
VEGF-A, several other inflammatory marker concentrations and protease activities in induced 
sputum were linked to disease severity, but no association with the number of exacerbations was 
observed (Chapter 4 and 6). It is possible that other than the classical roles of VEGF-A in 
angiogenesis, its functions in immune pathways including macrophage recruitment and T cell 
priming makes subject more susceptible to certain types of  infection that are more likely to result in 
an exacerbation (Cursiefen et al., 2004; Kim et al., 2009). Sputum IL-1, IL-8, NE activity and total 
MMP activity, which were increased in the presence of pathogenic microbes and were higher in 
patients with poor lung function may simply affect response to chronic infection.  
 
How do macrolide antibiotics work in bronchiectasis? 
As we have shown that bronchiectasis has a mixed inflammatory pattern (Chapter 4), treatments 
that target multiple immune pathways would be required to limit immunopathology. Macrolides 
which have been shown to modulate inflammatory marker concentrations and reduce mucin 
production were good candidates for bronchiectasis treatment (Ichikawa et al., 1992; Ratjen et al., 
2012). We observed a shift in inflammatory pattern after long-term low-dose erythromycin 
treatment, but no change in concentration of any particular inflammatory marker was observed 
(Chapter 7). Clinically, patients with more severe bronchiectasis (P. aeruginosa culture positive or 
more than 4 exacerbations in the prior 12 months) showed significant benefits with erythromycin 
treatment (Serisier et al., 2013). However, we could not identify any distinct inflammatory 
characteristics in these subgroups, nor could we identify any specific group of patients who had a 
greater anti-inflammatory response to erythromycin treatment. Therefore, the clinical benefits of 
long-term low-dose erythromycin could be acting by a non-typical anti-microbial property rather 
than anti-inflammatory function, and the subtle shift in immune response pattern could due to 
changes in microbial populations or their function.  
 
9.2 Significance of outcomes 
This project is the first study to comprehensively characterise the components of respiratory mucus 
in bronchiectatic sputum samples and the concentration of inflammatory markers in bronchiectatic 
airways. It is also the first set of complete longitudinal assessment comprising both clinical 
measurements and molecular marker concentrations. Comparison of inflammatory mediator 
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concentrations in induced sputum and BAL specimens helped to validate induced sputum as a non-
invasive marker of airway inflammation in bronchiectasis. Our gene expression study using 
endobronchial biopsies identified several genes of unknown function that may contribute to 
bronchiectasis pathogenesis. Our genomic study using the BLESS cohort ruled out the potential of 
MUC5B promoter SNP rs35705950 minor allele as a contributing factor to bronchiectasis 
development. The results also provide scientific evidence of the effects of long-term low-dose 
macrolide treatment on airway inflammation and mucus production. Characterisation of 
bronchiectatic bronchial epithelial cells grown using the air-liquid interface culture system provided 
insights into whether inherited or epigenetic epithelial defects are a causative factor in the 
development of bronchiectasis. 
 
9.3 Limitations of the project 
This project was part of a randomised-controlled, double-blinded clinical trial, where bronchial 
biopsies, BALF and sputum samples were collected for laboratory analysis. Patients enrolled in this 
study received tertiary level care in an Australian teaching hospital, whereas worldwide the burden 
of disease lies predominantly in the Third World, hence the underlying factors determining disease 
progression may be quite different. Also, the BLESS trial was powered to test the clinical benefits 
of erythromycin, and only a subset of these patients provided BAL samples. Hence, analyses of 
inflammatory patterns after erythromycin treatment and subgroup analyses may have been under-
powered due to insufficient sample size.  
 
Consistency and quality of clinical specimens are crucial in clinical studies, and only minimal 
artifacts are allowed. Air conditioning in the hospital, close contacts with people with viral 
respiratory tract infections, inhalation of dusts or pollen, and treatments for other diseases (eg. heart 
disease, diabetes, etc) could all possibly affect the inflammatory mediators in the airway when 
patients present for bronchoscopy. Although bronchoscopies were undertaken by the same 
respiratory physician, each biopsy from the same individual will vary, and a single biopsy may not 
be a representative sample of the diseased airway. Our gene expression data suggested that 
epithelial cells were not the dominant cell type in biopsy specimens. We attempted to overcome 
these problems by extracting tissue RNA from two biopsies for each subject in order to maximise 
the coverage of the area of study, and analyse these results in parallel with the results obtained from 
BALF and sputum, and hence obtain more representative data. The amount of BALF collected from 
each individual at each visit could be affected by multiple factors including the disease state. 
Although induced sputum may yield different results compared to spontaneous sputum samples, 
induced sputum samples produce reproducible results and contain a higher proportion of viable 
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cells (Bhowmik et al., 1998). Together, these experimental limitations are overcome by the large 
sample size of the study, as variations between individuals are expected to be greater than these 
technical limitations. In addition, analysis from the three sample types (biopsies, BALF and 
sputum) strengthened the reliability of the result by covering a wide variety of sampling conditions. 
Also, the strong correlations between marker levels in the longitudinal data provided some 
reassurance that the results were reproducible. 
 
A more complete dataset could be achieved by having a more comprehensive medical history of 
each patient. The BLESS cohort were recruited/referred from different general practitioners around 
Brisbane, and a complete and consistent record of medical history was not available in all cases. 
Information on clinical factors which could potentially influence genesis of their disease were also 
not available. These included a history of infections in childhood and adulthood, a history of 
antibiotic usage, or a family history of chronic respiratory diseases such as COPD or asthma. Also, 
information on environmental and life style factors, include exposure to woodfire or grass pollens, 
and living in high population density areas were not recorded. Assessing the relationship between 
these factors and bronchiectasis disease phenotype will be informative in understanding 
bronchiectasis aetiology. However, relying on patient’s self-reported medical history is notoriously 
difficult, hence having a complete and comprehensive medical history of each patient is unrealistic. 
A second limitation was the sensitivity of the assays used. Whilst we have tried to measure many 
inflammatory markers in BALF and sputum samples, in some cases levels of factors being assessed 
fell outside the range of detection.  
 
9.4 Future directions 
This project has comprehensively characterised the inflammatory pattern in non-CF bronchiectasis. 
The in vitro experiments have also helped to generate hypotheses for future follow-up studies. 
Future research within this project that would add to the knowledge accrued in the thesis includes:  
 We have preserved BALF cell pellets from the BLESS trial. Determining the expression of 
inflammatory response genes from immune cells would help to further characterise the 
inflammatory signalling pathways and gene expression in bronchiectasis. 
 Linking our inflammation data with microbiome data (currently being generated by 
collaborators) will further inform our understandings of how the bacterial community could 
modulate the inflammatory pattern in bronchiectasis, or, how the inflammatory 
microenvironment could determine susceptibility to specific types of infection. 
 Comparison of inflammatory marker concentrations in BALF, induced sputum, spontaneous 
sputum and serum may help to validate biomarkers to predict exacerbation or disease 
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progression using specimens which are easier to obtain (ie. spontaneous sputum or serum 
samples).  
 We have generated preliminary data characterising the differences between healthy and 
bronchiectatic epithelial cells. Repeated experiments with larger sample sizes are required to 
confirm these findings.  
 
In a broader view, future research that would add to the knowledge in understanding bronchiectasis 
includes: 
 Other than the epithelial cells, immune cells could also have different characteristics between 
healthy and bronchiectatic subjects. Therefore, characterising immune cell functions in 
bronchiectatic subjects could inform further understanding of the inflammation in 
bronchiectasis. 
 Further exploration of the differences in bronchiectasis inflammatory patterns between the 
clinically stable stage and during pulmonary exacerbations will provide further understanding 
of whether a strong activation of specific immune pathways during exacerbation is critical for 
bronchiectasis disease progression.  
 Children with protracted bacterial bronchitis (PBB) are believed to be at risk of developing 
bronchiectasis. Comparing inflammatory patterns between PBB and bronchiectatic subjects 
could help to understand the characteristics of “early stage bronchiectasis”, and further inform 
understanding of progression from PBB to bronchiectasis. Potential prevention therapy could 
be developed targeting these pathways. 
 
9.5 Conclusion 
Airway luminal inflammation in adult non-CF bronchiectasis subjects is characterised by a complex 
and mixed inflammatory profile indicating concurrent activation of multiple arms of immunity, 
which is relatively consistent in individuals over time. Several inflammatory markers and proteases 
were linked to the presence of pathogenic microbes and disease severity. Sputum mucin content 
was increased and changed in nature in bronchiectatic subjects, however these changes do not 
reflect disease severity, and the MUC5B promoter SNP rs35705950 minor allele does not contribute 
to bronchiectasis pathogenesis. Long-term low-dose erythromycin treatment results in subtle 
changes in inflammatory chemokine and cytokine production, however had no effect on sputum 
mucin content. Inherited variations in bronchial epithelial cells could predispose patient to 
bronchiectasis although this requires further exploration. This study comprehensively analysed the 
inflammatory pattern in non-CF bronchiectasis subjects, and how long-term low-dose erythromycin 
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treatment modifies the inflammatory pattern. Future studies linking the inflammatory pattern with 
microbiome data will increase understanding of this complex disease.  
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Appendix 1 ― BLESS study protocol 
In addition to their description below, details of recruitment and inclusion for the BLESS 
study are provided as part of a separate publication, (Serisier et al., 2013). 
 
Non-CF bronchiectasis subject inclusion criteria: 
1. Able to provide written informed consent. 
2. Confirmed diagnosis of bronchiectasis by HRCT within 3 years. 
3. Airways obstruction on spirometry (ratio FEV1/ FVC <0.7) and FEV1 25% predicted. 
4. Chronic productive cough with at least 5 mLs sputum production per day. 
5. At least two exacerbations of bronchiectasis requiring either oral or intravenous supplemental 
antibiotic therapy (of at least 7 days on each occasion) in the prior 12 months. 
6. Aged 20-85 inclusive. 
7. Clinically stable for at least four weeks (defined as no symptoms of exacerbation, no requirement 
for supplemental antibiotic therapy, and FEV1 within 10% of best recently recorded value where 
available). 
 
Exclusion criteria 
1. Bronchiectasis as a result of CF or focal endobronchial obstruction. 
2. Currently active tuberculosis or non-tuberculous mycobacterial (NTM) infection. Subjects with 
evidence of prior pulmonary NTM infection could be included only if they have completed a course 
of therapy that is deemed successful on the basis of negative NTM cultures following cessation of 
therapy. All subjects required a negative NTM culture prior to screening. 
3. Any symptoms or signs to suggest recent deterioration in respiratory disease, including 
exacerbation of pulmonary disease (as previously defined) in the preceding 4 weeks. 
4. Any change to medications in the preceding 4 weeks. 
5. Prescription of either oral or intravenous antibiotic therapy in the preceding 4 weeks. 
6. Cigarette smoking within the preceding 6 months. 
7. Any history of malignant arrhythmia (unless in the immediate post-myocardial infarction period 
and not requiring any regular therapy) or QTc prolongation on baseline ECG. 
8. Any of the following within the three (3) months prior to enrolment: 
 Acute MI 
 Acute CVA 
 Major surgery 
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9. History of any of the following: 
 Active malignancy (excepting non-melanoma skin malignancies that have been 
treated and considered cured) 
 Listed for transplantation 
 Any other significant active illness likely to affect the patient’s survival within 
12 months 
 Receiving long-term domiciliary oxygen therapy 
10. Allergy to macrolide antibiotics, other than minor, dose-related gastrointestinal intolerance that 
would not be anticipated to recur with low-dose erythromycin. 
11. Any prescription or receipt of long-term macrolide antibiotics, or receipt of a treatment course 
within 4 weeks. 
12. Predominant diagnosis of emphysema (rather than bronchiectasis) on HRCT scan of the chest. 
13. Requirement for supplemental oxygen therapy.  
14. Inability to complete required study procedures for whatever reason (including 6 minute walk 
test, hypertonic saline sputum induction). 
15. Respiratory symptoms (including cough, sputum production, recurrent exacerbations) not 
predominantly the result of bronchiectasis in the opinion of the PI; where treatable causes for 
exacerbations existed, these were treated before considering trial enrolment.  
 
Excluded medications 
1. Macrolide antibiotics – long-term macrolide use was an absolute exclusion, however subjects 
who had received a short duration (less than 6 weeks) treatment course were eligible provided 
they had at least 4 weeks washout. 
2. Long term oral antibiotic administration for infection prophylaxis (eg doxycycline). 
3. Any other intravenous or oral antibiotic within 4 weeks. 
4. While erythromycin in the current study was administered in a low dose, possible drug 
interactions in all patients entering the study were considered. Subjects using the following 
medications were not eligible for the study: 
 ergotamine or dihydroergotamine 
 triazolam/ alprazolam 
 sildenafil 
 azole antifungals (ketoconazole, itraconazole, fluconazole) 
 disopyramide 
 quinidine 
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Concomitant HMG-CoA reductase inhibitor (‘statin’) use was permitted, however subjects on high-
dose statins (equivalent to 80 mgs daily of simvastatin) required dose reduction by half at study 
entry. 
Subjects prescribed diltiazem or verapamil were screened to ensure no evidence of clinically 
relevant increases in levels of these medications. 
 
The following medications were permitted, provided they had been a regular medication for at least 
6 months (with the requisite number of exacerbations whilst on this therapy): 
1. Inhaled antibiotics in chronic, daily, stable dose. 
2. Inhaled mucolytic therapies (hypertonic saline, mannitol, dornase alpha, N-
acetylcysteine). 
3. Oral mucolytics or expectorants. 
 
Additional inclusion/ exclusion criteria for bronchoscopy subgroup (non-CF bronchiectasis): 
1. Never smokers. 
2. No hypogammaglobulinaemia (levels performed at screening) or ciliary dysfunction. 
3. Not asthmatic and without evidence of atopy on bloods (RAST/ s.IgE). 
4. FEV1>40% predicted. 
5. Not warfarinised or have other issues in relation to anticoagulation or bleeding 
diatheses that make them unsuitable for endobronchial biopsy due to bleeding risks. 
6. No clinically significant ischaemic or myocardial disease that increases the risk in 
relation to bronchoscopy. 
7. No hypercapnoea or evidence of overlap syndrome. 
 
Inclusion/ exclusion criteria for the normal control subjects: 
 1. Age 18 – 85 years. 
 2. Normal subjects without any identifiable airway disease. 
 3. Capable of providing written, informed consent to participate. 
 4. Lifelong non-smokers (< or = 2 pack year history of smoking). 
 5. Normal spirometry (defined as values for FEV1, FVC and ratio of FEV1:FVC all lying 
within the normal predicted range according to age and height, no significant acute response to 
inhaled bronchodilator and no evidence of small airways obstruction on flow-volume loops). 
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Exclusion criteria: 
1. Smoking history >2 pack year history of tobacco smoking. 
2. Any smoking history of other substances. 
3. History of any chronic respiratory disease including asthma, chronic obstructive pulmonary 
disease/ COPD, bronchiectasis, etc, or pneumonia within 8 weeks of bronchoscopy. 
4. Any respiratory tract infection (including upper respiratory tract infection) within 4 weeks of 
bronchoscopy. 
5. Medications: prescription of any antibiotic, antihistamine, corticosteroid, mast cell 
stabilising therapy, theophylline or any inhaled therapy within 4 weeks of bronchoscopy. 
6. Any condition with the potential to increase the risks of bronchoscopy/ bronchoalveolar 
lavage or endobronchial biopsy, including (but not limited to) bleeding diathesis (platelet 
count < 150, abnormal coagulation profile, warfarin therapy), any unstable medical 
condition (eg acute cardiac or cerebral ischaemic event within 3 months, active malignancy), 
any significant illness likely to impact upon survival of the patient within 12 months, 
requirement for domiciliary oxygen. 
7. Positive bronchial challenge test or chronic abnormalities detected on CT scan of the chest. 
 
Procedures 
Sputum induction procedure 
Subjects were instructed to perform their usual chest physiotherapy regime on the morning of the 
sputum induction procedure. Prior to commencement of hypertonic saline inhalation, any 
spontaneous sputum expectorated was collected for standard culture. Sputum induction (SI) was 
performed after inhalation of 400 µg of albuterol, using 4.5% hypertonic saline nebulised from an 
ultrasonic nebuliser (output >1 mL/ min) for 20 minutes in 4 periods of 5 minutes each, according 
to the standardised protocol recommended by the European Respiratory Society taskforce.(Paggiaro 
et al., 2002) Following mouth-rinsing and expectoration, sputum was collected following each 
nebulisation period, on each occasion preceded immediately by spirometry. The first sputum sample 
was refrigerated immediately and frozen at -80 °C. Ten, 15 and 20 minute samples were pooled and 
aliquoted. One aliquot was placed on ice immediately and transferred for inflammatory cell count 
processing within 60 minutes and the remaining aliquots rapidly frozen at -80
o
C. 
 
Bronchoscopy procedure 
Subjects were fully informed about the potential risks of the procedure and provide written consent. 
Bronchoscopy was performed as an outpatient procedure in the endoscopy unit of the operating 
theatres of the Mater Adult Hospital, using an Olympus flexible fibre-optic bronchoscope according 
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to the safety standards of the Thoracic Society of Australia and New Zealand(Monton et al., 1999), 
with details of the research bronchoscopy procedure adapted from prior methods.(Hattotuwa et al., 
2002; Hilliard et al., 2002; Wood-Baker et al., 2001) Subjects fasted for 6 hours before the 
procedure. The procedure was performed transorally, under light sedation using intravenous 
midazolam and fentanyl to ensure patient comfort. Topical lignocaine was applied to the vocal 
cords and bronchi by instillation through the bronchoscope. Where possible, no suction was 
employed prior to performing BAL in the target lobe. After wedging in a right middle lobe 
bronchus, BAL was performed. In non-CF bronchiectasis subjects without significant right middle 
lobe bronchiectasis (on HRCT), an alternative lobe with bronchiectatic change was selected 
according to a hierarchy –lingula, upper lobe (right or left), apical segment lower lobe. One hundred 
and forty (140) mLs of warmed sterile saline was gently instilled, followed by gentle aspiration 
through the bronchoscope’s suction channel. Following bronchoalveolar lavage, 8-10 endbronchial 
biopsies were then taken from subsegmental carinae of the lower lobes (starting at 5
th
 order 
airways) and working proximally as far as the 3
rd
 order bronchi if necessary (bifurcation of 
segmental and subsegmental bronchi). Subjects were observed for 2 hours after the bronchoscopy 
before being allowed home.  
 
Bronchial brushing 
After the application of 2% lignocaine to the vocal cords and airways, bronchial brushings were 
obtained using a nylon cytology brush, from segmental bronchi, usually from the right or left upper 
lobe. Separate large airway brushings were also collected from the right and left main bronchi. For 
subjects also undergoing bronchoalveolar lavage as part of the bronchoscopy procedure, brushings 
were collected from the lung contralateral to those performed for other procedures. 
 
Sputum microbiology  
Sputum processing for culture and sensitivity testing was performed in the Division of 
Microbiology, Mater Pathology. Sputum was transported to the laboratory within 60 min of 
collection and processed within 3 h (refrigerated at 4°C in the interim). The most purulent portion 
of the specimen was selected and streaked directly onto horse blood agar (HBA), MacConkey agar, 
chocolate agar supplemented with bacitracin (CHOC-B), Sabouraud agar, and mannitol salt agar. 
Plates were incubated at 37°C (HBA and CHOC-B in CO2 and CHOC-B anaerobically and the rest 
in O2) for at least 48 h and examined daily. Organism identification incorporated a combination of 
typical morphology, species specific manual tests (eg. catalase testing, coagulase testing, Gram 
stain, pigment production etc.), API, and Vitek identification. 
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Inflammatory cell counts on induced sputum  
Sputum was processed according to the methods of the US Cystic Fibrosis Therapeutics 
Development Network Standard Operating Procedure.(Hilliard et al., 2002) Briefly, an equal 
volume of sterile 10% dithiothreitol (DTT) (Sputolysin; Calbiochem-Novabiochem Corp., San 
Diego, CA), was added to the sputum, then incubated in a shaking water bath at 37° C for 5-10 min, 
and mixed using a transfer pipette at 5-min intervals. A further three times the volume of both DTT 
and phosphate-buffered saline (Dulbecco's; Gibco BRL, Grand Island, NY) was added and the 
mixture incubated again in the 37° C shaking water bath for another 5-10 min. 10 μl of 
homogenized sputum samples, mixed with Trypan Blue, was used to calculate total cell counts 
using a standard hemacytometer. A further 0.25-0.50 ml of both samples was used to prepare 
cytospin slides for differential cell counts. After staining the slides with Wright’s stain, 300 non-
squamous cells were counted and cell differentials calculated. 
 
Serum antibody measurements 
BLESS trial patients were screened for immunoglobulin concentration at the beginning of the trial. 
Depending on where the patients were referred from, the assays used immunoglobulin 
concentration measurement differ between pathology labs. Normal range for each immunoglobulin 
concentration is as below: total IgG (5-16 g/L), IgG1 (3.89-11.95 g/L or 4.9-11.4 g/L), IgG2 (1.59-
9.13 g/L or 1.5-6.4 g/L), IgG3 (0.35-2.57 g/L or 0.2-1.1 g/L), IgG4 (0.04-1.81 g/L or 0.08-1.4 g/L), 
IgA (0.9-3.4 g/L), and IgM (0.5-2.0 g/L). 
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